Matrix Metalloproteinase Expression in Models of Parkinson\u27s Disease by McClain, Justin
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2009
Matrix Metalloproteinase Expression in Models of
Parkinson's Disease
Justin McClain
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Physiology Commons
© The Author
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/1696
School of Medicine  
Virginia Commonwealth University  
 
 
 
This is to certify that the dissertation prepared by Justin A. McClain entitled MATRIX 
METALLOPROTEINASE EXPRESSION IN MODELS OF PARKINSON’S DISEASE 
has been approved by his or her committee as satisfactory completion of the dissertation 
requirement for the degree of Doctor of Philosophy 
 
 
 
Helen L. Fillmore, Ph.D., Director of Dissertation  
 
 
 
William C. Broaddus, M.D., Ph.D., School of Medicine 
 
 
 
Richard M. Costanzo, Ph.D., School of Medicine 
 
 
 
Linda L. Phillips, Ph.D., School of Medicine 
 
 
 
Thomas M. Reeves, Ph.D., School of Medicine 
 
 
 
Diomedes E. Logothetis, Ph.D., Chair, Department of Physiology and Biophysics 
 
 
 
Jerome F. Strauss, III, M.D., Ph.D., Dean, School of Medicine 
 
 
 
F. Douglas Boudinot, Ph.D., Dean, Graduate School 
 
 
Date
© Justin A. McClain 2009 
All Rights Reserved 
 
MATRIX METALLOPROTEINASE EXPRESSION IN MODELS OF PARKINSON’S 
DISEASE 
A Dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
 
by 
 
JUSTIN ADAM MCCLAIN 
B.A., Arcadia University, 2003 
 
 
  
 
 
 
Director: HELEN L. FILLMORE 
ASSOCIATE PROFESSOR, DEPARTMENT OF NEUROSURGERY 
 
 
 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
May 2009 
   
ii 
Acknowledgement 
 
I am incredibly fortunate to have received guidance, support, and encouragement 
from numerous individuals throughout this fulfilling endeavor.  For this, I am grateful.  
Without their assistance, achieving this goal would have seemed unattainable.  First, I 
would like to thank my advisor, Dr. Helen Fillmore, for assisting me with the 
development of this project and allowing me to pursue my ideas.  I am also grateful for 
the guidance provided by Dr. Linda Phillips, who helped propel this project forward with 
her encouragement and willingness to assist whenever asked.  I am also lucky to have had 
the opportunity to learn from Dr. Bill Broaddus, who always managed to ask the most 
thought-provoking questions.  I also greatly appreciate the contribution made by Dr. Rich 
Costanzo, who provided essential career advice, ensured that I stayed on the right path 
towards completion of this project, and made resources in his lab available for my use.  I 
also must thank Dr. Tom Reeves for his helpful scientific input for this project. 
Special thanks must go out to Pam Gigliotti, Peggy Keefe, Dr. Tim Van Meter, 
Dr. Zhi-jian Chen, and Nancy Lee who were patient enough to train me in the various 
techniques that were used throughout this work.  I would also like to thank Nick Pullen, 
Anil Kumar, Steve Bakos, and Melissa Bednarek for providing great scientific discussion 
and comic relief.  I also must thank other current and former members of the 
Broaddus/Fillmore lab for all of their assistance throughout the years:  Archana 
Chidambaram, Monika Anand, Patsy Cooper, Charlie Nottingham, Matthew Parry, and 
   
iii 
Aaron Clark.  Special thanks, too, to the MCV Foundation and Mr. and Mrs. Frederick 
Hafner for providing funding for this project. 
None of this would have been possible without the love and support provided by 
my family.  My parents made great sacrifices to ensure that I had every opportunity to 
pursue higher education.  They provided me with the tools for success and instilled in me 
the confidence that I could accomplish anything.  My deepest appreciation goes to my 
wife, Dana.  I could not have completed this journey without you.  You listened to my 
gripes, pushed me through the most difficult moments, and supported me in every way 
possible.  Your love and encouragement have been awesome!   
Lastly, I dedicate this work in loving memory of R.T. McClain, a true American 
hero and devoted family man.
  iv 
Table of Contents 
Page 
Acknowledgements .............................................................................................................ii 
List of Tables .....................................................................................................................vii 
List of Figures ..................................................................................................................viii 
List of Common Abbreviations ..........................................................................................xi 
Abstract .............................................................................................................................xii 
Chapter  
 1 Introduction to Parkinson’s Disease..................................................................... 1 
1.1 The Importance of Parkinson’s Disease ................................................. 1 
1.2 Early History of Parkinson’s Disease ..................................................... 4 
1.3 The Importance of Dopamine ................................................................. 5 
1.4 Pathological Features of the Substantia Nigra in Parkinson’s Disease... 8 
1.5 Environmental Risk Factors for Parkinson’s Disease............................. 9 
1.6 Genetic Risk Factors for Parkinson’s Disease ...................................... 10 
1.7 Complexities of Parkinson’s Disease: More than Dopaminergic 
Neurodegeneration................................................................................ 14 
1.8 Current Treatments for Parkinson’s Disease ........................................ 15 
1.9 Cell Replacement Therapies ................................................................. 19 
1.10 Towards Neuroprotective Therapies................................................... 21 
2 Neuroinflammation, Matrix Metalloproteinase, and Downstream Targets in 
Dopaminergic Neurodegeneration .............................................................. 23 
   
v 
2.1 The Role of Neuroinflammation in Parkinson’s Disease ..................... 23 
2.2 The Role of Neuroinflammation in Animal Models of Parkinson’s 
Disease .................................................................................................. 27 
2.3 Matrix Metalloproteinases .................................................................... 32 
2.4 The Role of Matrix Metalloproteinases in Parkinson’s Disease........... 38 
2.5 Relationship between α-Synuclein and Matrix Metalloproteinase-
mediated Dopaminergic Neurodegeneration ........................................ 41 
2.6 Connective Tissue Growth Factor in Inflammation and 
Neurodegeneration................................................................................ 44 
2.7 Project Hypotheses and Specific Aims ................................................. 48 
3 The Effect of 6-Hydroxydopamine on Matrix Metalloproteinase Expression in 
SH-SY5Y Cells and Hemi-parkinsonian Rats ............................................ 52 
3.1 Introduction........................................................................................... 52 
3.2 Materials and Methods.......................................................................... 57 
3.3 Results................................................................................................... 66 
3.4 Discussion ............................................................................................. 81 
4 Matrix Metalloproteinase Expression and Activation during 
Lipopolysaccharide-induced Dopaminergic Neurodegeneration ............... 89 
4.1 Introduction........................................................................................... 89 
4.2 Materials and Methods.......................................................................... 91 
4.3 Results................................................................................................... 99 
4.4 Discussion ........................................................................................... 118 
   
vi 
5 Matrix Metalloproteinase and Connective Tissue Growth Factor Expression in 
Lipopolysaccharide-treated BV-2 Microglia ............................................ 127 
5.1 Introduction......................................................................................... 127 
5.2 Materials and Methods........................................................................ 129 
5.3 Results................................................................................................. 134 
5.4 Discussion ........................................................................................... 143 
6 General Discussion........................................................................................ 148 
6.1 Summary of Important Findings......................................................... 148 
6.2 Comparing 6-OHDA and LPS Animal Models to Human Parkinson’s 
Disease:  Is there an Argument for MMP Involvement in PD?.......... 150 
6.3 Dual-role for Matrix Metalloproteinases in Inflammation-induced 
Dopaminergic Neurodegeneration ...................................................... 156 
6.4 Potential Role for Connective Tissue Growth Factor in Parkinson’s 
Disease ................................................................................................ 163 
6.5 Future Directions ................................................................................ 165 
6.6 Concluding Remarks........................................................................... 169 
References ....................................................................................................................... 171 
Appendix I....................................................................................................................... 207 
Appendix II...................................................................................................................... 211 
Appendix III .................................................................................................................... 212 
Vita .................................................................................................................................. 213 
   
vii 
List of Tables 
Page 
Table 2.1: Mammalian Matrix Metalloproteinases. .......................................................... 34 
Table 6.1: Comparison of 6-OHDA and LPS Models to PD. ......................................... 153 
   
viii 
List of Figures 
Page 
Figure 1.1: Schematic of Basal Ganglia Circuitry .............................................................. 3 
Figure 1.2: Catecholaminergic Neurotransmitter Biosynthesis .......................................... 6 
Figure 2.1: Self-sustaining Neurotoxic Cycle in DA Neurodegeneration......................... 28 
Figure 2.2: Role of Neuroinflammation in LPS and 6-OHDA Models of PD.................. 31 
Figure 2.3: Basic MMP Biology. ...................................................................................... 35 
Figure 2.4: CTGF/CCN2 Motifs ....................................................................................... 45 
Figure 3.1: Unilateral 6-OHDA Model of Parkinson’s Disease........................................ 55 
Figure 3.2: Methods for Obtaining Striatal and Ventral Midbrain Tissue Samples.......... 64 
Figure 3.3: 6-OHDA Dose Response Curve ..................................................................... 67 
Figure 3.4: Time-dependent 6-OHDA Toxicity in SH-SY5Y Cells ................................. 68 
Figure 3.5: Effect of 6-OHDA on MMP mRNA Expression in SH-SY5Y Cells ............. 70 
Figure 3.6: Effect of 6-OHDA on Striatal TH Protein Expression ................................... 73 
Figure 3.7: Effect of 6-OHDA on Nigral TH Protein Expression..................................... 74 
Figure 3.8: 6-OHDA-induced Nigral TH Depletion 3 Weeks Post-surgery ..................... 75 
Figure 3.9: Effect of 6-OHDA on Striatal MMP-2 Protein Expression............................ 77 
Figure 3.10: Effect of 6-OHDA on Nigral MMP-2 Protein Expression ........................... 78 
Figure 3.11: Effect of 6-OHDA on Striatal and Nigral MMP-3, -9, and -13 Protein 
Expression ......................................................................................................................... 80 
Figure 4.1: LPS Model of Parkinson’s Disease ................................................................ 96 
Figure 4.2: LPS-induced Nigral DA Neurodegeneration ................................................ 101 
   
ix 
Figure 4.3: LPS-induced Degeneration of DA Projections to the Striatum .................... 102 
Figure 4.4: LPS Increases Nigral TNF-α Production ...................................................... 104 
Figure 4.5: Effect of LPS on Nigral MMP-3 Expression and Activation ....................... 105 
Figure 4.6: Effect of LPS on Nigral MMP-2 Expression and Activation ....................... 109 
Figure 4.7: Effect of LPS on Nigral MMP-9 Expression................................................ 111 
Figure 4.8: Effect of LPS on Nigral MMP-13 Expression.............................................. 113 
Figure 4.9: MMP-3 Fluorogenic Substrate Assay........................................................... 115 
Figure 4.10: Effect of LPS on Nigral CTGF/CCN2 Expression..................................... 117 
Figure 5.1: Activation of BV-2 Microglial Cells with LPS ............................................ 135 
Figure 5.2: Effect of LPS on MMP-3 Expression in BV-2 Microglia ............................ 137 
Figure 5.3: Effect of Serum Withdrawal on LPS-induced Nitric Oxide Production in     
BV-2 Microglia ............................................................................................................... 138 
Figure 5.4: Effect of LPS on MMP-2, MMP-3, MMP-9, and CTGF/CCN2 Protein         
Expression in BV-2 Microglia ........................................................................................ 140 
Figure 5.5: Effect of Activated MMP-3 on 52kDa CTGF/CCN2 Immunoreactivity ..... 142 
Figure 6.1: Proposed Roles for MMP-2, MMP-3, and CTGF/CCN2 in the Support of 
Microglial Activation ...................................................................................................... 160 
Figure AI-1: SH-SY5Y Differentiation........................................................................... 207 
Figure AI-2: Neuronal Marker Expression in Undifferentiated and Differentiated              
SH-SY5Y Cells ............................................................................................................... 208 
Figure AI-3: Dose-dependent 6-OHDA Toxicity in Undifferentiated and Differentiated    
SH-SY5Y Cells .............................................................................................................. 209 
   
x 
Figure AI-4: Time-dependent 6-OHDA-mediated Neurotoxicity in Undifferentiated and 
Differentiated SH-SY5Y Cells ........................................................................................ 210 
Figure AII-1: Temporal CTGF/CCN2 Expression following Intrastriatal 6-OHDA     
Injection........................................................................................................................... 211 
Figure AIII-1: Amphetamine Challenge in LPS-lesioned Rat ........................................ 212 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
xi 
List of Common Abbreviations 
6-OHDA  6-hydroxydopamine 
APMA   4-aminophenylmercuric acetate 
BBB   Blood-brain Barrier 
BH4   Tetrahydrobiopterin 
CTGF/CCN2  Connective Tissue Growth Factor 
DA   Dopaminergic 
ECM   Extracellular Matrix 
IL-1β   Interleukin-1beta 
L-Dopa  Levodopa 
LPS   Lipopolysaccharide 
MMP   Matrix Metalloproteinase 
MPTP   1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
NNGH   N-isobutyl-N-(4-methoxyphenylsulfonyl)-glycyl hydroxamic acid 
PBS   Phosphate-buffered Saline 
PD   Parkinson’s disease 
ROS   Reactive Oxygen Species 
SDS   Sodium Dodecyl Sulfate 
SNc   Substantia Nigra Pars Compacta 
TBST   0.05% Tween-20 in Tris-buffered Saline 
TIMPs   Tissue Inhibitor of Metalloproteinases 
TH   Tyrosine Hydroxylase 
TLR4   Toll-like Receptor 4 
TNF-α   Tumor Necrosis Factor-alpha 
   
xii 
 
 
 
Abstract 
 
 
 
MATRIX METALLOPROTEINASE EXPRESSION IN MODELS OF PARKINSON’S 
DISEASE 
By Justin Adam McClain, B.A. 
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2009 
 
Major Director:  Helen L. Fillmore, Ph.D. 
Associate Professor, Department of Neurosurgery 
 
 
 
 Parkinson’s disease (PD) is a devastating neurodegenerative disorder characterized 
by progressive loss of dopaminergic neurons located in the substantia nigra.  Accumulating 
evidence indicates that microglia-driven neuroinflammation contributes significantly to 
chronic neurodegeneration in PD.  The matrix metalloproteinases (MMPs) play an 
important role in several neuroinflammatory paradigms; however, their relationship to 
dopaminergic neurodegeneration in PD remains relatively unexplored.  To address this, the 
temporal relationship between MMP-2, MMP-3, MMP-9, and MMP-13 expression and 
dopaminergic neurodegeneration was compared in the 6-hydroxydopamine (6-OHDA) and 
   
xiii 
lipopolysaccharide (LPS) models of PD.  In dopaminergic SH-SY5Y cells, 6-OHDA 
treatment significantly increased MMP-13 mRNA expression; however, examination of 6-
OHDA-lesioned rats demonstrated that MMP-13 protein expression does not change over 
the neurodegenerative time course, indicating that MMP-13 likely is not a major factor in 
neurotoxin-mediated neurodegeneration.  MMP-3 and MMP-9 were not detected in either 
6-OHDA model, but an increase in proMMP-2 expression was detected in nigral tissue 
samples 5 days post-surgery.  This holds potential significance; however, active MMP-2 
was not detected at any time point, suggesting that MMP-2-mediated proteolysis is not 
involved in 6-OHDA-induced neurodegeneration.  In contrast to the 6-OHDA models, LPS 
triggered dramatic increases in MMP-2 and MMP-3 expression and activation that 
correlated with the neurodegenerative phase of this model.  A significant increase in 
proMMP-9 was associated with this model, while no change in proMMP-13 was detected.  
In addition to MMP characterization, connective tissue growth factor (CTGF/CCN2), a 
protein that is transcriptionally and post-translationally regulated by MMPs was examined.  
In the LPS model, CTGF/CCN2 expression increased 5-fold and a protein fragment 
potentially representing cleaved CTGF/CCN2 was detected.  The changes in CTGF/CCN2 
occurred during peak increases in MMP-2 and MMP-3 activity.  These experiments 
illustrate a strong temporal relationship between increased MMP expression and activation, 
elevated CTGF/CCN2 expression, and inflammation-induced dopaminergic 
neurodegeneration.  There are clear differences between the 6-OHDA and LPS models that 
could hold significance for the pathogenesis of PD.  Future studies aimed at interrupting 
MMP and CTGF function in the LPS model are required to further establish their role in 
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inflammation-induced neurodegeneration and to assess their potential as a therapeutic 
target for the development of novel neuroprotective therapies for PD.   
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CHAPTER 1 
Introduction to Parkinson’s Disease 
 
1.1 The Importance of Parkinson’s Disease 
 Parkinson’s disease (PD) is the second most common neurodegenerative disease 
following Alzheimer’s disease.  In 2005, total PD prevalence among the world’s 10 most 
populous nations exceeded 4 million, with this number expected to double by 2030 as the 
population ages (53).  PD is a chronic syndrome that results in severe disability.  As a 
result, the economic burden of PD is staggering.  In 2002, the total cost of PD reached an 
estimated $23 billion in the United States, which is projected to exceed $50 billion by 
2040 (92).   
 PD is characterized by the progressive loss of dopaminergic (DA) neurons in the 
substantia nigra pars compacta (SNc).  The substantia nigra belongs to a group of 
extrapyramidal structures, the basal ganglia, which modulates motor activity through 
communication with supplemental and premotor cortex that control the initiation and 
proper sequence of movements (135, 159).  Major basal ganglia structures include the 
striatum (caudate and putamen), globus pallidus, subthalamic nucleus, and substantia 
nigra, which is divided functionally and anatomically into the pars compacta and pars 
reticulata.  DA neurons in the SNc project to the striatum where they release dopamine, a 
neurotransmitter that modulates two critical pathways connecting the striatum to the 
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globus pallidus (Figure 1.1A).  In the direct pathway, dopamine promotes excitation of 
GABAergic striatal neurons that project to GABAergic neurons located in the internal 
segment of the globus pallidus, resulting in decreased GABAergic outflow to its targets 
in the thalamus.  In the indirect pathway, dopamine decreases excitability of GABAergic 
striatal neurons that project to the external segment of the globus pallidus, whose neurons 
enhance inhibition of the subthalamic nucleus.  This decreases subthalamic excitatory 
output (glutamatergic) to the internal segment of the globus pallidus, causing a decrease 
in GABAergic outflow to the thalamus.  In both pathways, the overall effect of dopamine 
is to lessen tonic inhibition exerted by the internal segment of the globus pallidus on the 
ventral anterior nucleus of the thalamus, allowing information to flow to the 
supplemental and premotor cortex. 
 In PD, degeneration of DA neurons in the SNc results in the loss of dopamine 
influence in the striatum (Figure 1.1B).  A failure of excitatory thalamic output to the 
supplemental motor and premotor cortex ensues, interfering with basal ganglia control 
over movement and leading to the manifestation of the cardinal symptoms of PD: resting 
tremor, bradykinesia, and rigidity (135).  These symptoms are controllable in the early 
stages of PD using dopamine replacement therapies, such as Levodopa and dopamine 
agonists; however, as the disease progresses, their effectiveness dwindles and debilitating 
dyskinesias can result (115, 195).  Other symptoms of PD, such as freezing episodes and 
autonomic dysfunction, fail to respond to dopamine replacement therapies altogether  
(165).  The failure of dopamine replacement therapies to arrest PD progression 
underscores the need to develop new treatment strategies that target the underlying cause 
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FIGURE 1.1: Schematic of Basal Ganglia Circuitry  
A) Normal circuitry of the basal ganglia emphasizing the central modulatory role of the 
SNc on striatal output to the globus pallidus.  Dopamine influence over both the direct 
and indirect pathways decreases the tonic inhibition exerted by the internal segment of 
the globus pallidus over the ventral anterior nucleus of the thalamus.  B)  In PD, 
degeneration of DA neurons located in the SNc causes an imbalance (depicted by arrow 
thickness) within the basal ganglia which strengthen tonic inhibition on the thalamus. 
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of DA neurodegeneration.  This will require a better understanding of the disease 
mechanisms that contribute to the pathological features of PD. 
 
1.2 Early History of Parkinson’s Disease 
 In 1817, James Parkinson published his “Essay on the Shaking Palsy,” in hopes of 
generating interest among the scientific community for a disease he realized “had escaped 
particular notice” (166).  Earlier descriptions of Parkinsonian symptoms existed, 
particularly regarding the tremor.  These disorders were collectively referred to as 
shaking palsy, but Parkinson believed the symptoms he observed in six case studies 
represented a specific syndrome he termed paralysis agitans.  He described in detail the 
resting tremor, flexed-forward posture, and festinating gate and provided compelling 
arguments that this disorder differed from other forms of shaking palsy.   
 Parkinson’s work was well received by the medical community, but the next 
major advances did not occur until the 1880s with the French physician Jean-Martin 
Charcot (75).  He coined Parkinson’s disease and further characterized tremor by noting 
frequency, size of oscillations, and when tremor occurred.  Through these careful 
measurements Charcot succeeded in distinguishing the Parkinsonian tremor from tremor 
associated with multiple sclerosis and other neurological disorders (74).  Charcot’s 
biggest contributions were made with the detailed description of bradykinesia and 
rigidity.  Parkinson likely mistook these features for paralysis; however, Charcot proved 
that PD patients did not suffer from paralysis, but rather they were very slow in their 
execution of movements.  Charcot also noted that not all PD sufferers presented with the 
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same symptoms.  Some were dominated by tremor, while others presented with rigidity 
and bradykinesia as the predominant features.    
 In response to these early descriptions, a considerable amount of effort was 
invested to uncover the underlying pathology responsible for PD.  In 1910, Fritz Lewy 
described insoluble inclusion bodies present in the dorsal motor nucleus, nucleus basalis 
of Meynert, and substantia innominata in pathological specimens from PD patients (65).  
Nine years later, Konstantin Tretiakoff examined the SNc in 54 brains, 6 of which came 
from PD patients (120).  He discovered that in every PD case, there was a severe loss of 
pigmented neurons in the SNc, suggesting that the loss of these cells somehow 
contributed to PD.  In addition, he described the presence of Lewy Bodies in surviving 
pigmented neurons, which would later be recognized as the second pathological hallmark 
of PD. 
 
1.3 The Importance of Dopamine 
 The next major leap culminated in the early 1960s with the discovery of the 
importance of dopamine and development of the first rational therapy for PD.  
Catecholaminergic biosynthesis pathways (Figure 1.2) were uncovered in the late 1930s 
and methods were developed to detect these chemicals in isolated tissue preparations 
(75).  At first, dopamine was thought to function solely as the precursor to 
norepinephrine; however, measurements in brain tissue demonstrated that dopamine was 
found primarily in the caudate and putamen, suggesting that dopamine was functionally 
important in the striatum (9, 28, 194).  Norepinephrine was present in the striatum in only 
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FIGURE 1.2: Catecholaminergic Neurotransmitter Biosynthesis 
Tyrosine serves as the precursor to all catecholamines.  Tyrosine hydroxylase (TH) 
catalyzes the rate limiting step in catecholamine biosynthesis, adding a hydroxyl group 
onto the aromatic ring of tyrosine to form L-dihydroxyphenylalanine (L-Dopa).  Water 
forms as a byproduct and tetrahydrobiopterin (BH4) serves as a co-factor for this reaction.  
Aromatic L-amino acid decarboxylase (AAAD) converts L-Dopa to dopamine, releasing 
CO2.  If dopamine β-hydroxylase (DβH) is present within the neuron, dopamine will be 
converted to norepinephrine.  Epinephrine is generated from norepinephrine in a reaction 
catalyzed by phenylethanolamine N-methyl transferase (PNMT).  Other abbreviation: 
BH2=dihydrobiopterin, Asc=ascorbic acid, DHAsc=dehydroascorbic acid, SAMe=S-
adenosyl methionine, SAH=homocysteine. 
Tyrosine
Dopamine Norepinephrine EpinephrineL-Dopa
TH
DβH
O2 H20
BH4 BH2
AAAD
CO2 O2 H20
Asc DHAsc
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SAMe SAH
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trace amounts.  Given that PD was thought to involve the extrapyramidal system, Herbert 
Ehrlinger and Oleh Hornykiewicz (1960) compared dopamine and norepinephrine levels 
from various brain regions in neurologically normal, PD, and Huntington’s disease 
patients (58).  They found marked reductions in dopamine in striatal samples from all PD 
cases, while no changes were observed in samples from Huntington’s disease patients.  
This was the first demonstration that dopamine was centrally involved in PD 
pathogenesis.  At the time, it was known that extensive loss of striatal neurons was 
involved in Huntington’s disease, which indicated that the striatum was not the source of 
dopamine (58).  These studies formed the basis for the development of dopamine 
replacement therapies.   
 L-Dopa, the precursor to dopamine, was a likely candidate for the first attempt at 
dopamine replacement therapy because it readily crosses the blood-brain barrier (BBB), 
whereas, dopamine cannot.  Birkmeyer and Hornykiewicz (1962) were the first to employ 
L-Dopa in PD patients and their description of its incredible effects were as follows:   
“The effect of a single i.v. administration of L-DOPA was, in short, a complete 
abolition or substantial relief of akinesia.  Bedridden patients who were unable to 
sit up, patients who could not stand up from a sitting position, and patients who, 
when standing, could not start walking, performed all these activities after L-
DOPA with ease.  They walked around with normal associated movements and 
they even could run and jump.  The voiceless, aphonic speech, blurred by palilalia 
and unclear articulation, became forceful and clear again as in a normal person.  
For short periods of time the patients were able to perform motor activities which 
could not be prompted to any comparable degree by any other known drug” (12). 
 
These observations revolutionized the PD field and several drugs have since been 
developed that extend L-Dopa’s beneficial effects.  Unfortunately, as the disease 
progresses, L-Dopa loses its effectiveness and in many cases its prolonged use leads to 
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the development of disabling dyskinesias (115).  However, L-Dopa is still the most 
effective treatment known for PD (165). 
 Hornykiewicz suspected that the source of striatal dopamine somehow involved 
the SNc (89).  He measured SNc dopamine in PD patients and found that there was a 
dopamine deficiency similar in magnitude to what had been described earlier in the 
striatum.  Using this information, Poirer and Sourkes were able to show evidence that 
stereotaxic lesions placed into the SNc resulted in severe loss of striatal dopamine (170).  
Subsequent studies would later confirm the existence of a dopaminergic nigrostriatal tract 
(147). 
 
1.4 Pathological Features of the Substantia Nigra in Parkinson’s Disease 
 Three major features are associated with SNc pathology in PD: depigmentation 
due to degeneration of neuromelanin-containing DA neurons, widespread Lewy body 
pathology within surviving DA neurons, and chronic neuroinflammation characterized by 
microgliosis (99, 120).  Extreme depigmentation of the SNc can be detected without 
magnification.  In addition, much of the remaining melanin is extracellular or engulfed by 
activated microglia (46, 138).  Lewy bodies are eosinophilic, insoluble inclusion bodies 
that contain a dense core surrounded by lower density material (55).  Identification of α-
synuclein, an abundant pre-synaptic protein of still unknown function, as the principle 
protein component within these structures was a major breakthrough in PD research (179, 
211).  As described below, α-synuclein gene duplication, point mutation, and over-
expression have all been linked to PD (195).  Along with DA degeneration and formation 
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of Lewy Bodies, a significant inflammatory reaction is present characterized by 
microglial activation (138).  Early immunohistochemistry studies revealed that activated 
microglia surround degenerating DA neurons, leading to the hypothesis that microglia 
participate in neurodegeneration associated with PD.  Studies described in chapter 2 
provide compelling evidence that microglial-derived proinflammatory cytokines, nitric 
oxide, and reactive oxygen species (ROS) contribute significantly to DA neurotoxicity in 
PD (14). 
 
1.5 Environmental Risk Factors for Parkinson’s Disease 
 The first direct evidence for an environmental factor that could directly cause PD 
came from drug users who were accidentally exposed extreme levels of 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP).  These individuals believed they were 
injecting themselves with synthetic heroin; however, the drug was improperly 
synthesized and contained high levels of MPTP, a contaminating byproduct of synthesis 
(116).  They quickly developed severe L-dopa-responsive Parkinsonism and autopsy 
revealed significant loss of DA neurons and decreased striatal dopamine content and TH 
expression (48, 116).   
 Elucidation of the mechanism of MPTP-induced DA neurodegeneration provided 
strong support for the involvement of environmental factors in PD.  Neurotoxicity 
exhibited by MPTP requires its conversion to MPP+ by monoamine oxidase B within 
astrocytes (117).  MPP+ is selectively recognized by dopamine reuptake transporters 
located on DA neurons, leading to transport into the neuronal cytoplasm.  Once inside the 
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neuron, MPP+ accumulates within mitochondria via an energy-dependent mechanism, 
where it potently inhibits NADH dehydrogenase (complex I), (176).  Complex I 
inhibition interferes with mitochondrial electron transport chain function, resulting in 
increased superoxide production and oxidative stress (175).  It is this oxidative stress 
coupled to decreased mitochondrial ATP production that is believed to trigger neuronal 
death.  Selective DA neurotoxicity exhibited by MPTP raised the possibility that other 
complex I inhibitors or related structural compounds found in the environment may 
increase PD risk.  For example, the complex I inhibitor rotenone is the active substance in 
many insecticides used in the agricultural industry and paraquat, which is structurally 
similar to MPTP, is present in herbicides.  Although human exposure to these compounds 
has not been conclusively demonstrated to lead to PD, administration of rotenone or 
paraquat to rodents results in Parkinson-like pathology and symptoms (11, 24). 
 In addition to pesticide exposure, several additional environmental risk factors 
have been suggested to increase PD susceptibility.  These include chronic exposure to 
heavy metals, air pollution, well water and milk consumption, and high caloric intake 
(34, 141).  Certain occupations have also been linked to PD, such as farming, carpentry, 
cleaning, and welding.  While all of these factors are suggested to increase PD risk, none 
have been shown to directly cause PD (34). 
 
1.6 Genetic Risk Factors for Parkinson’s Disease 
 Gene mutations in α-synuclein, parkin, DJ-1, PTEN-induced putative kinase-1 
(PINK1), and leucine-rich repeat kinase-2 (LRRK2) have all been linked to inheritable 
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forms of PD.  Study of these gene mutations has provided valuable information regarding 
the mechanisms leading to DA neurodegeneration.  However, familial forms of PD 
account for less than 10% of all PD cases, the remaining arising in sporadic or idiopathic 
form (221).  Sporadic PD is thought to result from a complex combination of 
environmental and genetic factors that increase disease susceptibility.   
 Several point mutations in the α-synuclein gene have been identified in familial 
PD that result in single amino acid substitutions, including Ala53Thr, Ala30Pro, and 
Glu47Lys (112, 171, 244).  These point mutations are inherited in an autosomal dominant 
pattern.  In addition to point mutations, α-synuclein gene duplications and triplications 
have been described, resulting in over-expression of this protein in individuals carrying 
the mutation (157, 205).  The precise function of α-synuclein remains to be elucidated, 
but it is localized to presynaptic terminals, suggesting that it may be important in synaptic 
transmission (179).  α-Synuclein is the principle component of insoluble filament 
deposits in Lewy Bodies associated with sporadic PD, further indicating that this protein 
is intimately involved in PD pathogenesis (210, 211).   
 Parkin deletion mutations have been identified in families exhibiting autosomal 
recessive inheritance of PD (110).  The mutation is characterized by the complete loss of 
exon 4, resulting in complete loss of function.  Parkin mutations are the most common 
form of early onset familial PD, representing approximately 50% of these cases (195).  
Although severe loss of nigral DA neurons occurs, PD patients harboring parkin 
mutations do not display typical Lewy Body pathology associated with sporadic PD and 
those with α-synuclein mutations (110).  In addition, the role of activated microglia and 
   
12 
neuroinflammation is not known.  The parkin gene encodes an E3 ubiquitin ligase 
required for the proper ubiquitination of proteins destined for clearance by proteosome 
machinery (247).  Since the parkin mutation results in loss of function, DA toxicity is 
believed to be caused by accumulation of undigested proteins.  In sporadic PD, nitrated 
and S-nitrosylated parkin has been detected, which interferes with its E3 ligase function 
and promotes accumulation of its target proteins in cell culture models (40). 
 Early onset PD can also be traced to autosomal recessive mutations in the gene 
encoding DJ-1.  Two mutations have been identified: one involves a gene deletion that 
completely knocks out DJ-1 function and the second is a point mutation that causes DJ-1 
to accumulate in mitochondria (19).  DJ-1 is a ubiquitously expressed protein with 
unknown function; however, under conditions of oxidative stress it directly interacts with 
α-synuclein to inhibit fibril formation (251).  This function of DJ-1 was only expressed 
when the protein was oxidized, suggesting that under conditions of oxidative stress, DJ-1 
may perform important neuroprotective functions.  In support of this, cortical neurons 
isolated from DJ-1-/- mice displayed increased susceptibility to oxidative stress induced 
damage, while neurons engineered to overexpress DJ-1 were resistant to oxidative 
damage (103).  The presence of Lewy body and neuroinflammation pathology has not yet 
been associated with DJ-1 mutations. 
 Similar to parkin and DJ-1 mutations, point mutations or deletions of the PINK1 
gene have been associated with early onset PD (195).  A point mutation has been 
described in the PINK-1 kinase domain, while the deletion mutation results in truncated 
PINK1 that is missing its last 145 amino acids (226).  PINK1 is a ubiquitously expressed 
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serine-threonine kinase that localizes to mitochondria.  Target proteins for PINK1 
phosphorylation have not yet been identified (195).  Transfection of SH-SY5Y cells with 
mutant PINK1 resulted in increased mitochondrial dysfunction that was followed by 
apoptosis when stressed with a proteosome inhibitor (226).  In contrast, overexpression of 
PINK1 in SH-SY5Y cells protected them from the toxic effects of the inhibitor.  The 
presence of neuroinflammation and Lewy Body pathology has not been examined in PD 
patients harboring this mutation.   
 LRRK2 mutations have been associated with a large proportion of autosomal 
dominant inherited PD with 19 pathogenic mutations described to date (140, 252).  
LRRK2 is a large, highly conserved protein expressed in neurons, astrocytes, and 
microglia, as well as most other tissues (140).   PD patients harboring LRRK2 mutations 
display pathology typical of sporadic PD including loss of nigral DA neurons and 
widespread Lewy Body pathology (252); however, the presence of microglia-driven 
neuroinflammation in these cases has not been examined.  In fact, LRRK2 has been 
shown to accumulate within Lewy Bodies associated with sporadic PD and other similar 
protein deposits present in various other neurodegenerative diseases (140).  Expression 
appears to be cytoplasmic in addition to association with the mitochondrial outer 
membrane, and at least 3 of the LRRK2 point mutations are believed to impart a gain-of-
function in the protein’s kinase domain (195).  The association of LRRK2 and PINK1 
with familial PD indicates that regulation of protein phosphorylation may be critical in 
sporadic PD. 
 
   
14 
1.7 Complexities of Parkinson’s Disease:  More than Dopaminergic 
Neurodegeneration 
 Since the discovery of the importance of the nigrostriatal track in motor 
symptoms of PD, most research has focused solely on this system; however, many PD 
symptoms are not motor in nature, suggesting that brain structures in addition to the basal 
ganglia are involved in PD.  Sensory dysfunction occurs in most PD patients, 
characterized by hyposmia, pain hypersensitivity, and abnormal sensations (169).  
Evidence suggests that hyposmia precedes onset of cardinal motor symptoms and 
considerable research is exploring the use of olfactory tests as an early diagnostic tool for 
PD (54).  Constipation, urogenital dysfunction, and orthostatic hypotension indicate that 
the autonomic nervous system is involved in PD.  Additional non-motor symptoms 
common in PD patients include sleep disorders, mood disorders, dementia, and psychosis 
(169). 
 The cause of non-motor symptoms in PD is unknown, but a neuropathological 
staging hypothesis was recently developed in an attempt to explain their origin.  This 
hypothesis was based on rigorous analysis of Lewy Body pathology in PD patients, 
which revealed dozens of regions in the central and peripheral nervous systems that 
contain α-synuclein filled Lewy Bodies (21, 22).  The order of Lewy Body appearance in 
these structures has been divided into 6 stages, with 1 being the earliest stage of disease 
and 6 being end stage.  The hypothesis posits that in stage 1, Lewy Body pathology 
begins in the anterior olfactory nucleus, mitral and tufted cells in the olfactory bulb, and 
preganglionic parasympathetic neurons originating in the dorsal motor nucleus of the 
   
15 
vagus nerve that project to postganglionic neurons innervating that enteric nervous 
system (21).  Lewy Body pathology then is predicted to travel from the dorsal motor 
nucleus of the vagus throughout specific nuclei in the brainstem, including the SNc, and 
then towards various cortical brain regions involved in sensory perception, movement, 
and mood.  This staging hypothesis potentially explains many of the clinical non-motor 
features of PD.  It is interesting to note that in PD patients, activated microglia have been 
described in many of the same regions associated with Lewy Body pathology (70).  
Proponents of this hypothesis contend that early appearance Lewy body pathology in the 
enteric nervous system and olfactory bulb support the idea of environmental causes of 
PD, since neurons in these regions come into close proximity to external environmental 
substances (21). 
 
1.8 Current Treatments for Parkinson’s Disease 
 Current drug treatments for PD focus on replenishing the brain’s lost dopamine 
supply.  Initially, dopamine replacement therapies alleviate motor symptoms associated 
with PD; however, these therapies fail to arrest chronic neurodegeneration, resulting in 
the eventual return of motor difficulties combined with additional debilitating drug side 
effects.  The common theme among current PD therapies is that there is an initial period 
of great therapeutic effect followed by a slow decline in effectiveness due to continued 
disease progression.  The surgical technique of deep brain stimulation was developed for 
PD in order to manipulate the basal ganglia circuitry in an attempt to restore proper 
signaling.  This therapeutic approach holds great promise, but also has its shortcomings.  
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Novel therapies must address the issue of neuroprotection, which can only occur once the 
underlying causes of progressive neurodegeneration are uncovered.  Current therapeutic 
options for PD are briefly described below along with potential future neuroprotective 
strategies. 
 The dramatic initial observations following the first attempts using L-Dopa in PD 
patients provided the framework for rational drug design aimed at restoring lost brain 
dopamine.  L-Dopa is still regarded as the best available PD treatment option for three 
main reasons: 1) it markedly reduces morbidity and mortality in PD patients; 2) 
compared to other available dopamine replacement therapies, L-Dopa has the greatest 
therapeutic effect on debilitating motor symptoms; and 3) all PD patients (autopsy 
confirmed) are responsive to L-Dopa therapy (165, 178).  Its effects are due to its ability 
to efficiently cross the BBB where it reacts with aromatic amino acid decarboxylase to 
form dopamine.  L-Dopa therapy allows patients to maintain high quality of life for an 
average of 5 years.  At this point, L-Dopa’s effectiveness slowly declines and higher 
doses are needed to provide symptomatic relief.  This often leads to L-Dopa-induced side 
effects including dyskinesias and sudden on-off periods; therefore, drug development has 
focused on delaying the need for high-dose L-Dopa treatment (165).  This has resulted in 
discovery of several drugs that can prolong or enhance the effect of L-Dopa so that high 
dose therapy can be delayed as long as possible. 
 There are three classes of drugs approved for PD that extend the therapeutic effect 
of L-Dopa.  Typically, L-Dopa therapy is combined with carbidopa, a peripheral 
decarboxylase inhibitor, which maximizes L-Dopa transport into the brain by delaying its 
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conversion to dopamine until it has crossed the BBB.  Formation of dopamine in the 
periphery is undesirable because it cannot cross the BBB and high peripheral dopamine 
can cause nausea and hypotension (178).  In addition to carbidopa, peripheral catechol O-
methyltransferase (COMT) inhibitors and monoamine oxidase-B inhibitors (MAO-B) can 
be included in the drug regimen (165).  Peripheral COMT renders L-Dopa inert by 
degrading circulating L-Dopa into 3-O-methyldopa before it enters the brain.  Like 
carbidopa, COMP inhibitors extend the L-Dopa plasma half-life, resulting in increased 
delivery to the brain.  Studies have also indicated that COMT inhibitors can reduce L-
Dopa-associated side effects (165).  Blockade of MAO-B retards dopamine catabolism by 
preventing its conversion to 3,4-dihyroxyphenylacetic acid (178).  These drugs extend the 
half-life of dopamine, thus lowering the dose of L-Dopa needed for symptom alleviation.    
  Dopamine agonists represent an alternative approach to L-Dopa therapy in PD.  
These drugs mimic the effect of dopamine in the brain by binding to D1 and D2 receptors 
expressed on striatal neurons.   Clinical trials comparing various dopamine agonists to 
standard L-Dopa therapy demonstrate that a significant reduction in drug-induced 
dyskinesias can be attained with dopamine agonists (98).  Unfortunately, dopamine 
agonists are not as effective as L-Dopa in alleviating the motor symptoms associated with 
PD, and they often cause visual hallucinations, increased somnolence, and generalized 
edema.  Despite these shortcomings, dopamine agonist therapy may be best to treat early 
symptomatic PD.  Advocates of this therapeutic strategy believe that treatment with 
dopamine agonists delays the eventual need for L-Dopa therapy (115). 
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 In addition to dopamine replacement therapies, anticholinergic drugs and 
amantadine are occasionally used early in the symptomatic phase of PD.  Anticholinergic 
drugs have beneficial effects on resting tremor, but do not affect rigidity or bradykinesia 
(165).  Amantadine is an antiviral medication shown to relieve rigidity and bradykinesia, 
but its use is confined mainly to early disease stages due to neuropsychiatric side effects 
(98, 165). 
 Surgical treatment options can also be considered in the course of PD treatment, 
although these are usually delayed until the patient progresses to the point at which 
dopamine replacement therapies are no longer effective.  Deep brain stimulation (DBS) is 
the most common surgical option for PD patients.  This technique implants a thin-wire 
electrode into the brain, which is connected to a pacemaker-like, battery-driven 
neurostimulator implanted beneath the skin, usually near the clavicle (165).   The 
neurostimulator sends high frequency electrical signals through the electrode aimed to 
overcome deficits in basal ganglia output to the thalamus caused by DA denervation of 
the striatum.  DBS was developed to replace dated surgical techniques that lesioned or 
removed parts of the basal ganglia that sought to reduce inhibitory influence of the globus 
pallidus over the thalamus.   High frequency stimulation simulates these lesions without 
damaging the tissue (165).  The subthalamic nucleus is the most common DBS target in 
PD.  This procedure improves rigidity, tremor, bradykinesia, postural instability, and gait 
(81, 219).  The mechanism by which subthalamic DBS results in symptom improvement 
is not known.  Based on the current understanding of basal ganglia circuitry, loss of 
dopamine should cause subthalamic overactivation (Figure 1.1B), leading to increased 
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tonic inhibition over the thalamus.  Bilateral high frequency DBS reduces subthalamic 
activity, which would be expected to decrease activity in the internal segment of the 
globus pallidus, resulting in a reduction of thalamic inhibition.  Instead, subthalamic DBS 
reinforces tonic inhibition of the thalamus (228).  
 Subthalamic DBS provides patients with remarkable motor symptom 
improvement, but does not relieve non-motor complications associated with PD, which 
continue to worsen over time.  In addition, early improvements in gait, posture, and 
bradykinesia erode within 3-5 years of surgery although improvements in tremor and 
rigidity last for at least 5 years (81).  An emerging issue with subthalamic DBS is 
increased memory deficits after prolonged DBS (85).  Other important concerns include 
complications from surgery and periodic battery replacement, which requires subsequent 
surgery after initial neurostimulator placement (165).  These issues limit DBS therapy to 
later stages of disease progression. 
 
1.9 Cell Replacement Therapies 
 An alternative to drug-based dopamine replacement is the use of cell-based 
strategies to replace degenerated DA neurons.  Successful DA cell replacement therapies 
require that the transplanted cells terminally differentiate into DA neurons that release 
appropriate quantities of dopamine when needed (114).  In addition, these cells must 
integrate into the striatal circuitry by establishing new synapses with proper post-synaptic 
targets (224).  Based on successful demonstration of therapeutic benefit in animal 
models, transplantation of fetal mesencephalic tissue was attempted in humans with 
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varied success.  Grafted fetal tissue survived and new DA neurons integrated into the 
striatal circuitry; however, severe dyskinesias appeared in 15% of the patients and 
surviving grafted DA neurons displayed Lewy Body pathology at autopsy, leading to the 
conclusion that this is not an effective approach (163, 224).  The lack of therapeutic 
benefit has been attributed to the low population of DA neurons present in fetal grafts.  
DA neurons make up only 5-10% of the total graft population, emphasizing the need to 
develop techniques to obtain pure DA cells for transplantation (163).  Embryonic, neural, 
and adult stem cells from various tissues have been proposed as potential sources for DA 
neurons.  These sources have great therapeutic potential; however, they are not ready for 
clinical trial.  Large populations of DA neurons can be obtained from differentiated 
embryonic stem cells in culture; however, when transplanted into animal models, these 
neurons lose some DA characteristics, indicating that the cells are not stably 
differentiated, and a large proportion of animals develop tumors (114, 163).  Methods to 
obtain DA neuronal population large enough for transplantation from neuronal and adult 
stem cells are still under development (114, 224).   
 Additional cell-based approaches are being considered.  Instead of replacing lost 
DA neurons, transplanted cells could be used to deliver a continuous source of dopamine 
or therapeutic drug, such as a neuroprotective trophic factor.  For example, clinical trials 
are currently underway in which the therapeutic benefit of retinal pigment cell 
transplantation into the striatum is being considered.  These cells naturally secrete L-
Dopa, along with many other potentially therapeutic growth factors (163). 
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1.10 Towards Neuroprotective Therapies 
 Several targets have been identified for the development of neuroprotective 
therapies.  Many drugs have been shown to protect DA neurons in response to neurotoxic 
insults in cell culture and animal models, but translating these results to PD has proven 
difficult (164, 196).  However, knowledge gained from animal models of PD has led to 
clinical trials to test for potential neuroprotective properties of coenzyme Q10 (CoQ10), 
glial cell-line derived neurotrophic factor (GDNF), and MAO-B inhibitors.  MAO-B 
inhibitors are used to block the breakdown of dopamine into 3,4-dihyroxyphenylacetic 
acid and hydrogen peroxide; therefore, these drugs have anti-oxidant properties in 
addition to prolonging dopamine half-life.  PD patients placed on MAO-B inhibitors at 
the time of diagnosis show delayed need for dopamine replacement therapies.  This 
would seem to suggest a neuroprotective effect; however, the delay could be due to the 
symptomatic benefit of prolonged dopamine half-life (164).  CoQ10 is a mitochondrial 
protein with potent antioxidant properties due to its role in movement of electrons 
between complexes in the electron transport chain.  Animal studies with CoQ10 have 
been promising, but initial clinical trials have failed to show significant disease-
modifying effects indicative of slowed progression or neuroprotection (196).  Perhaps the 
most well-studied neuroprotective drug to date has been GDNF.  This neurotrophic factor 
clearly has neuroprotective properties in many PD models.  Unfortunately, these effects 
were not seen in PD patients, and clinical trials were discontinued due to the lack of 
neuroprotection and the appearance of severe side effects (98, 196).  Based on evidence 
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that oxidative stress contributes to DA neurodegeneration, drugs that reduce the oxidative 
load on DA neurons may hold promise as neuroprotective therapies.    
 Development of effective neuroprotective strategies to treat PD will require a 
better understanding of the underlying mechanisms that result in DA neurodegeneration.  
Neuroprotective therapies tested to date focused on disease mechanisms believed to be 
intrinsic to DA neurons, such as mitochondrial and dopamine-generated oxidative stress.  
In light of recent developments cataloging the vast pathology beyond the DA neuron in 
PD, such approaches may never succeed.  A better approach may be to focus on the 
common characteristics seen in regions affected in PD.  To date, this includes microglia-
driven neuroinflammation and α-synuclein pathology.  Understanding how these 
common disease mechanisms contribute to neurodegeneration in PD should result in 
better design of neuroprotective therapies.  
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CHAPTER 2  
Neuroinflammation, Matrix Metalloproteinases, and Downstream 
Targets in Dopaminergic Neurodegeneration 
 
2.1 The Role of Neuroinflammation in Parkinson’s Disease 
 In addition to DA neurodegeneration and Lewy Body formation, microgliosis 
represents a major pathological characteristic of PD (99).  As the resident innate immune 
component of the central nervous system, microglia continuously sample the extracellular 
environment with their highly ramified processes, monitoring tissue for damage and other 
pathophysiological events (218).  In addition, microglia provide important trophic 
support for normal neuronal function (15).  In response to tissue injury, microglia 
undergo a series of functional changes culminating into an activated microglial response.  
Microglial activation is characterized by rapid population expansion, proinflammatory 
factor release, and morphological transformation from a highly ramified state to an 
amoeboid state (113).  Fully activated microglia are capable macrophages which engulf 
and eliminate cellular debris, while secreting ROS, nitric oxide, and numerous 
proinflammatory cytokines, including tumor necrosis factor-α (TNF-α) and interleukin-
1β (IL-1β) (14, 16, 113).  The microglial response can be graded.  For example, microglia 
can respond to injury or disease by releasing proinflammatory factors without attaining 
phagocyte status (218). 
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 The importance of microglia and neuroinflammation in PD was first suggested 
following immunohistochemistry studies on postmortem samples obtained from PD 
patients.  The authors found that activated microglia clustered around areas of active DA 
neurodegeneration (138).  Subsequent PET imaging studies using the [11C](R)-PK11195 
ligand confirmed that widespread microglial activation was present PD patients at 
varying disease stages, indicating that the microglial response is chronic (70).  PK11195 
is a ligand that specifically binds to peripheral benzodiazepine binding sites, which are 
selectively increased in activated microglia (233).  In addition to the presence of activated 
microglia, several studies demonstrate that the SNc in PD patients is kept in a state of 
inflammation.  For example, TNF-α and IL-1β are elevated in nigral tissue samples 
collected from PD patients compared to age-matched controls (17, 145).  Enhanced 
markers of oxidative stress including protein oxidation, lipid peroxidation, and DNA 
oxidation have been demonstrated in these patients (80).  The SNc is also under 
nitrosative stress as indicated by high levels of nitrated and S-nitrosylated proteins (40).  
Since proinflammatory cytokines, oxidative stress, and nitrosative stress are components 
of the activated microglial response, activated microglia likely play a major role in PD 
pathogenesis. 
 The function of activated microglia in PD and other neurodegenerative diseases 
has been the subject of intense debate.  It is not known if activated microglia are clearing 
debris left behind by dying neurons or if they contribute directly to neurodegeneration.  
This seems to be dependent on the area of the brain affected; however, accumulating 
evidence strongly suggests that activated microglia contribute significantly to DA 
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neurodegeneration.  First, injection of lipopolysaccharide (LPS), a potent activator of 
microglia, systemically or directly into the rodent SNc specifically caused DA neuronal 
death, demonstrating that microglia-driven neuroinflammation can initiate DA 
neurodegeneration (32, 68, 173).  Second, injection of TNF-α and IL-1β together into the 
rat medial forebrain bundle reduced the number of DA neurons in the SNc, indicating 
that these microglia-derived proinflammatory cytokines contribute directly to 
neurodegeneration (30).  Third, activated microglia appear to be involved in neurotoxin-
induced DA neurodegeneration, since all neurotoxin models of PD are accompanied by 
activated microglial responses (232).  Fourth, inhibition of microglial activation with 
anti-inflammatory drugs, such as cyclooxygenase inhibitors or minocycline, confers 
significant neuroprotection against MPTP and 6-hydroxydopamine (6-OHDA) neurotoxic 
insults (62). 
 It is important to note that DA neurons are more susceptible to inflammation than 
other neuronal types.  Injection of LPS into the SNc results in loss of DA neurons, but 
nigral GABAergic and serotonergic neurons are spared (84).  Moreover, injection of 
identical quantities of LPS into the SNc, hippocampus, and cortex revealed that 
neurodegeneration only occurred in the SNc (104).  Three characteristics of the SNc and 
DA neurons explain this increased sensitivity to inflammation.  First, the SNc has the 
highest concentration of microglia in the central nervous system (104).  This high 
microglial density likely means that more microglia are activated for a given stimulus 
than other parts of the brain resulting in greater production of proinflammatory cytokines, 
ROS, and nitric oxide.  Second, constant low levels of dopamine auto-oxidation place DA 
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neurons under enhanced oxidative stress even under normal conditions (130).  Third, 
heavy metal accumulation, particularly iron, within the SNc is postulated to further 
enhance oxidative stress by driving hydroxyl radical formation from hydrogen peroxide 
by the Fenton reaction (8).  
The presence of chronically activated microglia and the high susceptibility of DA 
neurons to microglial-derived inflammatory factors indicate that microglia are important 
components of neurodegeneration in PD.  The driving force behind microglia activation 
is unknown but is hypothesized to arise from an initial insult to DA neurons that results in 
the release of microglial activating factors (16, 80, 153).  The idea that factors released 
from degenerating neurons, which trigger inflammatory reactions is not new.  
O’Callaghan and colleagues demonstrated that MPTP-induced striatal astrogliosis was 
dependent on DA terminal degeneration (180).  Treatment with the dopamine transporter 
inhibitor, nomifensine, completely blocked the glial response to MPTP, indicating that 
the astroglial response depended on neurodegeneration (160).  Recent studies have 
identified several potential microglial activating factors originating from degenerating 
DA neurons.  In primary culture studies, extracellular neuromelanin, α-synuclein, and 
matrix metalloproteinase-3 (MMP-3) have each been shown to activate microglia (106, 
108, 234, 246).  In addition, when neuromelanin is injected into the SNc it induces DA 
neurodegeneration that is accompanied by microglial activation (245).  In mixed 
mesencephalic cultures, MMP-3, released by DA neurons after MPP+ treatment, was 
required for TNF-α and ROS production when added to microglia (106, 108).  
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Importantly, MPP+-induced DA neurodegeneration requires microglial activation, which 
can be blocked with α-synuclein antibodies or by genetic knockout of MMP-3 (106, 246).   
The ability of mediators released from stressed DA neurons to activate microglia 
has important implications for PD.  Upon neurotoxic insult, DA neurons release several 
factors as they degenerate which can activate microglia.  DA neurons are very sensitive 
to the products of microglia activation: proinflammatory cytokines, ROS, and nitric 
oxide.  This combination presents the possibility for a self-sustaining neurotoxic cycle 
(Figure 2.1).  Importantly, both neurotoxic and inflammatory agents could act as 
initiators of this cycle, implying that DA neurodegeneration can be triggered through 
different primary insults (14, 16).  Mechanisms such as this could explain the 
progressive, chronic nature of neurodegeneration associated with PD.  Breaking 
communication between degenerating DA neurons and resting microglia could halt 
neuroinflammation in PD and protect DA neurons from microglia-mediated 
neurodegeneration.   
 
2.2 The Role of Neuroinflammation in Animal Models of Parkinson’s Disease 
 Neuroinflammation, described by the presence of morphologically activated 
microglia, occurs in every neurotoxin PD animal model described to date (232).  The role 
of neuroinflammation in the LPS and 6-OHDA rodent models (those used in chapters 3 
and 4) are described below. 
 LPS Model of DA Neurodegeneration.  Mechanisms involved in 
neuroinflammation-induced DA neurodegeneration can be directly examined using LPS.  
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FIGURE 2.1: Self-sustaining Neurotoxic Cycle in DA Neurodegeneration 
Evidence suggests that microglial activation following a neurotoxic insult is triggered by 
the release of microglial-activating factors from degenerating DA neurons.  Factors 
identified to date include MMP-3, α-synuclein (SYN) and neuromelanin (NM).  Since 
DA neurons are sensitive to several proinflammatory factors produced by activated 
microglia, including cytokines, ROS, and nitric oxide (NO), a self-sustaining neurotoxic 
cycle may be responsible for chronic DA neurodegeneration associated with PD. 
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LPS-mediated DA neurodegeneration is completely dependent on microglia, since DA 
neurons are protected from LPS in neuronal-enriched primary cultures (23).  Subsequent 
development of in vivo models established that direct intranigral infusion of LPS in rats 
results in cell death of nigral DA neurons that was accompanied by robust microglial 
activation (32).  In addition to activation of microglia, a strong, long-lasting astrocyte 
response is initiated, although the role of astrocytes in DA neurotoxicity is not known 
(95).  This lesion is highly specific for DA neurons:  striatal and nigral GABA and 
serotonin levels remain steady, and LPS injection into the cerebral cortex or hippocampus 
fails to induce neurodegeneration (84, 104).  The reason for this selectivity is likely to be 
due to the large density of microglia in the SNc compared to other brain regions and the 
enhanced susceptibility of DA neurons to oxidative stress and proinflammatory cytokines 
(104).  DA neurotoxicity produced by LPS depends on production of ROS by NADPH 
oxidase present in microglia.  Ablation of functional NADPH oxidase blocks LPS-
induced microglial activation and renders DA neurons resistant to LPS neurotoxicity 
(172).  The LPS model demonstrates that microglial-driven neuroinflammation is capable 
of acting as the initial neurodegenerative stimulus in the self-sustaining neurotoxic cycle 
hypothesized to drive progressive loss of DA neurons in PD (14).   
 The most commonly used LPS model employs intranigral injection of 2-10µg.  
This results in an acute, powerful inflammatory response that causes 70-80% loss of DA 
neuronal cell bodies in the SNc by 48 hours (96).  Degeneration of DA terminals lags 
behind with no loss at 48 hours and complete loss by day 30.  Due to this anterograde 
degeneration, striatal dopamine levels remain steady at early time points and behavioral 
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deficits do not manifest until 3-4 weeks post-surgery (95, 96, 250).  Although this model 
induces neurodegeneration through inflammatory mechanisms, rapid loss of DA neurons 
prevents the development of chronic self-sustaining neurotoxicity (Figure 2.2B).  The 
loss of DA neurons is permanent, but does not progressively worsen at least between 
days 2 and 30 (96). 
 6-OHDA and Neuroinflammation.  6-OHDA selectively lesions DA neurons 
when introduced into the nigrostriatal pathway.  The lesion can be achieved by 
stereotaxic injection of 6-OHDA into the SNc, medial forebrain bundle, or striatum and is 
usually done unilaterally, so that the contralateral side can serve as an internal control 
(52).  Similar to MPP+, 6-OHDA gains entrance to DA neurons through dopamine 
transporters, due to its structural similarity to dopamine.  Once taken up by the neuron, 6-
OHDA quickly degrades resulting in ROS production that leads to apoptotic cell death.  
Injection of 6-OHDA into the medial forebrain bundle or SNc causes rapid and complete 
loss of nigral DA neurons, while striatal 6-OHDA injection can induce dose-dependent 
loss of DA neurons in a retrograde direction that is slower and completed within 4 weeks.  
Astrogliosis and microglial activation in 6-OHDA rat models have been reported by 
several investigators (41, 182, 215).  Intranigral injection of 6-OHDA caused a 
significant increase in astroglial GFAP expression in the striatum (204, 214).  This occurs 
despite the inability of 6-OHDA to enhance GFAP expression when directly added to 
astrocytes, indicating that 6-OHDA’s effects on GFAP must be dependent on DA 
neurodegeneration (214).  Intrastriatal injection of 6-OHDA results in morphological 
activation of microglia at time points consistent with active DA neurodegeneration (41). 
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FIGURE 2.2: Role of Neuroinflammation in LPS and 6-OHDA Models of PD 
A)  Intranigral LPS causes rapid microglial activation and DA neurodegeneration.  In this 
model, chronic cyclical DA neurodegeneration fails to develop due to the acute action of 
LPS.  Too few DA neurons survive the initial insult to sustain microglial activation.  B) 
Intrastriatal 6-OHDA induces DA neurodegeneration that results in rapid activation of 
microglia.  At least in the first 12 days post-surgery, loss of DA neurons is due 
completely to the neurotoxic action of 6-OHDA; therefore, cyclical DA 
neurodegeneration does not take place prior to this time.   
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These experiments add more support for the idea that stressed DA neurons release factors 
that promote neuroinflammation.    
 There is strong evidence that neuroinflammation accompanies 6-OHDA 
neurotoxicity; however, it appears that significant 6-OHDA-mediated DA 
neurodegeneration still occurs when microglia activation is blocked by cyclooxygenase 
inhibitors (193).  Rats were treated daily with oral administration of celecoxib (Celebrex) 
starting just prior to surgery.  At day 12, vehicle and celecoxib-treated rats both displayed 
40% loss of nigral DA neurons, indicating that neurodegeneration prior to this time point 
was solely due to 6-OHDA toxicity.  However, progressive DA neurodegeneration 
occurring between days 12 and 21 was significantly blocked by celecoxib, suggesting 
that neurodegeneration triggered by 6-OHDA progresses in 2 phases: the first driven by 
6-OHDA toxicity, the second involving microglia-induced neurotoxicity.  This first phase 
provides a window in which to study neurotoxin-induced neurodegeneration in the 
absence of microglia-mediated neurotoxicity.  In this phase, active neurodegeneration has 
commenced and microglia have activated, but the microglia do not yet contribute to 
neurodegeneration (Figure 2.2A). 
 
2.3 Matrix Metalloproteinases   
 MMPs are a family of 22 zinc-dependent endopeptidases that degrade 
components of the extracellular matrix (ECM).  By cleaving ECM substrates, MMPs 
stimulate matrix turnover and remodeling associated with wound healing, embryonic 
development, and bone growth.  In addition, ECM barriers are removed, promoting cell 
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migration, angiogenesis, and extension of axonal growth cones (152).  MMPs also 
regulate the bioavailability of important signaling molecules by causing the release of 
growth factors and cytokines sequestered in the ECM or attached to plasma membranes, 
permitting them to mediate cell signaling pathways (136).   
 MMP domains and inserts.   MMPs have been divided into five categories based 
on substrate specificity and structural properties (Table 2.1).  Generally, the MMPs 
contain at least an N-terminal signal peptide followed by a prodomain, catalytic domain, 
hinge region, and a C-terminal hemopexin-like domain (227) (Figure 2.3A).  Known 
exceptions include the matrilysins, which lack the hinge insert and hemopexin-like 
domain, and MMP-23, which has a unique cysteine array and C-terminal IgG-like 
domain in place of the hemopexin-like domain and is a type II membrane protein (167).  
The signal peptide directs MMP translation to the rough endoplasmic reticulum.  Here, 
MMPs enter the secretory pathway and are ultimately expressed on the plasma membrane 
or secreted into the ECM.  The function of the prodomain is to maintain MMP latency.  
The highly conserved PRCG(V/N)PD cysteine switch is located near the C-terminal end 
of the prodomain.  The cysteine within this sequence forms a critical bond with an 
essential Zn2+ ion located in the active site of the catalytic domain (Figure 2.3B).  
Disruption of the cysteine switch by proteolytic or non-proteolytic mechanisms results in 
prodomain removal and activation (150).  The catalytic domain holds the MMP 
proteolytic machinery and contains the essential Zn2+ ion, which is anchored to 3  
histidine residues within the conserved peptide sequence HEXGHX(L/M)G(L/M)XH 
located at the active site (150).  The hemopexin-like domain is a propeller structure 
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Table 2.1:  Mammalian Matrix Metalloproteinases
Type MMP Designation Common Name
Collagenase MMP-1 Collagenase-1
MMP-8 Collagenase-2
MMP-13 Collagenase-3
Gelatinase MMP-2 Gelatinase-A
MMP-9 Gelatinase-B
Stromelysin MMP-3 Stromelysin-1
MMP-10 Stromelysin-2
MMP-11 Stromelysin-3
MMP-19 Stromelysin-4
Matrilysin MMP-7 Matrilysin
MMP-26 Matrilysin-2
Membrane Type MMP-14 MT1-MMP
MMP-15 MT2-MMP
MMP-16 MT3-MMP
MMP-17 MT4-MMP
MMP-24 MT5-MMP
MMP-25 MT6-MMP
Other MMP-12 Metalloelastase
MMP-20 Enamelysin
MMP-23 Cysteine-Array MMP
MMP-27
MMP-28 Epilysin
   
35 
 
 
 
FIGURE 2.3: Basic MMP Biology 
A)  The general domain arrangement for all mammalian MMPs is diagramed.  B) 
Schematic representation of the cysteine switch mechanism that controls activation of 
latent MMPs.  A single zinc ion is held in place at the active site by 3 highly conserved 
histidine residues.  MMP latency is maintained by the highly conserved cysteine located 
in the prodomain with occupies the fourth coordination site of zinc, preventing water 
from entering the active site.  Proteolytic removal of the prodomain exposed the active 
site so that it can interact with target substrates and allows water to interact with zinc, 
which is required before hydrolysis can occur.   
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involved in substrate recognition and in recognition of MMPs by the tissue inhibitor of 
metalloproteinases (TIMPs). 
 In addition to the common domains, several MMPs have other functionally 
important domains and peptide inserts.  The MT-MMPs are tethered to the plasma 
membrane by a single-pass type I transmembrane domain or by GPI anchors and localize 
MMP activity to the pericellular environment.  The gelatinases contain three fibronectin 
inserts within their catalytic domain which assist in gelatin recognition (235).  MMP-9 
also contains an extended hinge region that resembles the α2 chain of type V collagen 
(236).  MMP-11, -23, -28, and the six MT-MMPs contain a furin cleavage site between 
the prodomain and catalytic domain that is involved in intracellular MMP activation 
(174). 
 Regulation of MMPs.  The regulation of MMPs is complex and occurs at several 
levels.  Inflammatory cytokines, including TNF-α and IL-1β, along with several growth 
factors trigger intracellular signaling cascades that result in MMP transcriptional 
activation.  For example, the MAP kinase cascades stimulated by IL-1β and TNF-α result 
in activation of AP-1 transcription factors, which bind to several MMP promoters (51).  
Pathways that activate NF-κB and Ets transcription factors are also involved in 
upregulating transcription of MMPs.  Conversely, transcription of several MMPs is 
suppressed by glucocorticoids, retinoic acid, and anti-inflammatory cytokines such as 
TGF-β1 and IFN-β (152).  TGF-β1 and IFN-β stimulate activation of the SMAD and 
STAT transcription factor families, respectively, which bind to and inhibit transcription 
of MMPs containing the appropriate DNA binding sites (51).  Cell-cell or cell-matrix 
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interactions mediated by adhesion molecules and integrins can also lead to transcriptional 
regulation of MMPs (152).   
MMP prodomain removal is required for expression of MMP proteolytic function 
and presents an important point of regulation.  Activation can occur due to a proteolytic 
event near the N-terminus of the prodomain.  This causes a conformation change that 
disrupts the cysteine switch and results in autocatalysis that removes the remainder of the 
prodomain (151).  Serine proteases (including plasmin, urokinase and tissue plasminogen 
activator, and furin) and MMPs are the major proteases involved in proteolytic activation 
of MMPs.  ROS and reactive nitrogen species present in large quantities during 
inflammation also can modify the cysteine switch to induce activation (66, 78, 162).  
Activation of proMMP-2 appears unique among the MMPs in which the binding of 
TIMP-2 to proMMP-2 is required for proMMP-2 activation by membrane-type MMPs 
(150).  Each of these MMP activation mechanisms are themselves tightly regulated and 
MMP activation cannot occur unless their activators are present.  Therefore, 
transcriptional upregulation of MMPs does not translate into an increase in MMP activity 
unless activation mechanisms are already in place.   
Once activated, several mechanisms exist to suppress the proteolytic activity of 
MMPs.  The TIMPs are a family of 4 proteins that serve as the major endogenous 
inhibitors of MMPs, binding to MMPs in a 1:1 ratio (152).  Because of this ratio, MMPs 
must outnumber TIMPs in order for MMP-mediated proteolysis to occur.  TIMPs have 
varying affinities for the MMPs and each MMP is inhibited by at least one TIMP.  α2-
Macroglobulin is another endogenous inhibitor that suppresses activated MMPs.  
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Receptor-mediated endocytosis can also limit MMP activity.  MMP-13 has been shown 
to bind to a specific cell surface receptor that results in MMP-13 internalization (7).  
 Tight MMP regulation is essential.  Deregulation of MMP proteolytic activity can 
have disastrous consequences and is commonly associated with chronic inflammatory 
diseases outside the central nervous system, such as rheumatoid arthritis and 
atherosclerosis where excessive ECM degradation contributes significantly to disease 
pathology (3, 156).  Moreover, increasing evidence suggests that MMPs have important 
roles in neuroinflammation associated with neurodegenerative diseases including 
Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, and PD (107, 242).   
 
2.4 The Role of Matrix Metalloproteinases in Parkinson’s Disease 
 Accumulating evidence suggests that MMPs may be important contributors to PD 
pathogenesis.  Analysis of nigral tissue collected post-mortem demonstrates that dramatic 
upregulation of MMP-1 and MMP-9 occurs in a subset of PD patients (127).  In MPTP-
treated mice, MMP-2 and MMP-9 expression and activation significantly increased 
during the neurodegenerative phase of this model (128).  Importantly, pretreatment with 
the broad-spectrum hydroxamate-based MMP inhibitor, Ro-28-2653, partially protected 
nigral DA neurons and striatal dopamine depletion induced by MPTP-mediated 
neurotoxicity (128).  In this study, MMP-9 expression was localized to neurons and 
microglia, suggesting that neuroinflammation contributed to the observed changes in 
MMP-9 expression.   
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 Additional evidence signifying the potential importance of MMPs in PD stems 
from studies on MMP-3.  Initial experiments by Kim and colleagues demonstrated that 
conditioned media from serum-starved PC12 cells induced activation of BV-2 microglia 
cells (108).  The PC12 cell line is commonly used as an in vitro tool to study 
catecholaminergic neuronal biology.  Subsequent experiments with these cell lines 
revealed that the key activator of microglia present in PC12 conditioned media was 
MMP-3, indicating that MMP-3 can serve as a microglial activating factor (108).  Further 
investigation showed that MMP-3-mediated activation of BV-2 microglia was dependent 
on ERK and NF-κB activation.  In a separate study, treatment of primary murine mixed 
mesencephalic cultures with MPTP caused increased production of MMP-3 within 
degenerating DA neurons (106).  Addition of activated MMP-3 to primary microglia 
cultures resulted in production of TNF-α and stimulated NADPH oxidase-dependent 
ROS generation, both important markers for microglial activation.  Genetic ablation of 
MMP-3 completely spared DA neurons from MPTP toxicity and prevented activation of 
microglia.  These finding were extended with in vivo observations which showed that 
MMP-3-/- mice exhibit remarkable resistance to MPTP toxicity and display an absence of 
neuroinflammation (106).  Based on these results, in vivo MMP-3 expression should have 
been induced following MPTP administration in wild-type mice; however, despite 
attempts with multiple antibodies, MMP-3 protein was not detected at any point (106).   
 In addition to acting as a potential microglial activating factor, MMP-3 may 
support activation of microglia through other mechanisms.  LPS-stimulated nitric oxide 
and TNF-α in microglia can be blocked with N-isobutyl-N-(4-methoxyphenylsulfonyl)-
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glycylhydroxamic acid (NNGH), a broad-spectrum MMP inhibitor with preference 
towards MMP-3 (237).  Dose-dependent inhibition of ERK, p38 MAP kinase, JNK, NF-
κB, and AP-1 activation were all shown to be involved in the NNGH effect.  These 
studies suggest that maximum activation of microglia by LPS requires MMP-3 activity.  
Additional studies are needed to confirm these observations because NNGH may have 
off-target effects that have not been described.  NNGH is a hydroxamate MMP inhibitor, 
which are notorious for inhibiting multiple MMPs and other metalloproteinase proteins.  
To my knowledge, NNGH inhibition towards other MMPs has not been measured (129).  
 In addition to supporting microglial activation, MMP-3 may perform novel 
intracellular functions that promote DA neurodegeneration as described by Choi and 
colleagues (37).  They were intrigued by the observation that MMP-3 released by DA 
neurons stressed by MPTP, serum starvation, or tetrahydrobiopterin (BH4) was already in 
the activate state (37, 106, 108).  This suggested that activation occurred within the cell, 
implying that MMP-3 could have novel intracellular functions.  In support of this, both 
pro and active MMP-3 were detected in cell lysates after treatment with BH4, and 
inhibition of MMP-3 through pharmacological or siRNA methods partially protected the 
cells from BH4 neurotoxicity (37).  These studies suggest that MMP-3 contributes to DA 
neurodegeneration by direct action on the DA neuron and through initiation of 
neuroinflammation. 
 Further evidence from PD animal models indirectly supports an important role for 
MMPs in DA neurodegeneration.  In other models that involve neuroinflammation, 
MMP-2, MMP-3, and MMP-9 disrupt the BBB by targeting the ECM in the basal lamina 
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and proteins that form tight junctions (47, 148, 184, 185).  BBB disruption occurs in both 
the 6-OHDA and MPTP animal models of PD.  Importantly, leakage of the BBB in both 
models was found to be limited to areas of microglia activation and active DA 
neurodegeneration (31, 248).  Although it is not known if the BBB is compromised in PD 
patients, emerging data indicates that the peripheral immune system plays a significant 
role in PD neurodegeneration (146).  In PD, T-cells show an increased ability to infiltrate 
the brain parenchyma, suggestive of BBB dysfunction. 
 
2.5 Relationship between α-Synuclein and Matrix Metalloproteinase-mediated 
Dopaminergic Neurodegeneration 
 Along with MMP-3, α-synuclein has been identified as a potential microglial 
activating factor.  α-Synuclein is the major protein component of Lewy Bodies and is 
believed to be an important contributor to DA neurodegeneration (195).  This is based on 
the discovery of genetic mutations and duplications in the α-synuclein gene associated 
with familial PD and the propensity for overexpression of α-synuclein in sporadic PD.  
The physiological function of α-synuclein remains to be elucidated, but overexpression in 
transgenic mice and in cell culture models has demonstrated that it can be neurotoxic 
(130, 195, 217).  Several recent studies show that α-synuclein toxicity may be partly 
dependent on its ability to directly activate microglia.  Addition of α-synuclein to primary 
microglia caused activation of NADPH oxidase and induced iNOS expression along with 
increased prostaglandin, IL-1β, IL-6, and TNF-α production (216, 246).  Moreover, 
addition of α-synuclein to mixed mesencephalic cultures resulted in DA neurotoxicity 
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that was completely microglia-dependent (246).  Experiments with transgenic mice that 
overexpress human α-synuclein specifically in DA neurons showed significant activation 
of microglia prior to detectable cell loss (216, 220).  These studies implicate α-synuclein 
as a microglial activating factor and point to microglia-mediated neurotoxicity as an 
important mechanism by which α-synuclein triggers DA neurodegeneration.  In addition, 
activation of microglia may be an early event in the neurodegeneration cascade, since 
activated microglia are present prior to measurable DA neuron loss (216). 
 An important point to address regarding α-synuclein’s role as a microglial 
activating factor is that it must be released from DA neurons.  α-Synuclein is typically 
regarded as an intracellular protein, since it does not contain the obligatory N-terminal 
signal peptide that would send it through the secretory pathway.  However, studies 
analyzing cerebrospinal fluid from PD patients and age-matched controls have detected 
this protein in abundance (20, 59).  α-Synuclein secretion from healthy cells has been 
demonstrated in several cell lines, including MN9D DA cells (59, 216).  The mechanism 
of α-synuclein secretion may be related to its ability to associate with membranes.  
Although α-synuclein has no signal peptide, it does contain 2 di-acidic motifs near its C-
terminus that has been predicted to act as an alternative signal to gain entry into the 
endoplasmic reticulum and secretory pathway (59).  Surprisingly, studies of cerebrospinal 
fluid show that the amount of α-synuclein present does not differ between idiopathic PD 
and control samples (20).  If extracellular α-synuclein activates microglia, then why is 
widespread microglial activation absent in neurologically normal individuals?  The 
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ability of α-synuclein to activate microglia seems to depend on its conformation, which 
could be strongly influenced by MMP-mediated proteolysis.  
 In its native state, α-synuclein remains in a soluble, random coil conformation 
with no defined tertiary or quaternary structure.  Several post-translational modifications, 
including phosphorylation, nitration, and oxidation, cause α-synuclein to reorganize into 
β-sheet conformations that are vulnerable to oligomerization, fibril assembly, and 
eventual insoluble aggregate formation (179).  A dynamic equilibrium exists between the 
random-coil and β-sheet conformations that favor the native conformation under 
physiological conditions (131).  However, appropriate α-synuclein point mutations, post-
translational modifications (phosphorylation, nitration, and oxidation), or interactions 
with other proteins or heavy metals shifts equilibrium towards the β-sheet conformation 
and subsequent fibril formation and aggregation (130).  Aggregated α-synuclein is the 
predominant form deposited in Lewy Bodies (195, 210, 211).  In addition, analysis of 
cerebrospinal fluid samples demonstrate that α-synuclein aggregates are the most 
prominent form in PD patients, whereas, the soluble, random coil conformation 
predominates in age-matched controls (60).  In terms of neurotoxicity, α-synuclein 
oligomers appear most important, since they exhibit greater neurotoxicity than monomers 
or large insoluble fibril aggregates (130, 217).   
  Emerging evidence strongly indicates that MMP-mediated proteolysis may 
negatively affect α-synuclein conformation status.  Sung and colleagues (217) 
overexpressed α-synuclein in dopaminergic SK-N-BE cells.  Upon treatment of these 
cells with the nitric oxide donor sodium nitroprusside, MMP-dependent cleavage of α-
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synuclein was observed.  Upon further examination, MMP-1, MMP-2, MMP-3, and 
MMP-14 were all capable of degrading α-synuclein, with MMP-3 being most efficient.  
Importantly, the authors demonstrated that MMP-3-digested α-synuclein increased α-
synuclein oligomer and aggregate formation, which significantly enhanced α-synuclein 
neurotoxicity.  Recently, the ability of α-synuclein fragments to induce aggregate 
formation was tested for MMP-1, MMP-3, trypsin, and proteinase-K (121).  In agreement 
with the previous study, partial α-synuclein digestion with MMP-1 and MMP-3 resulted 
in increased aggregate formation.  Trypsin and proteinase-K-digested α-synuclein failed 
to enhance aggregation, suggesting that proteolysis-mediated α-synuclein aggregation is 
MMP specific.  Although not yet tested experimentally, MMP-directed digestion could 
enhance activation of microglia by α-synuclein, since aggregated α-synuclein effectively 
induces microglial ROS and prostaglandin production (246).  The roles of other MMP 
targets in DA neurodegeneration have not been studied. 
 
2.6 Connective Tissue Growth Factor in Inflammation and Neurodegeneration 
 Connective tissue growth factor (CTGF/CCN2) is a 38kDa cysteine-rich matrix 
associated protein involved in the signaling modification of other growth factors and 
molecules associated with the ECM.  Depending on cell type, upstream signaling 
pathways, and the presence or absence of certain growth factors, CTGF/CCN2 can 
influence cell proliferation, differentiation, survival, apoptosis, migration, chemotaxis, 
neoplastic transformation, and adhesion (39, 49, 241).  All CCN proteins contain four  
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FIGURE 2.4: CTGF/CCN2 Motifs 
CTGF/CCN2 contains four functional motifs.  The insulin growth factor-like binding 
protein motif (IGFBP) and von Willebrand factor motif (VWF-C/CT) is separated from 
the thrombospondin-1 and C-terminal motifs by the hinge region.  The hinge region is 
susceptible to proteolytic cleavage by several MMPs.  Cleavage of CTGF/CCN2 by 
MMPs results in 2 fragments of approximate equal molecular weight (20-22kDa). 
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motifs:  insulin-like growth factor binding protein, von Willebrand factor, 
thrombospondin-homology, and heparin-binding cysteine knot (Figure 2.4).   
 CTGF/CCN2 is upregulated in both fibrotic and peripheral inflammatory diseases 
where it is thought to stimulate ECM accumulation and reorganization (118, 190).  Little 
is known about CTGF/CCN2 function in the central nervous system, although it is 
expressed primarily by distinct neuronal populations.  For instance, CTGF/CCN2 
expression has been localized to neurons in the deep and intermediate regions of the 
olfactory bulb and pyramidal neurons in layers III, V, and VII of the cerebral cortex (87, 
111, 225).  In addition to neurons, ependymal cells lining the ventricles and central canal 
show strong CTGF/CCN2 expression.  Its expression in astrocytes is debatable: Kondo et 
al, (111) found strong CTGF/CCN2 protein labeling of astrocytes throughout cortical and 
spinal white matter, but Heuer et al, (87) failed to localize CTGF/CCN2 mRNA to 
astrocytes.  Microglia and oligodendrocytes do not normally express CTGF/CCN2.  
Despite the expression of CTGF/CCN2 in a variety of cells and locations in the central 
nervous system, its physiological significance is unknown, although emerging evidence 
indicates that CTGF/CCN2 may be important in the injured brain.  For example, in 
ischemic and traumatic brain injury, CTGF/CCN2 accumulates in reactive astrocytes 
found around glial scars, suggesting that CTGF/CCN2 may be involved in scar formation 
(197, 198).  Importantly, this increase in expression begins by day 1 following injury and 
persists for several months post-injury.  In mice, kainic acid-induced lesion of the 
hippocampus resulted in upregulated CTGF/CCN2 expression in both neurons and 
reactive astrocytes (86).  CTGF/CCN2 may also be involved in neurodegeneration.  In 
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patients with amyotrophic lateral sclerosis, CTGF/CCN2 is over-expressed in reactive 
astrocytes and surviving motor neurons of the spinal cord, but not in activated microglia 
(212).  In addition, increased CTGF/CCN2 expression has been described in Alzheimer’s 
disease, concentrated around β-amyloid deposits in reactive astrocytes and degenerating 
axons (225).  When CTGF/CCN2 was added directly to neuronal cell cultures, it induced 
γ-secretase activity through an Akt-dependent mechanism that resulted in increased 
release of amyloidogenic Aβ peptide, suggesting that CTGF/CCN2 contributes to plaque 
pathology (249).  To my knowledge, the role of CTGF/CCN2 in DA neurodegeneration 
and PD has yet to be examined. 
 Data is emerging linking CTGF/CCN2 biology with that of MMPs.  For example, 
the hinge region located between the Von Willebrand factor and thrombospondin-
homology motifs can be cleaved by MMP-1, -2, -3, -7 and -13 (83).  In each case, MMP-
mediated cleavage of CTGF/CCN2 results in the generation of two CTGF/CCN2 
fragments that are 20-23kDa in size.  These fragments have been shown to have different 
effects on biologic activities (6).  It appears that N-terminal fragments mediate 
differentiation whereas the C-terminal fragments control signaling leading to cell 
proliferation (77).  MMP-3 may also regulate CTGF/CCN2 function at the transcriptional 
level.  MMP-3 contains 6 nuclear localization signals and has been identified in the 
nucleus of cultured chondrocytes and hepatocytes (57, 206).  Intranuclear MMP-3 has 
been shown to enhance CTGF/CCN2 transcription though direct interaction with the 
CTGF/CCN2 promoter (57).  MMP-3 DNA binding to the CTGF/CCN2 promoter was 
confirmed with EMSA and ChiP assays.  Overexpression of MMP-3 increased 
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CTGF/CCN2 expression, while pharmacological MMP inhibition repressed transcription 
of the CTGF/CCN2 gene.  Importantly, exogenously added recombinant proMMP-3 
could be internalized and transported to the nucleus.  In addition to direct regulation of 
CTGF/CCN2 transcription, recent evidence indicates that active intracellular MMP-3 
participates in DA neuronal cell death and hepatocyte apoptosis (37, 206).  
 It is unclear whether proteolytic cleavage and/or transcriptional regulation of 
CTGF/CCN2 by MMPs is important in vivo.  However, it is interesting to note that these 
two proteins are often found in the similar structures in various pathologies.  For 
example, MMP-3 is over-expressed in complicated atherosclerotic plaques, β-amyloid 
plaques, and arthritic joints (1, 123, 243).  In separate studies, CTGF/CCN2 was found to 
be over-expressed in these same structures (42, 133, 225).  Together with direct in vitro 
evidence showing MMP-mediated regulation of CTGF/CCN2 and data demonstrating 
expression of these proteins in similar structures, CTGF/CCN2 may mediate some 
downstream effects of MMP-3-mediated neurodegenerative processes. 
 
2.7 Project Hypotheses and Specific Aims 
 This project further explores the role of MMPs in PD using three different PD 
models.  The goal is to compare the temporal MMP response in neurotoxin and 
inflammatory models to determine if MMPs could be involved in DA neurodegeneration 
caused in either case.  In addition, the effect of DA neurodegeneration on CTGF/CCN2, a 
potential downstream MMP target is examined.  Aside from MMP-3, the role of other 
MMPs in DA neurodegeneration is relatively unexplored and the potential involvement 
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of CTGF/CCN2 in DA neurodegeneration has never been examined.  It was hypothesized 
that MMPs could be involved in DA neurodegeneration through two mechanisms (Figure 
2.2).  First, MMPs may initiate microglial-driven neuroinflammation following 
neurotoxic insult to the nigrostriatal tract.  This is supported by MMP-3 studies which 
demonstrate that MMP-3 is released by degenerating DA neurons in response to MPTP 
and is capable of stimulating TNF-α and superoxide production in primary microglia 
cultures (106, 108).  Second, MMPs could function in the neuroinflammatory reaction 
that directly contributes to DA neurodegeneration.  This is supported by data implicating 
microglia and astrocytes as sources of various MMPs in other neuroinflammatory 
reactions (47, 184, 185).   
 
Hypothesis 1:  MMPs are involved in 6-OHDA-induced DA neurodegeneration. 
 
Specific Aim 1a:  Examine the effect of 6-OHDA on DA SH-SY5Y cell viability and 
temporal MMP expression. 
 SH-SY5Y cells are an immortalized neuroblastoma cell line that exhibit 
catecholaminergic properties such as TH and dopamine transporter expression and 
stimulated release of dopamine and norepinephrine.  Due to these properties, SH-SY5Y 
cells are commonly used to study mechanisms of cell death induced by DA-specific 
neurotoxins such as 6-OHDA.  Techniques for specific isolation and maintenance of DA 
neurons in primary culture do not exist.  In contrast, SH-SY5Y cells are easily grown in 
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culture and provide a homogenous population of DA-like cells, making them ideal to 
study the effect of 6-OHDA on MMP expression.  
 
Specific Aim 1b:  Measure the effect of 6-OHDA on temporal nigral and striatal MMP 
expression in hemiparkinsonian rats. 
 The purpose of this study is to confirm findings described in specific aim 1a using 
an in vivo 6-OHDA model.  When injected into the striatum, 6-OHDA causes 
degeneration of DA neurons due to specific uptake through dopamine transporters and 
subsequent oxidative stress.  The neurodegeneration is accompanied by activation of 
microglia and astrogliosis, suggesting that factors released from degenerating DA 
neurons induce neuroinflammation (41, 204).  Changes in MMP expression will be 
measured at time points consistent with active neurodegeneration. 
 
Hypothesis 2:  MMPs and CTGF/CCN2 are involved in LPS-induced DA 
neurodegeneration. 
 
Specific Aim 2a:  Correlate changes in MMP and CTGF/CCN2 protein expression with 
DA neurodegeneration in LPS-induced Parkinsonism. 
 MMP expression is associated with microglia and astrocytes in response to 
neuroinflammation that occurs in stroke, multiple sclerosis, and Alzheimer’s disease (47, 
184, 185).  In addition, CTGF/CCN2, a proteolytic and transcriptional target for MMPs, 
may be involved in neuroinflammation present around amyloid-β plaques and active 
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areas of spinal cord neurodegeneration associated with Alzheimer’s disease and 
amyotrophic lateral sclerosis, respectively (212, 225).  The effect of a direct 
neuroinflammatory stimulus on MMP and CTGF/CCN2 expression in a PD model has 
yet to be examined. The LPS model of PD will be used to examine these proteins.  When 
injected into the SNc, LPS induces robust microglial activation followed by specific 
degeneration of DA neurons (32, 84). 
 
Specific Aim 2b:  Measure the effect of LPS on MMP and CTGF/CCN2 expression in 
BV-2 microglia. 
 LPS acts by directly binding to toll-like receptor-4 (TLR4) and the MAC-1 
receptor complex present on the surface of microglia (168).  Therefore, changes in MMP 
and CTGF/CCN2 expression may occur within microglia.  To examine this possibility, 
MMP and CTGF/CCN2 expression was measured after LPS treatment in BV-2 cells.  
The BV-2 cell line is an immortalized murine microglia cell line used to study the 
molecular biology of microglial activation. 
 
Successful completion of these specific aims will provide important information 
regarding the role of MMPs and CTGF/CCN2 in the self-sustaining neurotoxic cycle 
hypothesized to drive chronic DA neurodegeneration in PD.  In addition, the MMP 
response to both neurotoxin and inflammation-induced neurodegeneration will be 
elucidated. 
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CHAPTER 3 
The Effect of 6-Hydroxydopamine on Matrix Metalloproteinase 
Expression in SH-SY5Y Cells and Hemi-parkinsonian Rats 
 
3.1 Introduction 
 PD is the second most common neurodegenerative disorder, currently affecting 
more than 4 million individuals throughout the world’s 10 most populous nations (53).  
The cardinal motor symptoms of PD, including resting tremor, rigidity, and bradykinesia, 
result from striatal dopamine depletion caused by progressive degeneration of 
nigrostriatal DA neurons (135).  Its greatest risk factor is age with both genetic and 
environmental factors contributing to disease onset (34, 195).  To date, no cure exists for 
PD and current treatments target disease symptoms while having no effect on the 
underlying pathological mechanisms that drive disease progression.  A better 
understanding of PD pathogenesis is required for the development of neuroprotective 
therapeutic strategies aimed at slowing or even arresting disease progression. 
 Accumulating evidence suggests that MMPs play an important role in PD 
pathogenesis.  MMPs are zinc-dependent endopeptidases that degrade components of the 
ECM, shed important cell signaling regulators from plasma membranes, and release 
growth factors and cytokines sequestered within the ECM (33, 136, 152).  With a wide 
range of targets, MMPs can exert control over many important physiological processes
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including wound healing, bone growth, cell migration, and angiogenesis (152); however, 
excessive proteolytic activity can contribute to a variety of disease processes, such as 
plaque disruption in advanced stages of atherosclerosis, cartilage destruction associated 
with rheumatoid arthritis, and BBB leakage characteristic of multiple sclerosis and 
reperfusion injury following stroke (3, 156, 184).  In a postmortem PD study, increased 
MMP-1 and MMP-9 expression was detected in SNc samples in a subset of patients 
(127).  In addition, MMP-9 expression was increased in striatal and nigral tissue samples 
following MPTP-induced DA neurodegeneration in mice (128).  In this same model, 
transient increases in striatal MMP-2 expression were detected (128).  Importantly, MMP 
inhibition with the broad spectrum MMP inhibitor Ro-282653 protected DA neurons 
from MPTP-mediated neurotoxicity (128), suggesting that MMPs may be an attractive 
therapeutic target in PD. 
 In this chapter, two models will be used to study the MMP response to the DA 
neurotoxin 6-OHDA: the in vitro human SH-SY5Y cell model and the in vivo 
hemiparkinsonian rat model.  SH-SY5Y cells are a human neuroblastoma cell line that 
express TH and DAT, synthesize dopamine, and display sensitivity to DA-specific 
neurotoxins, including 6-OHDA (36, 189, 213).  Due to these properties, SH-SY5Y cells 
are commonly used to study events associated with DA neurodegeneration.  Moreover, 
changes in MMP expression in response to DA neurotoxicity have yet to be studied in a 
human DA neuronal model.    
 Hemi-parkinsonian rats will be generated with a triple intrastriatal injection of 6-
OHDA.  Like dopamine, 6-OHDA cannot cross the BBB and must be injected directly 
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into the brain (10).  Typically, 6-OHDA is injected unilaterally to create a hemi-
parkinsonian lesion in which the nigrostriatal tract ipsilateral to the injection site is 
lesioned, while the contralateral side remains intact, serving as an internal control when 
examining protein expression.  Intrastriatal injection of 6-OHDA triggers retrograde 
degeneration of DA terminals (Figure 3.1).  The protocol used in these studies generates a 
lesion which leaves the ventral tegmental DA neurons intact, while nigral DA neuronal 
loss approaches 60% and striatal dopamine depletion reaches 70% (109).  This relatively 
mild lesion models the extent of nigrostriatal damage present during the early 
symptomatic phase of PD (109).   
 Three key observations suggest that MMPs may play an important role in DA 
neurodegeneration in response to 6-OHDA injection.  First, two other DA-specific 
neurotoxins, MPTP and BH4, induce MMP-3 expression in dying DA neurons in vitro 
(37, 108).  MPTP-induced MMP-3 expression was critical for generation of the activated 
microglial response in mixed-mesencephalic cultures, supporting that MMP-3 could 
serve as a microglial activating factor (106).  Data from BH4-induced MMP-3 expression 
suggested that MMP-3 could contribute to DA neurodegeneration through novel 
intracellular mechanisms (37).  These studies suggest that MMP release may be an 
important characteristic of DA neurons once exposed to neurotoxic insults.  Second, 
injection of 6-OHDA anywhere along the nigrostriatal tract results in focal disruption of 
the BBB concentrated around areas of active neurodegeneration both in the striatum and 
SNc, indicating that BBB dysfunction may contribute to nigrostriatal degeneration (31, 
43).  MMPs are well known for their ability to disrupt the BBB in models of stroke.  
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FIGURE 3.1: Unilateral 6-OHDA Model of Parkinson’s Disease 
Unilateral intrastriatal 6-OHDA causes selective DA degeneration that proceeds in a 
retrograde fashion with severe dopamine depletion in the injected striatum completed 
prior to cell soma degeneration in the SNc.  The contralateral nigrostriatal tract remains 
intact. 
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They contribute to BBB leakage through degradation of the ECM forming the basal 
lamina and cleavage of tight junction proteins located between capillary endothelial cells 
(27, 188, 240).  Astrocyte-derived MMP-2, pericyte-derived MMP-3, and neutrophil-
derived MMP-9 all coordinate BBB disruption in response to reperfusion injury 
following cerebral ischemia (27, 183).  Third, several immunohistochemical studies have 
identified activated microglia in the SNc and striatum following 6-OHDA administration 
(31, 41, 193, 215).  Activated microglia have been recognized as important sources for 
MMP-3 in vascular dementia and rodent models of stroke (79, 187, 208).  In addition, 
primary microglia cultures release large amounts of MMP-9 upon LPS-induced activation 
(237).   
 The goals for experiments executed in this chapter were as follows: 1) determine 
the 6-OHDA dose-response relationship and time-dependent effect on SH-SY5Y cell 
viability; 2) examine the temporal effect of 6-OHDA on MMP mRNA expression in SH-
SY5Y cells in order to identify MMPs released by stressed SH-SY5Y that could mediate 
6-OHDA neurotoxicity; 3) characterize the 6-OHDA neurodegenerative response in vivo 
by elucidating the time course for striatal and nigral TH depletion; (4) measure the 
temporal protein expression and activation profile of striatal and nigral MMP-2, -3, -9, 
and -13; and (5) correlate changes in MMP expression and activation with DA 
neurodegeneration assessed by depletion of TH protein expression.  These experiments 
will identify other MMPs that could serve as candidate microglial activating factors and 
will determine if a direct nigrostriatal tract neurotoxic insult entails upregulation and 
activation of MMPs.    
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3.2 Materials and Methods 
 Materials.   Human SH-SY5Y neuroblastoma cells were purchased from ATCC 
(Manassas, VA).  Ketamine (100mg/mL), xylazine (100mg/mL), and buprenorphine 
(0.3mg/mL) were obtained from the central pharmacy at Main Hospital, Medical College 
of Virginia campus.  Pentobarbitol was supplied in a Euthasol formulation (390mg/mL) 
by the Department of Animal Resources, Virginia Commonwealth University.  
DMEM/F-12, Penicillin/streptomycin, phosphate-buffered saline (PBS), 0.25% trypsin-
EDTA, 0.4% trypan blue, TRIzol reagent, 4-12% polyacrylamide 10 and 15-well Bis-Tris 
gels, 0.45µm nitrocellulose membranes, sample reducing agent, LDS sample buffer, MES 
running buffer, antioxidant solution, and western blot transfer buffer were acquired from 
Invitrogen Corp. (Carlsbad, CA).  Millex sterile syringe filters, mouse anti-rat TH (Cat# 
MAB318), goat anti-mouse MMP-13 (Cat# AB8120), and rabbit anti-human cyclophilin-
A (Cat# 07-313) were procured from Millipore (Billerica, MA).  Culture flasks and 
plates, chloroform, 2-propanol, sterile drapes, No. 3 scalpel blades, bone wax, 4-0 
chromic gut sutures, 10% povidone/iodine solution, alcohol prep pads, coronal small 
rodent brain matrix, cutting mat, brain matrix razor blades, sodium dodecyl sulfate 
(SDS), NaCl, Tween-20, deoxycholic acid, Tris-HCl, and bovine serum albumin (fraction 
V) were purchased from Fisher Scientific (Pittsburgh, PA).  6-hydroxydopamine-HCl 
(Cat # H4371-100MG), L-ascorbic acid, diethyl pyrocarbonate (DEPC), and NP-40 were 
obtained from Sigma-Aldrich (St. Louis, MO).  Fetal bovine serum (FBS) was secured 
from Gemini Bio-products (West Sacramento, CA).  Goat anti-mouse MMP-2 (Cat# 
AF1488) and goat anti-mouse MMP-9 (Cat# AF909) were obtained from R&D Systems, 
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Inc. (Minneapolis, MN).  Goat anti-human MMP-3 (Cat# ab18898) and full length 
recombinant mouse MMP-9 were purchased from Abcam, Inc. (Cambridge, MA).  Goat 
anti-mouse IgG-HRP and goat anti-rabbit IgG-HRP were purchased from Rockland 
Immunochemicals, Inc. (Gilbertsville, PA).  Bovine anti-goat IgG-HRP (Cat# sc-2350) 
was procured from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).  SuperSignal West 
Dura extended duration HRP substrate solution was obtained from Pierce (Rockford, IL).  
Enhanced Chemiluminescence HRP substrate solution was purchased from GE 
Healthcare (United Kingdom).  Protease inhibitor cocktail was purchased from 
Calbiochem (San Diego, CA).  Absolute ethanol was purchased from AAPER Alcohol 
and Chemical Company (Shelbyville, KY).  RQ1 Dnase kit was purchased from Promega 
Corp. (Madison, WI).  Universal human reference RNA was obtained from Stratagene 
(Cedar Creek, TX).  Non-fat dry milk was bought from The Kroger Co. (Cincinnati, OH).  
Methanol was purchased from Colonial Scientific, Inc. (Richmond, VA). 
 SH-SY5Y Cell Culture.  Human SH-SY5Y neuroblastoma cells were maintained 
in DMEM/F-12 supplemented with 10% FBS, 100U/mL penicillin, and 100µg/mL 
streptomycin.  Cells were passed regularly as needed and spent media was refreshed 
twice weekly.  Only cells from passages 7-11 were used for cell viability and real-time 
PCR experiments.  For cell viability measurements, cells were plated at a density of 
20,000 cells/cm2 in T25 flasks.  For Real-time PCR experiments, cells were plated at a 
density of 30,000 cells/cm2 in T25 flasks to increase RNA yield.  Prior to 6-OHDA 
treatment, serum was reduced to 5% FBS for 24 hours, then to 2% FBS for 24 hours, and 
finally to 0.5% FBS for 24 hours.   
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 6-OHDA Treatment.  All 6-OHDA preparations were made immediately prior to 
use.  6-OHDA was dissolved in 2mg/mL ascorbic acid prepared in PBS to make a 10mM 
stock solution.  This solution was sterilized by passage through a syringe filter containing 
0.45µm diameter pores.  Ascorbic acid is included in the vehicle solution in order to 
minimize oxidative degradation of 6-OHDA prior to addition to cell cultures.  To 
formulate treatment media, sterile 6-OHDA stock solutions were diluted to 15, 30, 45, 60, 
75, or 90µM directly in DMEM/F-12 containing 0.5% FBS.  Vehicle media contained the 
appropriate volume of 2mg/mL ascorbic acid.   
 Trypan Blue Exclusion Cell Viability Assay.  Treatment media was aspirated 
and saved.  Cultures were washed twice with PBS and washes were combined with saved 
treatment media so that all detached cells were collected.  Remaining attached cells were 
incubated in 1.5mL 0.25% trypsin-EDTA for 5-15 minutes at 37°C and then were made 
into a single cell suspension by passing them through a 1mL pipet tip 50 times.  The 
trypsin reaction was stopped with 2mL 10% FBS in DMEM/F-12.  Cells were combined 
with saved treatment media and were centrifuged for 6 minutes at 1000 rpm.  Supernatant 
was discarded and cell pellet was resuspended in 300µL serum free DMEM/F-12.  Cell 
suspension aliquots (100µl) were combined 1:1 with 0.4% trypan blue.  After 3 minutes, 
unstained viable cells were counted in both chambers of a brightline hemocytometer with 
improved Neubauer ruling (Hausser Scientific, Horsham, PA).  The total number of 
viable, dye excluding cells in each culture was calculated with the following equation: 
Total viable cells = (a/b)*cd 
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where ‘a’ is equal to the number of viable cells per mm2, ‘b’ is equal to the total volume 
of the counted area (10-4cm3), ‘c’ is equal to the dilution factor (2), and ‘d’ is equal to the 
total volume of cell suspension. 
 RNA Extraction and Quantitative Real-Time RT-PCR.  SH-SY5Y RNA was 
extracted with TRIzol reagent following the manufacturer’s instructions.  Briefly, cells 
grown and treated in T25 flasks were incubated in 1mL TRIzol reagent for 5 minutes to 
lyse the cells.  Cells were scraped and the homogenate was transferred to a 1.5mL 
microcentrifuge tube.  Chloroform (200µL) was added and samples were mixed 
vigorously for 15 seconds and then were incubated at room temperature for 2.5 minutes.  
Samples were centrifuged at 12,000 x g for 15 minutes at 4°C.  The aqueous phase was 
saved and RNA was precipitated with the addition of 500µL 2-propanol and subsequent 
incubation at room temperature for 10 minutes.  RNA was pelleted by centrifugation at 
12,000 x g for 15 minutes at 4°C.  Supernatant was discarded and RNA pellet was gently 
washed with 75% ethanol and centrifuged at 7,500 x g for 5 minutes at 4°C.  Supernatant 
was discarded; pellet was dried, resuspended in DEPC-treated nanopure water, and 
heated to 57°C for 10 minutes to ensure complete dissolution.  RNA concentration and 
purity was determined by measuring A260/A280 on the Ultrospec 2000 UV/visible 
spectrophotometer (GE Healthcare, UK).  RNA samples were treated with RQ1 Dnase.  
Dnase reactions were carried out at 37°C for 30 minutes.  Reaction was terminated with 
addition of RQ1 Dnase stop solution and subsequent heating to 65°C for 10 minutes.  
Dnase-treated RNA samples were sent to the Nucleic Acid Core Facility at Virginia 
Commonwealth University for quantitative real-time PCR measurements.  TaqMan 
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primer and probe sequences were designed by this core facility for MMP-2, -3, -7, -9, -
13, -14, -15, and -24.  Measurements were made using the ABI Prism 7900 Sequence 
Detection System (Applied Biosystems, Carlsbad, California).  Cyclophilin-A expression 
was used as the endogenous control, while total human reference RNA was used as the 
positive control for MMP expression and to construct standard curves used to quantify 
MMP expression.   
 Surgical Procedures.  Twenty-three adult male Sprague-Dawley rats (250-350g) 
were housed individually in an AAALAC accredited (#00036), USDA registered (#52-R-
007), and PHS approved (#A-3281-01) animal facility.  Room temperature and humidity 
were kept constant, a 12-hour light/dark cycle was maintained, and food and water were 
available ad libitum.  Rats were monitored by qualified animal technicians throughout the 
studies and were examined daily after surgery to check for weight loss, lethargy, 
periorbital crusting or bleeding, and gait.  If deficits were observed, appropriate measures 
were taken to alleviate pain and suffering.  All experiments were carried out in 
accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals and were approved by the Institutional Animal Care and Use 
Committee of Virginia Commonwealth University. 
 Immediately prior to intrastriatal injection of 6-OHDA, rats were anesthetized 
with ketamine/xylazine (100mg/kg/10mg/kg, i.p.).  Hair was removed from the scalp and 
the surgical area was cleaned with alternating povidone/iodine antiseptic and alcohol 
washes.  After the rat was draped and mounted onto the rodent stereotaxic frame (Kopf 
Instruments, Tujunga, CA), a single incision was made through the skin along the 
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rostrocaudal length of the scalp using a No.10 scalpel blade attached to a No. 3 handle.   
Three injections were made into the DA terminal region of the right striatum along its 
rostrocaudal axis using the following coordinates in relation to Bregma (in mm):  AP 
+1.0, ML -3.0, DV -5.0; AP -0.1, ML -3.7, DV -5.0; and AP -1.2, ML -4.5, DV -5.0 
(109).  At each site, a burr hole was drilled and 10µg of 6-OHDA (2µl of 5µg/µl) or 
ascorbic acid (2µl of 2mg/mL) was delivered with a 10µl Hamilton syringe fitted with a 
26-guage needle.  The needle was held in place for 5 minutes prior to injection.  Flow 
rate (1µl/min) was kept constant with a motorized syringe pump (BASi, West Lafayette, 
IN).  Five minutes after the conclusion of the injection, the needle was slowly removed to 
prevent fluid backflow through the needle track (quarter turn per 10 seconds).  Burr holes 
were filled with bone wax and the wound was sutured closed.  Body temperature was 
maintained at 37°C throughout the duration of the surgery with a homeothermic blanket 
(Harvard Instruments, Holliston, MA) and post-operative pain was managed with 
buprenorphine (0.02mg/kg) injected in 12 hour intervals during the first 48 hours post-
surgery.  Rats were kept under a heat lamp until recovered from anesthesia.  Based on 
previous studies, it is expected that the lesion will result in a 60-70% loss of nigral DA 
neurons after 3 weeks (109). 
 Protein Extraction.  Rats were euthanized with pentobarbital (150mg/kg, i.p.) 
followed by rapid decapitation 1, 5, 10, and 21 days post-surgery.  Brains were rapidly 
removed and placed ventral-side up in a rat brain matrix.  Two 2mm thick coronal tissue 
blocks were cut through the striatum and a single 2mm coronal tissue block was cut 
through the midbrain using brain matrix razor blades (Figure 3.2).  Tissue blocks were 
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transferred to the cutting mat, which was kept cold with an ice pack.  Ventral midbrain or 
striatum was dissected, cut through the midline to separate ipsilateral and contralateral 
tissue, and immediately placed in 1.5mL microcentrifuge tube containing 100µl (300µl 
for striatum) ice-cold protein extraction buffer (50mM Tris-HCl pH 7.2, 150mM NaCl, 
1% sodium deoxycholate, 1% NP-40, 0.5% SDS) with an added protease inhibitor 
cocktail.  Tissue chunks were homogenized with microcentrifuge tube pestles and 
homogenates were centrifuged at 14,000 x g for 30 minutes at 4°C.  Supernatants were 
saved and stored at -80°C until use.   
 Western Blot.  Sample protein concentrations were determined with the DC 
protein assay (Bio-Rad Laboratories, Hercules, CA) using bovine serum albumin 
solutions to construct the standard curve.   LDS sample buffer and sample reducing agent 
were added to samples (40µg for MMP blots, 5µg for TH blots).  Samples were heated to 
70°C for 10 minutes, loaded on 4-12% polyacrylamide Bis-Tris gels, separated by SDS-
PAGE (50 minutes at 200V), and transferred to nitrocellulose membranes (2 hours at 
30V).  All western blots used for MMP-13 detection were run under non-reducing 
conditions (all procedures are identical to reducing conditions except that reducing agent 
was omitted from the sample preparation and antioxidant was not added to the running 
buffer).  Membranes were blocked for 1 hour in 5% non-fat dry milk prepared in tris-
buffered saline containing 0.05% Tween-20 (TBST).  Membranes were incubated in TH, 
MMP-2, MMP-3, MMP-9, or MMP-13 primary antibody overnight at 4°C.  Membranes
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FIGURE 3.2: Methods for Obtaining Striatal and Ventral Midbrain Tissue Samples 
Two striatal tissue blocks were cut, each 2mm thick (top and middle coronal sections).  
Tissue block was cut just anterior to the anterior commisure to eliminate the ventral 
cortex.  Next, a cut was made along the medial border of the lateral ventricles to remove 
basal forebrain tissue.  This cut also served to separate injected and contralateral striata.  
Then, striatum was carefully pulled away from the corpus collosum at the lateral and 
anterior border of the striatum.  A single 2mm thick tissue block containing midbrain 
tissue was collected (bottom coronal section).  A large artery on the ventral surface of the 
midbrain was removed, and the section was cut in half through the midline to separate 
injected and contralateral midbrain.  Ventral midbrain was cut just anterior to the anterior 
gray/white border separating the substantia nigra from the medial lemniscus. 
Substantia Nigra
Striatum
Striatum
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were washed 4 x 5 minutes in TBST.  Membranes were incubated in goat anti-mouse 
IgG-HRP or bovine anti-goat IgG-HRP secondary antibody for 90 minutes at room 
temperature and then were washed an additional 6 times in TBST.  MMP 
immunoreactivity was visualized with SuperSignal West Dura substrate followed by 
exposure to film.  Membranes were stripped and reprobed with cyclophilin-A primary 
antibody followed by goat anti-rabbit IgG-HRP.  For detection of cyclophilin-A and TH 
immunoreactivity, visualization was accomplished with Enhanced Chemiluminescence 
substrate followed by exposure to film.  To quantify protein expression, digital images of 
developed film were obtained using GeneSnap image acquisition software (version 6.07) 
connected to the G-Box CCD camera (Synoptics, Cambridge, England).  Background-
corrected immunoreactive band densities were measured using GeneTools software 
(version 3.06, Synoptics, Cambridge, England). MMP and TH immunoreactivity was 
normalized to cyclophilin-A, which served as the loading control.  
 Statistical Analysis. All statistical tests were performed using JMP software 
(version 7.0).  Cell viability dose response and time-dependent experiments were 
analyzed with one-way ANOVA (α=0.05), followed by the Tukey-Kramer post-hoc test, 
which was used to determine where significant differences in the data resided.  Similarly, 
temporal changes in MMP mRNA expression in 6-OHDA-treated SH-SY5Y cells were 
analyzed by one-way ANOVA (α=0.05), followed by the post-hoc Tukey-Kramer test.  
MMP-2 and TH protein densitometry data was analyzed by ANOVA using a two-way 
design, where treatment (ascorbic acid or 6-OHDA) and time points (1, 5, and 10 days) 
were the independent variables.  The post-hoc Tukey-Kramer test was performed when a 
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significant overall model and independent variable interaction effect was detected.  Data 
is presented as the mean ± standard error of the mean. 
 
3.3 Results 
 SH-SY5Y Experiments.  The sensitivity to 6-OHDA, a selective 
catecholaminergic neurotoxin was measured in SH-SY5Y cells.  To establish the dose-
reponse relationship, cells were treated with 0, 15, 30, 45, 60, 75, or 90µM 6-OHDA.  
Cell viability was assayed by the trypan blue exclusion method 24 hours after treatment 
(Figure 3.3).  As expected, 6-OHDA treatment induced a dose-dependent decrease in cell 
viability (F=53.8, p<0.001) with an LD50 dose of 37.6 ± 6.82µM.  Based on the dose 
response experiments, 45µM 6-OHDA treatments were used for all subsequent 6-OHDA 
experiments with the expectation that this dose would drop the number of viable cells to 
35.5 ± 10.3% of ascorbic acid-treated cells.  This loss is comparable in magnitude to DA 
degeneration associated with the intrastriatal 6-OHDA model (109).  The time course for 
6-OHDA-induced reduction in cell viability was measured to determine the optimum 
time points for subsequent real-time PCR experiments.  SH-SY5Y cell viability was 
measured following treatment with 45µM 6-OHDA for 0, 3, 6, 12, 24, 48, and 96 hours 
after 6-OHDA treatment (Figure 3.4).  6-OHDA treatment induced a significant time-
dependent decline in cell viability (F=52.7, p<0.001).  The decline in cell viability 
occurred entirely between 6 and 24 hours, dropping from 102 ± 7.23% at 6 hours to 30.1 
± 0.16% at 24 hours.  The total number of viable cells remained fairly stable at later time 
points (27.0 ± 1.15% at 96 hours).  
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FIGURE 3.3: 6-OHDA Dose Response Curve 
Cells were treated with 0-90µM 6-OHDA for 24 hours prior to cell viability 
measurements using the trypan blue exclusion assay.  6-OHDA treatment caused a dose-
dependent decline in SH-SY5Y cell viability (p<0.001; LD50=37.6 ± 6.82µM).  Asterisks 
denote significance compared to untreated control as determined by post-hoc Tukey-
Kramer test.  Data presented as the mean ± standard error of the mean from 4 
independent experiments.   
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FIGURE 3.4: Time-dependent 6-OHDA Toxicity in SH-SY5Y Cells  
SH-SY5Y cells were treated with 45µM 6-OHDA for 0-96 hours prior to measuring cell 
viability with the trypan blue exclusion assay.  6-OHDA induced a time-dependent loss 
of cell viability (p<0.001).  Viability remained stable over the first 6 hours following 
treatment and then sharply declined between 6-24 hours.  No significant decline in cell 
viability occurred between 24 and 96 hours.  Asterisks denote significance compared to 0 
hour time point as determined by post-hoc Tukey-Kramer test.  Data presented as the 
mean ± standard error of the mean from 2 independent experiments.   
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 Following establishment of the dose-response and time line for 6-OHDA toxicity 
in SH-SY5Y cells, the effect of 6-OHDA on MMP mRNA expression was measured.  
Cells were treated with 45µM 6-OHDA for 0, 2, 4, 6, and 8 hours.  RNA was extracted at 
each time point, samples were Dnase-treated, and then MMP-2, -3, -7, -9, -13, -14, -15, 
and -24 mRNA was measured by quantitative real-time PCR using TaqMan primers. 
Cyclophilin-A mRNA expression served as the internal control and all MMP mRNA 
quantities were normalized to this gene.   These time points were chosen based on the 
hypothesis that MMPs contribute to SH-SY5Y cell death induced by 6-OHDA.  It was 
reasoned that if MMPs were involved in this process, then mRNA expression would 
increase just prior to the steep decrease in cell viability.  The 8 hour time point was 
chosen as the final time point because cell detachment, indicative of cell death, had 
started by this time.  MMP-3, -7, -9, and -24 were not detected at any time point 
examined.  These transcripts were detected in control human reference RNA standards, 
indicating that the primer and probes were functional.  SH-SY5Y cells displayed basal 
mRNA expression levels of MMP-2, -13, -14, and -15.  MMP-2 was the most abundant 
MMP detected, but 6-OHDA treatment did not result in changes in expression at any time 
point (Figure 3.5A; F=1.3, p=0.30).  Similarly, MMP-14 and MMP-15 mRNA did not 
change in response to 6-OHDA (Figure 3.5C and D; F=2.96, p=0.055 and F=0.19, 
p=0.94, respectively).  In contrast, 6-OHDA induced a significant increase in MMP-13 
mRNA expression (Figure 3.5B; F=6.2, p=0.003).  MMP-13 mRNA increased 2.7 fold at 
8 hours compared to basal expression levels.  The correlation between the start of SH-
SY5Y cell viability decline and the temporal increase in MMP-13 mRNA expression  
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FIGURE 3.5: Effect of 6-OHDA on MMP mRNA Expression in SH-SY5Y Cells 
Cells were treated with 45µM 6-OHDA for 0-8 hours, covering the time points leading 
up to the sharp drop in cell viability.  RNA was extracted at each time point and samples 
were sent to the real-time PCR core facility at Virginia Commonwealth University for 
measurement of MMP-2, -3, -7, -9, -13, -14, -15, and -24.  MMP-3, -7, -9, and -24 were 
not detected at any time point.  A)  MMP-2 displayed the greatest level of endogenous 
MMP mRNA expression, but was not significantly affected by 6-OHDA treatment 
(p=0.30).  B)  Compared to 0 hours, MMP-13 mRNA increased 2.7-fold 8 hours 
following 6-OHDA treatment (p=0.0034).  The 2-6 hour time points were not 
significantly different from expression at the start of the experiment.  C, D) 6-OHDA 
treatment had no effect on MMP-14 (p=0.055) or MMP-15 (p=0.94) expression.  
Asterisks denote significance compared to 0 hour time point as determined by post-hoc 
Tukey-Kramer test.  Data presented as the mean ± standard error of the mean from 3-5 
independent experiments.   
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suggests that MMP-13 may be an important mediator of 6-OHDA neurotoxicity.  MMP 
protein was not measured due to the requirement that FBS be present in the treatment 
media.  FBS drastically interferes with gel-based methods of protein detection.  To get 
around this issue, future experiments aimed at measuring changes in extracellular protein 
expression in SH-SY5Y cells should use ELISA-based methods. 
 Intrastriatal 6-OHDA Hemi-parkinsonian Rat Experiments.  The previous set 
of experiments used an isolated system, testing the direct effect of 6-OHDA on MMP 
expression in neuronal cells.  The MMP response to 6-OHDA in vivo may differ greatly 
from that seen with the SH-SY5Y model.  For instance, the SH-SY5Y model ignores 
potential important contributions of other cell types, such as microglia and astrocytes.  
Altered expression of various MMPs, including MMP-2, -3, and -9, have been attributed 
to both cell types (27, 183).  The intrastriatal 6-OHDA hemi-parkinsonian rat model was 
studied in an attempt to confirm the 6-OHDA effect on MMP-13 and to determine if 
MMP-2, -3, or -9 expression or activation changed in response to 6-OHDA in vivo. 
 TH is routinely measured to examine the extent of nigrostriatal injury due to its 
selective expression within DA neurons.   In order to verify that the 6-OHDA injection 
protocol used in these experiments produced a nigrostriatal lesion and to elucidate the 
time course of neurodegeneration, TH protein expression was measured by western blot 
1, 5, and 10 days post-surgery.  TH was normalized to cyclophilin-A immunoreactivity to 
correct minor differences in protein loading.  To determine the extent of TH depletion, 
normalized lesioned tissue TH values were expressed as a percentage of the normalized 
contralateral, intact tissue TH values.  As expected, there was a significant overall model  
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effect on TH expression in both the striatum (F=16.6, p<0.001) and SNc (F= 4.94, 
p=0.009).  In the striatum, there was a significant interaction effect detected between 
treatment groups (6-OHDA and vehicle) and time points examined (F=5.6, p=0.017).  
Compared to the contralateral side, ipsilateral striatal TH expression decreased to 31.9 ± 
4.08% at day 5, which progressed to 7.46 ± 3.09% at day 10 in the 6-OHDA group 
(Figure 3.6).  In contrast, TH expression remained unchanged in the ascorbic acid group 
(119.5 ± 6.85% at day 5 and 111.8 ± 6.77% at day 10).   
 In contrast to the striatum, considerable nigral TH depletion was not observed 
until 10 days post-surgery (Figure 3.7).  Compared to the contralateral side, nigral TH 
expression decreased to 57.0 ± 10.1% in the 6-OHDA group, demonstrating that 
intrastriatal injection of 6-OHDA resulted in significant nigral neurodegeneration.  
Ascorbic acid had no effect on TH expression at this time point (95.6 ± 10.8%).  This 
pattern of degeneration is consistent with the expected retrograde neurodegeneration 
response caused by an intrastriatal DA injury (Figure 3.1).    
 The reduction in nigral TH falls short of the expected 66% decrease in the number 
of TH positive nigral neurons reported in the original description of this 6-OHDA model 
(109); however, the 66% measurement was made 3 weeks post-surgery.  To determine if 
nigral TH decline continued to worsen at later time points, a small pilot experiment was 
completed measuring TH protein expression by western blot 21 days post-surgery (Figure 
3.8).  Compared to the contralateral side, TH expression declined to 36% in animals 
injected with 6-OHDA.  This 64% overall reduction in TH closely matches the 66% 
decline published previously (109).  
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FIGURE 3.6: Effect of 6-OHDA on Striatal TH Protein Expression  
TH measurements after intrastriatal 6-OHDA (n=3) or ascorbic acid (vehicle, n=3-4) 
injection.  Cyclophilin-A expression was measured to ensure equal protein loading.  A) 
Representative western blots demonstrating temporal changes in TH expression 
(I=ipsilateral, C=contralateral).  B) TH densitometric analysis in striatal tissue samples.  
Vehicle had no effect on striatal TH expression, whereas, 6-OHDA treatment resulted in 
massive, time-dependent TH depletion.  Asterisks denote significance determined by 
Tukey-Kramer test.  Bars represent mean ± standard error of the mean.  
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FIGURE 3.7: Effect of 6-OHDA on Nigral TH Protein Expression  
TH measurements after intrastriatal 6-OHDA (n=3) or ascorbic acid (vehicle, n=3-4) 
injection.  Cyclophilin-A expression was measured to ensure equal protein loading.  A) 
Representative western blots demonstrating temporal changes in TH expression 
(I=ipsilateral, C=contralateral).  B) TH densitometric analysis in nigral tissue samples.  
Vehicle had no effect on nigral TH expression; however, 6-OHDA treatment resulted in 
time-dependent TH depletion that was evident 10 days post-surgery.  Asterisks denote 
significance determined by Tukey-Kramer test.  Bars represent mean ± standard error of 
the mean.  
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FIGURE 3.8: 6-OHDA-induced Nigral TH Depletion 3 Weeks Post-surgery 
TH measurements 3 weeks after intrastriatal 6-OHDA (n=2) or ascorbic acid (vehicle, 
n=2) injection.  Cyclophilin-A expression was measured to ensure equal protein loading.  
A) Representative western blots demonstrating decreased nigral TH expression at day 21 
(I=ipsilateral, C=contralateral).  B) TH densitometric analysis in nigral tissue samples.  In 
the 6-OHDA treatment group, TH depletion reached 64%.  Bars represent mean ± 
standard deviation.   
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 After examination of TH, temporal MMP-2, -3, -9, and -13 protein expression 
was measured in striatal and nigral tissue samples in order to correlate changes in MMP 
expression with DA neurodegeneration.  ProMMP-2 was detected in all striatal and nigral 
tissue samples, and data was analyzed as described above in the TH experiment.  Overall, 
there was a significant experimental model effect on striatal proMMP-2 expression 
(Figure 3.9; F=4.16, p=0.023); however, there was no time point and treatment group 
interaction effect (F=0.21; p=0.81).  Considering these variables independently, there was 
a significantly time dependent effect on proMMP-2 expression (F=9.89, p=0.004), while 
there was no treatment group effect (F=0.78, p=0.40).  This relationship is readily 
apparent in the representative western blots, which show modest increases in proMMP-2 
expression 5 and 10 days post-surgery in both treatment groups (Figure 3.9A).  These 
results indicate that the time dependent increase in striatal MMP-2 expression was likely 
due to the tissue injury response, rather than any specific toxic effect of 6-OHDA.    
 Similar to the striatum, there was a significant overall model effect on proMMP-2 
expression in SNc tissue samples (Figure 3.10; F=4.9, p=0.013).  There was no 
significant interaction between the time and treatment group variables (F=3.3, p=0.075).  
Despite the apparent lack of an interaction effect, there was both a significant time-
dependent (F=6.01, p=0.017) and treatment-dependent effect (F=5.19, p=0.044) on 
proMMP-2 expression when these variables were considered independently.  When 
examining the densitometry graph (Figure 3.10B), there is an apparent trend towards a 
treatment effect on proMMP-2 expression 5 days post-surgery.  Compared to the 
contralateral side, proMMP-2 expression increased to 199.3 ± 24.6% in the 6-OHDA 
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FIGURE 3.9: Effect of 6-OHDA on Striatal MMP-2 Protein Expression  
MMP-2 measurements after intrastriatal 6-OHDA (n=2-3) or ascorbic acid (vehicle, n=3-
4) injection.  Cyclophilin-A expression was measured to ensure equal protein loading.  A) 
Representative western blots demonstrating temporal changes in proMMP-2 expression 
(I=ipsilateral, C=contralateral).  B)  ProMMP-2 densitometric analysis in striatal tissue 
samples.  Both 6-OHDA and ascorbic acid induced a time-dependent increase in 
proMMP-2 expression.  There was no difference in the magnitude of this effect between 
the two treatment groups.  Bars represent mean ± standard error of the mean. 
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FIGURE 3.10: Effect of 6-OHDA on Nigral MMP-2 Protein Expression  
MMP-2 measurements after intrastriatal 6-OHDA (n=2-3) or ascorbic acid (vehicle, n=3-
4) injection.  Cyclophilin-A expression was measured to ensure equal protein loading.  A) 
Representative western blots demonstrating temporal changes in proMMP-2 expression 
(I=ipsilateral, C=contralateral).  B)  ProMMP-2 densitometric analysis in nigral tissue 
samples.  ProMMP-2 expression significantly increased in response to 6-OHDA, but the 
effect was not time-dependent, despite the apparent increase at day 5.  This is likely due 
to small sample size (n=3).  Bars represent mean ± standard error of the mean.   
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group.  In contrast, proMMP-2 expression did not appear different from 100% (121.6 ± 
14.82%).  When the post-hoc Tukey-Kramer test is applied to this data, a significant 
difference is detected between the treatment groups 5-days post-surgery; however, since 
no treatment/time interaction effect was detected with the two-way ANOVA (p=0.07), it 
cannot be said with certainty that these groups are different.  An increased sample size is 
needed in order to determine for sure if there is a 6-OHDA effect on nigral proMMP-2 
expression 5 days post-surgery.  Regardless if there is an increase in proMMP-2 or not, 
no activated MMP-2 protein was detected on nigral western blots, suggesting that MMP-
2 is not involved in nigral neurodegeneration.   
 Pro and active MMP-3 was undetectable in both striatal and nigral tissue samples 
from the 6-OHDA treatment group (Figure 3.11A).  In chapter 4, proMMP-3 expression 
is described at 60kDa.  One sample from the chapter 4 experiments was included here as 
a positive control to demonstrate where proMMP-3 should appear on the western blot.  
The 60kDa proMMP-3 band was not present in any sample; however, a slightly lower 
molecular weight band was detected in most striatal and nigral tissue samples.  Curiously, 
several intense immunoreactive bands were detected specifically in day 10 striatal and 
nigral samples, but the molecular weights were all 62kDa or greater.  In addition to 
MMP-3, striatal and nigral tissue samples lacked proMMP-9 (Figure 3.11B).  In all 
samples, a faint 100kDa immunoreactive band was detected which was higher than the 
molecular weight of mouse recombinant proMMP-9, which appears at 92kDa.  This band 
was not affected by injection of 6-OHDA.  In contrast to MMP-3 and MMP-9, proMMP-
13 protein was detected at all time points in both striatal and nigral tissue samples;  
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FIGURE 3.11: Effect of 6-OHDA on Striatal and Nigral MMP-3, -9, and -13 Protein 
Expression.  MMP protein measurements after intrastriatal 6-OHDA injection.  
Cyclophilin-A expression was measured to ensure equal protein loading (I=ipsilateral, 
C=contralateral).  A) ProMMP-3 expression was not detected at any time point in striatal 
or nigral tissue samples. LPS=nigral sample from intranigral LPS experiments (chapter 
4), which was used as a positive control for proMMP-3 expression.  The intense 
immunoreactivity detected in the day 10 samples was greater than 62kDa.  A faint band 
just below 60kDa was detected in all striatal samples and most nigral samples.  B)  
ProMMP-9 was not detected in any sample from 6-OHDA or vehicle group.  Faint 
immunoreactivity was typically present around 100kDa, which is larger than proMMP-9.  
The rMMP-9 lane consisted of 12.5ng recombinant mouse MMP-9, which was used as 
the positive control.  C)  ProMMP-13 was detected in all samples at all time points; 
however, 6-OHDA appeared to have no affect on protein expression.    
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however, within the 6-OHDA group ipsilateral proMMP-13 expression did not appear to 
change compared to contralateral samples within each time point (Figure 3.11C).  
 
3.4 Discussion 
 Based on emerging data identifying potentially important functions for MMP-3 in 
DA neurodegeneration in vitro in response to MPTP and BH4 (37, 106), it was 
hypothesized that the degenerative response to 6-OHDA also involved upregulation and 
activation of MMPs.  Significant time-dependent DA neurotoxicity was confirmed in 
each 6-OHDA model by cell viability measurements for the SH-SY5Y studies and by TH 
western blot measurements for the in vivo experiments.  Several key MMPs were 
examined in both models following 6-OHDA treatment.  In SH-SY5Y cells, MMP-13 
mRNA expression increased 8 hours after 6-OHDA treatment, suggesting that MMP-13 
could serve an important function in 6-OHDA-mediated neurotoxicity.  However, in an 
attempt to confirm this effect in vivo, striatal and nigral MMP-13 protein expression 
failed to change 1, 5, or 10 days post-6-OHDA injection.  In contrast to MMP-13, MMP-
2 mRNA expression did not change in 6-OHDA treated SH-SY5Y cells, while striatal 
proMMP-2 protein expression increased in a time-dependent fashion due to tissue injury 
caused by multiple needle insertions into the brain.  In addition, nigral proMMP-2 
expression trended towards an increase in the 6-OHDA group 5 days post-surgery, but no 
active MMP-2 was detected at any of the three time points.  Interesting, MMP-3 and 
MMP-9 were not detected in response to 6-OHDA in either model.  Contrary to MPTP 
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and BH4 PD models, these studies suggest MMPs are likely not involved in 6-OHDA 
mediated DA neurotoxicity.  
 6-OHDA Neurotoxicity.  The first goal of these studies was to define the 
neurodegeneration time course following 6-OHDA treatment in SH-SY5Y cells and 
hemi-parkinsonian rats.  In SH-SY5Y experiments, cell viability remained stable over the 
first 6 hours after treatment and then dropped significantly, reaching a maximum of 
64.5% depletion by 24 hours.  This data agrees with previous experiments examining the 
6-OHDA-induced decline in SH-SY5Y cell viability (213).  Based on this time course, 
MMP mRNA expression was measured 0-8 hours after 6-OHDA treatment to assess 
expression at time points leading up to cell death.   
 The 6-OHDA lesion protocol employed in these studies was first described by 
Kirik et al., (109); however, detailed analysis of the neurodegeneration time course in this 
specific model was lacking.  In a similar model which distributed 6-OHDA over 4 sites 
within the striatum, significant loss of striatal TH expression was evident 3 days post-
surgery, with almost complete TH depletion present at day 10 (41).  Significant loss of 
TH+ neurons in the SNc progressed from 20% at day 3, to 50% at day 10, and then to 
80% by day 21 (41).  The time course described in that study closely matches the 
temporal TH decline observed with the triple intrastriatal 6-OHDA injection used in the 
current study.  With this protocol, over 90% of striatal TH and 47% of nigral TH 
expression was eliminated 10 days post-surgery.  The maximum extent of nigral injury 
reached 3 weeks post-surgery was 16% less with the triple striatal injection than the 
quadruple injection protocol (41); however, the 64% loss in nigral TH observed in the 
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current study, agrees with the initial description of the triple intrastriatal injection, which 
found that 66% of nigral DA neurons were lost by this time point (109).  Based on these 
results, it is clear that active DA neurodegeneration is occurring at the time points 
examined, making them appropriate times to examine temporal changes in MMP 
expression in response to 6-OHDA-mediated neurotoxicity. 
 Effect of 6-OHDA on MMP-3 Expression.  Previous studies have shown that 
MPTP increases MMP-3 expression in DA neurons present in neuronal cultures derived 
from mouse mesencephalic tissue (106).  Based on this, it was expected that 6-OHDA 
would induce MMP-3 expression in SH-SY5Y cells; however, this did not occur.  No 
MMP-3 was detected in either untreated or 6-OHDA-treated SH-SY5Y cells.  MMP-3 
mRNA was detected in both total human reference RNA and U251 cells (data not shown) 
confirming that the primer and TaqMan probe set was appropriately designed.  
Examination of the SH-SY5Y cell karyotype reveals that no chromosome abnormalities 
are associated with the location of the MMP-3 gene (209), eliminating the possibility that 
deletions, insertions, or rearrangements of chromosome 11 as the cause for the lack of 
MMP-3 expression in these cells.  In addition, MMP-13, which is also located on 
chromosome 11, was detected in these studies.  Species differences may explain the 
results obtained.  This study is the first to examine MMP-3 expression in response to a 
DA-specific neurotoxin in a human model of PD.  The investigations mentioned earlier 
were carried out in various rodent models (37, 106, 108).   
 Similar to the SH-SY5Y model, in vivo administration of 6-OHDA failed to 
induce MMP-3 expression or activation, suggesting that species differences do not 
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account for the different MMP-3 responses between 6-OHDA and MPTP models.  The 
inability of 6-OHDA to induce MMP-3 in two separate PD model systems strongly 
indicates that elevated MMP-3 is not a general response to DA neurotoxicity, but rather is 
neurotoxin-specific.  Differences between the direct neurotoxic mechanisms initiated by 
MPTP and 6-OHDA most likely account for this discrepancy.  Both models typically are 
used such that the lesion produced develops acutely, which appears to rely on generation 
of high levels of oxidative stress (10).  A key difference may involve the mechanisms 
responsible for elevating oxidative stress within DA neurons.  In MPTP-mediated 
neurotoxicity, its metabolite MPP+ is selectively taken up by DA neurons, which then 
specifically targets complex I of the mitochondrial electron transport chain, resulting in 
increased superoxide production and fatal disruption of mitochondrial energetics (117, 
175, 213).  In comparison, 6-OHDA gains entry into DA neurons via identical transport 
mechanisms and has also been shown to inhibit complex I in isolated mitochondria; 
however, 6-OHDA autooxidation rapidly occurs in the presence of molecular oxygen 
resulting in the formation of quinones, which do not inhibit mitochondrial respiration (10, 
72, 73, 192), suggesting that 6-OHDA may be metabolized before it is presented with the 
opportunity to bind to complex I (213).  Rather than generating oxidative stress by direct 
interaction with mitochondria, superoxide and hydrogen peroxide released upon 6-OHDA 
autooxidation are likely the major contributors to enhanced oxidative stress (213).  The 
ability for MPP+ to induce MMP-3 in DA neurons may depend on its direct interaction 
with mitochondria and consequent activation of mitochondrial related signaling 
pathways.  Although differences between the neurotoxic mechanisms involved in the 6-
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OHDA and MPTP models may explain the different MMP-3 response, it is important to 
note that MMP-3 induction by MPTP has only been conclusively demonstrated in 
primary cell cultures.  Although MMP-3-/- mice exhibit essentially complete resistance to 
MPTP neurotoxicity, expression or activation of MMP-3 in response to MPTP in wild 
type mice has yet to be demonstrated (106).  
 Effect of 6-OHDA on MMP-13 Expression.  Despite the lack of MMP-3 
expression in SH-SY5Y cells, there was a significant increase in MMP-13 expression in 
response to 6-OHDA, at least at the transcript level.  Expression peaked 8 hours 
following 6-OHDA treatment, suggesting that MMP-13 could play a role in 6-OHDA-
mediated neurotoxicity.  However, in contrast to the SH-SY5Y experiments, 6-OHDA 
had no effect on MMP-13 protein expression at the time points examined.  Several 
factors could explain the difference in MMP-13 expression between these two model 
systems.  First, the assays used to measure MMP-13 were different.  MMP-13 mRNA 
expression was measured in SH-SY5Y experiments, while MMP-13 protein was 
examined in the in vivo experiments.  It may be possible that the increase in MMP-13 
mRNA expression failed to result in a corresponding elevation of MMP-13 protein due to 
translational or post-translational regulatory mechanisms.  Second, SH-SY5Y cells are an 
immortalized cell line derived from a neuroblastoma tumor.  Although these cells retain 
important DA qualities, they clearly are not nigrostriatal DA neurons; therefore, the 
molecular events ultimately leading to cell death likely differ between these two cell 
types.  It would be interesting to examine MMP-13 expression in response to 6-OHDA in 
a primary cell culture system derived from the rat ventral midbrain.  Third, species 
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differences could explain the apparent disconnect in MMP-13 results described for these 
two models although the effects on MMP-3 and MMP-9 were identical in the both 
models. 
 Effect of 6-OHDA on MMP-2 Expression.  No change in MMP-2 mRNA 
expression was observed in response to 6-OHDA in SH-SY5Y cells.  In contrast, 6-
OHDA and ascorbic acid treatment groups both exhibited a 2-3 fold increase in 
proMMP-2 expression 5 and 10 days post surgery, suggesting that trauma caused by 
insertion of the needle may be responsible for the changed expression.  Alterations in 
MMP-2 expression following needle stick injury have been reported previously in other 
neurosurgical models.  For example, proMMP-2 mRNA expression increased transiently 
2 hours after a single intrastriatal saline injection in Sprague-Dawley rats (148).  In a 
similar study, MMP-9 gelatinolytic activity increased 24 hours following saline injection, 
but no change in MMP-2 activity was observed (79).  No published data exists on the 
long-term effect of needle stick injury on MMP-2 expression. To my knowledge, the data 
presented in this chapter is the first to describe delayed, but prolonged induction of 
proMMP-2 expression in response to needle stick injury; although, similar sustained 
increases in MMP-2 expression have been reported in other models of mechanical brain 
trauma.  For instance, proMMP-2 expression increased 3-10 days in the olfactory bulb 
following olfactory nerve transection (44).  The effect on MMP-2 peaked 7 days post-
surgery and was marked by the appearance of active MMP-2.  Peak MMP-2 expression 
and activation correlated with recovery, suggesting that MMP-2 plays an important role 
in controlling the regeneration of olfactory neurons (44).  In another example, MMP-2 
   
87 
expression and activity peaked 7-14 days after spinal cord injury (76).  At these time 
points, MMP-2 was associated with reactive astrocytes surrounding the lesion border 
separating damaged tissue from intact cord (90).  In addition, MMP-2-/- mice displayed 
more severe glial scar formation, increased chondroitin sulfate proteoglycan expression, 
decreased axonal plasticity, and significantly impaired motor recovery (90).  As with the 
olfactory nerve transection model, data from this spinal cord injury model strongly 
suggests that delayed MMP-2 expression promotes neuronal recovery following 
traumatic injury, likely involving degradation of axonal growth inhibiting chondroitin 
sulfate proteoglycans.  Perhaps the sustained increase in striatal proMMP-2 following 
needle stick injury observed in the intrastriatal 6-OHDA model serves an analogous 
purpose.   
 In contrast to the striatum, 6-OHDA significantly increased nigral proMMP-2 
expression compared to ascorbic acid; however, this did not turn out to be a time-
dependent effect although it would appear that there is an increase at day 5.  This increase 
precedes measurable loss of nigral TH expression, which was evident 10 days post-
surgery, indicating that the increase in nigral MMP-2 expression was not in response to 
tissue repair as suggested above for changes in MMP-2 expression detected in the 
striatum.  Instead, nigral MMP-2 may play an important role in focal BBB disruption 
associated with neurodegeneration reported to occur in response to intrastriatal 6-OHDA 
injection (31).  In models of cerebral ischemia, transient increases in MMP-2 activity are 
responsible for an early phase of BBB disruption (186).  It is important to note that no 
active MMP-2 was detected in nigral protein samples in either treatment group; however, 
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it cannot be ruled out that active MMP-2 was present at levels below the detection limit 
of the antibody used.  To address this, gelatin or in situ zymography could be performed 
to directly measure nigral gelatinase activity following intrastriatal 6-OHDA injection.  In 
addition, immunolocalization of MMP-2 could determine if its expression is associated 
with the vasculature. 
 Conclusions.  The results in the present study suggest that 6-OHDA neurotoxicity 
fails to induce significant MMP expression or activation in correlation with DA 
neurodegeneration; however, the potential effect of 6-OHDA on nigral proMMP-2 
expression hinted at in this study warrants further scrutiny.  In contrast, MPTP-mediated 
neurodegeneration depends on induction of MMP-3 in DA neurons, which serves as a 
microglial activating factor (106).  The difference in the MMP requirement between 6-
OHDA and MPTP-mediated neurodegeneration, suggests that neurodegeneration induced 
by these neurotoxins occurs by different mechanisms.  This difference has potential 
important implications for PD.  It has been hypothesized that idiopathic PD could be 
initiated by exposure to a variety of neurotoxins present in the environment (34, 141).  If 
the mechanisms of neurodegeneration associated with each neurotoxin differ 
significantly, then effective neuroprotective treatments for PD may require the 
development therapeutic strategies that are tailored to specific neurotoxins.   
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CHAPTER 4  
Matrix Metalloproteinase Expression and Activation during 
Lipopolysaccharide-induced Dopaminergic Neurodegeneration 
 
4.1 Introduction 
 In the previous chapter, 6-OHDA induced a time-dependent loss of TH expression 
in both the striatum and SNc that was accompanied by a modest increase in nigral 
proMMP-2 expression, but not activation.  Neurodegeneration was not associated with 
changes in MMP-13 expression or activation, while MMP-3 and MMP-9 were 
undetectable at the three time points examined.  These experiments indicate that a direct 
neurotoxic insult to DA neurons does not trigger a major MMP response.  In addition to a 
direct neurotoxic insult, neuroinflammatory stimuli can trigger DA neurodegeneration.  
Intranigral injection of LPS has been used extensively to examine neuroinflammatory 
mechanisms that contribute to DA cell death.  LPS induces a robust neuroinflammatory 
response characterized by microgliosis, proinflammatory cytokine production, release of 
ROS, and secretion of nitric oxide, which results in selective degeneration of DA neurons 
(4, 32, 56, 84, 95).  The neurodegenerative response to LPS appears to be specific for the 
SNc, since direct injection of identical quantities into the cortex or hippocampus fails to 
induce neuronal loss (104).  In addition, intranigral LPS injection has no effect on 5-HT 
or its metabolite, 5-HIAA, in either the SNc or striatum 
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(84).  GABAergic neurons also appear to be resistant to neuroinflammation induced by 
LPS since expression of the GABAergic marker, GAD67, in the substantia nigra pars 
reticulata does not change (84).  Thus, DA neurons are selectively destroyed by 
neuroinflammation triggered by LPS. 
 The events associated with neuroinflammation are initiated when LPS interacts 
with TLR4 expressed on the plasma membrane of microglia and astrocytes (56).  LPS is 
not capable of acting directly on DA neurons, due to their lack of TRL4 expression; 
therefore, neurodegeneration resulting from LPS occurs purely through glia-mediated 
mechanisms, making it an ideal model to examine the role of MMPs in 
neuroinflammation-mediated DA neurodegeneration. 
 The purpose of the current study was two-fold.  First, the temporal pattern of 
MMP-2, -3, -9, and -13 expression and activation was examined in relationship to LPS-
induced DA neurotoxicity.  Intracerebral injection of LPS results in upregulation and 
activation of MMP-2, MMP-3, and MMP-9 (26, 27, 79, 148, 149); however, the MMP 
response to injection of LPS into the SNc has not been characterized.  In addition, these 
studies will provide important information regarding the expression of these MMPs in 
relationship to DA neurodegeneration.  Second, a potential downstream MMP-3 target 
that may be involved in the neurodegenerative process was measured.  Recent evidence 
indicates that CTGF/CCN2 is a target of MMP-3 activity.  MMP-3 controls CTGF/CCN2 
function in 2 ways.  First, MMP-3 cleaves CTGF/CCN2 protein into two fragments of 
~20kDa that are thought to have distinct functions (83).  Second, MMP-3 acts 
intracellularly to enhance CTGF/CCN2 transcription by directly binding to the 
   
91 
CTGF/CCN2 promoter (57).  The function of CTGF/CCN2 in the brain is poorly 
understood; however, it has been localized to amyloid-β plaques in Alzheimer’s disease 
brain and degenerating spinal cord regions in amyotrophic lateral sclerosis patients, areas 
known to be affected by neuroinflammation (212, 225).   
 
4.2 Materials and Methods 
 Materials.  Ketamine (100mg/mL), xylazine (100mg/mL), and buprenorphine 
(0.3mg/mL) were obtained from the central pharmacy at Main Hospital, Medical College 
of Virginia campus.  Pentobarbital was supplied in a Euthasol formulation (390mg/mL) 
by the Department of Animal Resources, Virginia Commonwealth University.  PBS, 
100mM ethylenediaminetetraacetic acid (EDTA), 4-12% polyacrylamide 15-well bis-tris 
gels, 0.45µm nitrocellulose membranes, sample reducing agent, LDS sample buffer, MES 
running buffer, antioxidant solution, and western blot transfer buffer were acquired from 
Invitrogen Corp. (Carlsbad, CA).  Mouse anti-rat TH (Cat# MAB318), goat anti-mouse 
MMP-13 (Cat# AB8120), and rabbit anti-human cyclophilin-A (Cat# 07-313), were 
procured from Millipore (Billerica, MA).  Sterile drapes, No. 3 scalpel blades, bone wax, 
4-0 chromic gut sutures, 10% povidone/iodine solution, alcohol prep pads, coronal small 
rodent brain matrix, cutting mat, brain matrix razor blades, citrisolve, Permount mounting 
media, absolute ethanol, SDS, CaCl2·2H2O, NaCl, Tween-20, deoxycholic acid, Tris-
HCl, and bovine serum albumin (fraction V) were purchased from Fisher Scientific 
(Pittsburgh, PA).  LPS (serotype 0127:B8), paraformaldehyde, 3,3”-diaminobenzidine 
tetrahydrochloride (DAB), imidazole, 30% Brij-35, Triton X-100, NaOH, 4-4-
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aminophenylmercuric acetate (APMA), NP-40, and mouse anti-human β-actin (Cat# 
A2228) were obtained from Sigma-Aldrich (St. Louis, MO).  Goat anti-mouse IgG-HRP 
and goat anti-rabbit IgG-HRP were obtained from Rockland Immunochemicals, Inc. 
(Gilbertsville, PA).  MMP FRET peptide XIII was purchased from Anaspec (San Jose, 
CA).  SuperSignal West Dura extended duration HRP substrate solution was obtained 
from Pierce (Rockford, IL).  Enhanced Chemiluminescence HRP substrate solution was 
purchased from GE Healthcare (United Kingdom).  Protease inhibitor cocktail was 
purchased from Calbiochem (San Diego, CA).  Full length recombinant human MMP-3 
and goat anti-human MMP-3 (Cat# ab18898) were procured from Abcam, Inc. 
(Cambridge, MA).  Goat anti-human CTGF/CCN2 (Cat# sc-14939) and bovine anti-goat 
IgG-HRP (Cat# sc-2350) were purchased from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA).  Goat anti-mouse MMP-2 (Cat# AF1488) and goat anti-mouse MMP-9 (Cat# 
AF909) were obtained from R&D Systems, Inc. (Minneapolis, MN).  Anti-mouse 
Vectastain ABC Elite kit was purchased from Vector Laboratories (Burlingame, CA).  
Non-fat dry milk was bought from The Kroger Co. (Cincinnati, OH).  Methanol was 
purchased from Colonial Scientific, Inc. (Richmond, VA).  
 Surgical Procedures.  Forty-four adult male Sprague-Dawley rats (250-350g) 
were housed individually in an AAALAC accredited (#00036), USDA registered (#52-R- 
007, and PHS approved (#A-3281-01) animal facility.  Room temperature and humidity 
were kept constant, a 12-hour light/dark cycle was maintained, and food and water were 
available ad libitum.  Rats were monitored by qualified animal technicians throughout the 
studies and were examined daily after surgery to check for weight loss, lethargy, 
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periorbital crusting or bleeding, and gait.  If deficits were observed, appropriate measures 
were taken to alleviate pain and suffering.  All experiments were carried out in 
accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals and were approved by the Institutional Animal Care and Use 
Committee of Virginia Commonwealth University. 
 Immediately prior to intranigral injection of LPS, rats were anesthetized with 
ketamine/xylazine (100mg/kg/10mg/kg, i.p.).  Hair was removed from the scalp and the 
surgical area was cleaned with alternating povidone/iodine antiseptic and alcohol washes.  
After the rat was draped and mounted onto the rodent stereotaxic frame (Kopf 
Instruments, Tujunga, CA), a single incision was made through the skin along the 
rostrocaudal length of the scalp using a No.10 scalpel blade attached to a No. 3 handle.  A 
single burr hole was drilled 4.8mm caudal and 1.7mm to the right of bregma.  LPS (2µl 
of 5µg/µl) or PBS was injected 8.0mm below the dura with a 10µl Hamilton syringe 
fitted with a 26-guage needle.  The needle was held in place for 5 minutes prior to 
injection.  Flow rate (1µl/min) was kept constant with a motorized syringe pump (BASi, 
West Lafayette, IN).  Five minutes after the conclusion of the injection, the needle was 
slowly removed to prevent fluid backflow through the needle track (quarter turn per 10 
seconds).  Burr hole was filled with bone wax and wound was sutured closed. Body 
temperature was maintained at 37°C throughout the duration of the surgery with a 
homeothermic blanket (Harvard Apparatus, Holliston, MA) and post-operative pain was 
managed with buprenorphine (0.02mg/kg) injected in 12 hour intervals.  Rats were kept 
under a heat lamp until recovered from anesthesia. 
   
94 
 It is imperative that the following procedure be followed for LPS use in future 
studies.  LPS was dissolved in ice cold sterile PBS to make 5µg/µl stock solution.  The 
stock solution was divided into 20µl aliquots and was stored at -20°C.  Aliquots were 
thawed immediately prior to use and were never re-frozen.  Each aliquot was used on 
only 1 rat.  Optimization studies revealed that once thawed, LPS losses its potency 30-60 
minutes after initial thaw and is not stable enough to undergo multiple freeze-thaw 
cycles.  In addition, LPS has the tendency to bind to the wall of the Eppendorf tube and 
should be vigorously vortexed prior to administration.  
 Immunohistochemistry.  Forty-eight hours (n=3) or 7 days (n=1) post-surgery, 
rats were euthanized with pentobarbital (150mg/kg, i.p.) and were transcardially perfused 
with ice-cold saline (300-400mL) followed by 4% paraformaldehyde (400-500mL).  
Whole brain was removed, post-fixed overnight in 4% paraformaldehyde, and then stored 
in PBS until sectioning.  The non-lesioned side of the brain was notched in order to 
maintain ipsilateral/contralateral orientation throughout the staining procedure.  Notched 
brain was sectioned with a vibratome (Leica Microsystems, Wetzlar, Germany).  Floating 
40µm thick midbrain and striatal tissue sections were blocked in 10% normal horse 
serum containing 0.2% Triton X-100 for 1 hour and then were incubated overnight at 4°C 
in mouse anti-rat TH diluted in 1% normal horse serum.  Sections were washed 3 x 10 
minutes in 1% normal horse serum and then were incubated for 1 hour in biotinylated 
anti-mouse secondary antibody.  After 3 PBS washes, sections were incubated in avidin-
biotin complex for 1 hour and then were washed 3 x 10 minutes in PBS followed by 2 x 
10 minutes in phosphate buffer.  Immunoreactivity was visualized with 0.5% DAB 
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containing 0.3% imidazole.  Sections were mounted, dried overnight, dehydrated in 
ethanol, cleared in citrisolve, and coverslipped in Permount mounting media.  Sections 
were analyzed on a Nikon Optiphot microscope and images were captured with a Coolpix 
990 3.34 megapixel digital camera (Nikon, Tokyo, Japan). 
 Protein Extraction.  Rats were euthanized with pentobarbital (150mg/kg, i.p.) 
followed by rapid decapitation 12, 24, 48 hours, or 30 days post-surgery.  Brains were 
rapidly removed and placed ventral-side up in a rat brain matrix (Figure 4.1).  For the 12, 
24, and 48 hour time points, a single 2mm coronal tissue block containing the midbrain 
was cut using brain matrix razor blades.  For the 30 day time point, 2 2mm coronal tissue 
blocks containing striatum were collected.  Tissue blocks were transferred to the cutting 
mat, which was kept cold with an ice pack.  Ventral midbrain or striatum was dissected, 
cut through the midline to separate ipsilateral and contralateral tissue, and immediately 
placed in 1.5mL microcentrifuges tube containing 100µl (300µl for striatum) ice-cold 
protein extraction buffer (50mM Tris-HCl pH 7.2, 150mM NaCl, 1% sodium 
deoxycholate, 1% NP-40, and 0.5% SDS) with an added protease inhibitor cocktail. 
Tissue chunks were homogenized and then centrifuged at 14,000 x g for 30 minutes at 
4°C.  Supernatants were saved and stored at -80°C until use.   
 Western Blot.  Sample protein concentration was determined with the DC protein 
assay (Bio-Rad Laboratories, Hercules, CA) using bovine serum albumin solutions to 
construct the standard curve.   LDS sample buffer and sample reducing agent were added 
to samples (40µg).  Samples were heated to 70°C for 10 minutes, loaded on 4-12% 
polyacrylamide bis-tris gels, separated by SDS-PAGE (50 minutes at 200V), and 
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FIGURE 4.1: LPS Model of Parkinson’s Disease 
Stereotaxic injection of LPS directly into the SNc induces neuroinflammation, which 
directly leads to selective anterograde neurodegeneration of nigrostriatal DA neurons.  
The lesion is confined to the side ipsilateral to the injection site, resulting in a unilateral 
loss of striatal dopamine.  The contralateral side remains intact and serves as the control 
in all experiments. 
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transferred to nitrocellulose membranes (2 hours at 30V).  All western blots used for 
MMP-13 detection were run under non-reducing conditions (all procedures are identical 
to reducing conditions except that reducing agent was omitted from the sample 
preparation and antioxidant was not added to the running buffer).  Membranes were 
blocked for 1 hour in 5% non-fat dry milk prepared in tris-buffered saline containing 
0.05% Tween-20 (TBST).  Membranes were incubated in TH, MMP-3, MMP-9, or 
MMP-13 primary antibody overnight at 4°C.  Membranes were washed 4 x 5 minutes in 
TBST.  Membranes were incubated in bovine anti-goat IgG-HRP secondary antibody for 
90 minutes at room temperature and then were washed an additional 6 times in TBST.  
Immunoreactivity was visualized with SuperSignal West Dura substrate followed by 
exposure to film.  All MMP-3 blots were reprobed with CTGF/CCN2, while MMP-9 
blots were reprobed with MMP-2 primary antibodies.   Membranes were stripped once 
more and were reprobed with cyclophilin-A (MMP-3 and MMP-9 blots) or β-actin 
(MMP-13 blots) primary antibody followed by goat anti-rabbit or anti-mouse IgG-HRP.  
For these loading controls, immunoreactivity was visualized with Enhanced 
Chemiluminescence Substrate followed by exposure to film.  To quantify protein 
expression, film was scanned with the Personal Densitometer (Molecular Dynamics) and 
background-corrected band densities were measured using ImageQuant software (version 
5.1, Molecular Dynamics).  MMP and CTGF/CCN2 immunoreactivity was normalized to 
cyclophilin-A or β-actin, which served as the loading control. 
 TNF-α ELISA.  TNF-α was quantified in nigral protein lysates following the 
manufacturer’s instructions (eBioscience, San Diego, CA).  Briefly, wells were incubated 
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in capture antibody overnight at 4°C.  After 5 washes, wells were blocked for 1 hour at 
room temperature, washed, and then incubated with samples overnight at 4°C.  Wells 
were washed, incubated in detection antibody for 1 hour, washed again, incubated in 
avidin-HRP for 30 minutes, washed, and incubated in substrate solution for 15 minutes. 
Stop solution was added to each well prior to measuring A450nm.  Sample TNF-α 
concentration was calculated from a TNF-α standard curve.  TNF-α ELISA was 
performed by Steve Bakos in Dr. Richard Costanzo’s lab. 
 Activation of Recombinant Human MMP-3.  APMA stock solution (10mM) 
was prepared in 50mM NaOH.  1mL APMA stock solution was diluted to 2mM APMA 
with 4mL assay buffer (50mM Tris-HCl pH 7.5, 5mM CaCl2·2H20, 0.05% Triton X-100).  
Recombinant human MMP-3 stock solution was diluted to 5ng/µl with assay buffer.  
Equal volumes (15µl) of 5ng/µl MMP-3 and 2mM APMA were combined in 0.6mL 
microcentrifuge tubes and were incubated for 4 hours at 37°C.  Reaction mixtures were 
immediately used for MMP-3 activity assays. 
 MMP-3 Activity Assay.  Rats were euthanized with pentobarbital (150mg/kg, 
i.p.) followed by rapid decapitation 24 hours post-surgery.  Nigral protein was extracted 
as described above with one exception.  The protein extraction buffer used contained 
50mM Tris-HCl (pH 7.5), 150mM NaCl, 10mM CaCl2·2H20, 0.05% Brij-35, and 1% 
Triton X-100.  The protease inhibitor cocktail was omitted from this preparation in order 
to maintain MMPs in their active state.  Protein concentration was determined using the 
DC protein assay prior to measuring MMP-3 activity.  MMP-3 proteolytic activity was 
measured using the fluorogenic MMP FRET substrate XIII.  The manufacturer claims 
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that MMP-3 shows stronger proteolytic activity towards this FRET peptide than other 
MMPs.  Protein (100µg) was mixed with an equal volume of 2µM substrate (1µM final 
substrate concentration).  Positive control consisted of 75ng APMA-activated 
recombinant human MMP-3.  Three negative controls were made: (1) 200µl of assay 
buffer; (2) 100µl substrate and 100µl assay buffer; and (3) 75ng APMA-activated 
recombinant human MMP-3 with 2µl EDTA, 100µl substrate, and 68µl assay buffer.  
Reaction components were combined in a 96-black well plate.  As soon as possible, 
fluorescence measurements at 485ex/520em were read using the Fluostar Optima plate 
reader (BMG Labtech, Durham, NC).  Measurements were made in 5-minute intervals 
for 60 minutes. 
 Statistical Analysis. Statistical tests were performed using JMP software 
(version 7.0).  For quantitative densitometric analysis, treatment group (LPS or PBS) and 
time-dependent differences were computed using two-way ANOVA (α=0.05).  If a 
significant model effect was detected, then the Tukey-Kramer test was conducted to 
reveal which experimental groups were significantly different.  Bonferroni corrected p-
values were calculated for all comparisons made by the Tukey-Kramer test. Quantitative 
data is presented as mean ± standard error of the mean.   
 
4.3 Results 
 TH immunohistochemistry was performed on midbrain tissue sections 48 hours 
post-surgery and on striatal tissue sections 7 days post-surgery to confirm that intranigral 
injection of LPS resulted in DA neurodegeneration.  Ipsilateral and contralateral TH 
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staining was compared qualitatively.  At 48 hours, contralateral midbrain displayed 
numerous intensely stained TH+ neuronal cell bodies, indicative of an intact SNc (Figure 
4.2).  In contrast, few TH+ neurons were detected in the LPS-injected SNc.  Most TH+ 
neurons resided in the ventral tegmental area, while the few remaining in the SNc stained 
faintly (Figure 4.2 inset).  Striatal tissue sections collected 7 days post surgery showed a 
similar relationship between ipsilateral and contralateral TH staining intensity; however, 
the decreased staining intensity associated with the LPS injection was not as dramatic as 
that observed for the SNc (Figure 4.3A).   
 Western blot performed on samples collected 30 days post-surgery confirmed that 
intranigral administered LPS resulted in prolonged striatal TH depletion, consistent with 
permanent DA neurodegeneration (Figure 4.3B).  To measure the extent of TH depletion, 
TH immunoreactivity was normalized to cyclophilin-A expression.  The ratio of 
normalized ipsilateral TH expression to normalized contralateral TH expression was 
calculated to obtain the percent of contralateral TH expression.  This comparison 
demonstrated that ipsilateral TH depletion reached 60% (Figure 4.3C).  In contrast, the 
PBS-injected rat showed no loss of ipsilateral striatal TH expression, indicating that 
neither PBS nor injury caused by the surgery resulted in permanent damage to the 
nigrostriatal tract. 
 LPS-mediated DA neurodegeneration has been shown to be dependent on 
microglial-derived proinflammatory cytokines, nitric oxide, and ROS.  To verify that an 
active neuroinflammatory reaction was present during active DA neurodegeneration, 
TNF-α expression was measured in nigral protein samples collected 24 hours following 
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FIGURE 4.2: LPS-induced Nigral DA Neurodegeneration 
Representative TH stained midbrain section 48 hours post-LPS injection (n=3).  
Intranigral LPS injection resulted in substantial loss of TH+ DA neurons in the SNc.  The 
side contralateral to the injection remains intact.  Remaining DA neurons on the 
ipsilateral side have decreased TH expression compared to the contralateral side.  Arrows 
indicate areas of enlargement shown in the inset.  Scale bar = 100µm for large images 
and 20µm for insets. 
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FIGURE 4.3: LPS-induced Degeneration of DA Projections to the Striatum.  A) 
Representative TH-stained striatal tissue section from LPS lesioned animal 7 days post-
surgery.  TH immunoreactivity was decreased on the side ipsilateral to the LPS injection.  
Scale Bar equals 250µm.  B) Western blot demonstrating depletion of striatal TH 30 days 
post-LPS injection (I=ipsilateral, C=contralateral).  C) Densitometric analysis of TH 
western blot (n=1).  TH:cyclophilin-A density ratio was calculated for each lane.  
Ipsilateral density ratio was divided by the contralateral density ratio to obtain percent of 
contralateral TH expression.  LPS injection resulted in 60% loss of striatal TH, while no 
decrease in TH was detected following PBS injection. 
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LPS or PBS injection.  Protein samples were sent to Steve Bakos in Dr. Costanzo’s lab 
for the TNF-α ELISA measurement.  TNF-α was detected only in the ipsilateral sample 
from the LPS-lesioned rat, indicating that LPS induced a localized neuroinflammatory 
response (Figure 4.4).   
 MMP-2, MMP-3, MMP-9, and MMP-13 protein expression and activation were 
measured by western blot 12, 24, and 48 hours post-surgery.  These time points were 
chosen based on the known time course of DA neurodegeneration in which maximum 
nigral neuronal loss is reached in 48 hours (94, 96).  Time points preceding this loss were 
assayed in an attempt to correlate changes in MMP expression and activation with 
neuroinflammation-induced DA neurodegeneration.  Cyclophilin-A or β-actin expression 
was measured and served as the loading control for each lane.   
 First, the effect of intranigral LPS on MMP-3 expression and activation was 
examined.  ProMMP-3 was detected in all samples from the LPS group but was only 
observed 12 hours post-surgery in the PBS group, indicating that a transient change in 
proMMP-3 expression was associated with tissue injury (Figure 4.5A).  Mean 
densitometry values for all groups were compared using two-way ANOVA.  Overall, 
there was a significant experimental effect on proMMP-3 protein expression (F=24.5, 
p<0.001).  In addition, a significant interaction effect was detected between the time 
points measured and treatment groups (F=16.2, p<0.001).  Within the LPS group, the 
effect on proMMP-3 expression was time-dependent, peaking 24 hours post-surgery 
(Figure 4.5B, p<0.001).  At this time point, proMMP-3 expression was 4-fold and 3.4- 
fold greater than expression at 12 and 48 hours, respectively.  In contrast, PBS had no
   
104 
 
 
 
 
 
 
 
 
 
FIGURE 4.4: LPS Increases Nigral TNF-α Production 
TNF-α ELISA was performed on ventral midbrain tissue samples collected 24 hours 
post-LPS or PBS injection (n=1, assay performed by Steve Bakos).  TNF-α was detected 
in the ipsilateral sample from the LPS injected rat.  No TNF-α was detected on the 
contralateral side or in either sample from the PBS injected rat.  This assay confirms that 
LPS triggers neuroinflammation when introduced into the SNc.
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FIGURE 4.5: Effect of LPS on Nigral MMP-3 Expression and Activation 
MMP-3 measurements after intranigral LPS (n=6) or PBS (n=6) injection.  Cyclophilin-A 
expression was measured to ensure equal protein loading.  A) Representative western blot 
demonstrating temporal changes in pro and active MMP-3 expression (I=ipsilateral, 
C=contralateral).  B) Densitometric analysis of proMMP-3 in ipsilateral nigral tissue 
samples.  ProMMP-3 was significantly elevated 24 hours post-surgery in the LPS group 
compared to the PBS group.  Within the LPS group, proMMP-3 expression peaked at 24 
hours.  C) Densitometric analysis of MMP-3 in ipsilateral tissue samples.  MMP-3 
activation increased 24 and 48 hours post-surgery in the LPS group compared to the PBS 
group.  Data presented as mean ± standard error of the mean.  Asterisks indicate 
significance compared to PBS group, while # denotes significance compared to 12 hour 
LPS time point. 
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time-dependent effect on proMMP-3 expression despite being detected only 12 hours 
post-surgery.  It should be noted that expression of proMMP-3 in this group was only 
detectable in 3 of the 6 animals.  Compared to the PBS group, proMMP-3 expression in 
the LPS group was significantly increased at 24 hours (p<0.001), but not at 48 hours 
post-surgery (p=0.17).  Although a significant difference was not detected at 48 hours, it 
should be emphasized that proMMP-3 was detected in all 6 LPS-injected rats, but was 
completely absent in all 6 PBS-injected rats.   
 MMP-3 activation requires prodomain removal, the ~10kDa N-terminal portion of 
the protein that maintains enzyme latency (150).  Prodomain removal causes a molecular 
weight shift that allows pro and active MMP-3 to be distinguished on western blots.  
Activated MMP-3 was detected at all time points in ipsilateral samples collected from 
LPS-injected rats (Figure 4.5A).  Mean densitometry values for all groups were compared 
using two-way ANOVA.  Overall, there was a significant experimental effect on the 
amount of active MMP-3 protein (F=18.7, p<0.001).  In addition, a significant interaction 
effect between the time points measured and treatment groups was detected (F=14.4, 
p<0.001).  MMP-3 activation was more prominent at 24 hours than at 12 hours in the 
LPS group, a change that was maintained through the 48 hour time point (Figure 4.5C, 
p=0.007).  In one LPS animal, low MMP-3 expression was noted on the contralateral side 
at 48 hours.  In addition, a slight injury-induced effect on MMP-3 activation was 
observed in the PBS group 12 hours post-surgery; however, active MMP-3 was never 
detected beyond this point.  These results indicate that LPS-mediated neuroinflammation 
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induces proMMP-3 expression and activation that is temporally related to DA 
neurodegeneration, suggesting that MMP-3 may be involved in the degenerative process. 
 In addition to MMP-3, the temporal relationship between gelatinase expression 
(MMP-2 and MMP-9) and DA neurodegeneration was examined.  Consistent with results 
from previous 6-OHDA in vivo experiments, proMMP-2 (72kDa) was detected in all 
tissue samples, indicating that proMMP-2 is normally expressed in the ventral midbrain 
(Figure 4.6A).  Mean normalized densitometry values for ipsilateral and contralateral 
samples were analyzed separately by two-way ANOVA (Figure 4.6B).  For ipsilateral 
samples, there was a significant overall experimental effect on proMMP-2 expression 
(F=5.12, p=0.003).  In addition, a significant interaction effect between the time point 
measured and treatment groups was detected (F=6.25, p=0.007).  There was a significant 
time-dependent effect on ipsilateral proMMP-2 expression in the LPS group, with 
expression peaking 24 hours post-surgery (p=0.0495).  In contrast, there was no time-
dependent effect on ipsilateral proMMP-2 expression in the PBS group.  Compared to the 
PBS group, proMMP-2 expression was significantly increased at the 24 hour time point 
(p=0.004).  There was no difference in proMMP-2 between the LPS and PBS group at 12 
and 48 hours post-surgery. 
 In addition to ipsilateral proMMP-2 expression, there was a significant 
experimental effect on contralateral proMMP-2 expression (F=4.39, p=0.004), although 
there was no significant interaction between the chosen time points and treatment groups 
(F=2.66, p=0.091).  There was no difference between the LPS and PBS animals (F=2.25, 
p=0.1463); however, there was a significant time-dependent effect on contralateral 
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proMMP-2 expression (F=7.7, p=0.0026).  When the effect of time is considered 
independently of treatment group, contralateral proMMP-2 expression increased 4.5 fold 
48 hours post-surgery compared to the 12 hour time point (Figure 4.6B, p=0.002).  The 
absence of a treatment-induced effect suggests that the increase in contralateral proMMP-
2 is likely caused by needle injury; however, if this was the case, then proMMP-2 
expression would have been expected to also increase in the ipsilateral SNc of the PBS 
group.  Although there was a significant effect on contralateral proMMP-2 expression, 
the magnitude of this effect was not nearly as great as was present in ipsilateral samples: 
the contralateral proMMP-2:cyclophilin ratio was 0.52 at 48 hours, while the peak 
proMMP-2:cyclophilin-A ratio 24 hours post-LPS in ipsilateral samples was 3.1.   
 Similar to the results for MMP-3, substantial MMP-2 activation was detected in 
association with intranigral LPS injection, particularly 24 hours post-surgery (Figure 
4.6A).  Ipsilateral tissue samples from PBS and LPS groups were compared by two-way 
ANOVA.  Overall, there was a significant experimental effect on MMP-2 activation 
(F=8.25, p<0.001).  In addition, a significant interaction effect was detected between the 
time points studied and treatment groups (F=7.59, p= 0.003).  Intranigral PBS injection 
resulted in MMP-2 activation 12 hours post-surgery; however, no activated MMP-2 
immunoreactivity was detected at later time points.  In contrast, intranigral LPS injection 
caused long lasting time-dependent MMP-2 activation that peaked 24 hours post-surgery 
(Figure 4.6C, p=0.02).  Activation at 24 hours was 3.6 and 2.6 fold greater than the 
amount of activated MMP-2 detected at 12 and 48 hours, respectively.  Compared to the 
PBS group, LPS-induced MMP-2 activation was significantly greater only at the 24 hour
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FIGURE 4.6: The Effect of LPS on Nigral MMP-2 Expression and Activation 
MMP-2 measurements after intranigral LPS (n=5) or PBS (n=5) injection.  Cyclophilin-A 
expression was measured to ensure equal protein loading.  A) Representative western blot 
demonstrating temporal changes in pro and active MMP-2 expression (I=Ipsilateral, 
C=contralateral).  B)  Densitometric analysis of proMMP-2 expression.  LPS caused a 
time-dependent increase in proMMP-2 expression in ipsilateral ventral midbrain tissue 
samples with peak expression levels reached 24 hours post-surgery.  When comparing 
LPS and PBS ipsilateral samples, proMMP-2 was significantly elevated at the 24 hour 
time point in LPS samples.  In addition, there was a time-dependent increase in proMMP-
2 expression in contralateral tissue samples that was not dependent on treatment group.  
Contralateral proMMP-2 expression peaked 48 hours post-surgery. C)  Densitometric 
analysis of active MMP-2 in ipsilateral tissue samples.  At 12 hours, active MMP-2 was 
identical in both groups; however, increased active MMP-2 persisted 24 and 48 hours 
post-surgery only in the LPS group.  Data presented as mean ± standard error of the 
mean.  Asterisks indicate significance compared to PBS group, while # denotes 
significance compared to 12 hour LPS time point.   
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time point (p<0.001).  Although a significant difference was not detected 48 hours post-
surgery (p=0.65), it should be emphasized that active MMP-2 was detected in all LPS-
injected rats, but was completely absent in all PBS-injected rats.  Importantly, these 
results demonstrate that along with MMP-3, active MMP-2 is present during the 
neurodegenerative phase of this model, suggesting that MMP-2 could be involved in 
events leading to DA neuronal loss. 
 In addition to proMMP-2 and proMMP-3, both LPS and PBS induced an increase 
in proMMP-9 protein expression that was associated with the ipsilateral SNc only (Figure 
4.7).  However, analysis of normalized proMMP-9 densitometry values revealed that 
there was no significant overall model effect (F=1.66, p=0.182).  This means that neither 
treatment nor measured time point had an effect on proMMP-9 expression.  This was 
surprising, particular when comparing LPS and PBS proMMP-9 expression 24 hours 
post-surgery.  At this time point, the average proMMP-9:cyclophilin-A ratio was 1.06 ± 
0.21 in LPS-injected samples, compared to just 0.13 ± 0.08 in PBS-injected samples, an 
8-fold difference.  This difference is masked by the extreme variability present in the 48 
hour LPS group in which the standard deviation (1.32) was greater than the group’s mean 
(0.79).  When the 48 hour time point was omitted from the two-way analysis, a 
significant overall model effect was revealed (F=3.69, p=0.034).  Importantly, the 8-fold 
increase due to LPS at the 24 hour time point becomes significant (p=0.029).  No 
difference between the 2 groups was detected 12 hours post-surgery, indicating that tissue 
injury induced a transient increase in proMMP-9.  
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FIGURE 4.7: The Effect of LPS on Nigral MMP-9 Expression 
MMP-9 measurements after intranigral LPS (n=5) or PBS (n=5) injection.  Cyclophilin-A 
expression was measured to ensure equal protein loading.  A) Representative western blot 
demonstrating temporal changes in pro and active MMP-9 expression (I=Ipsilateral, 
C=contralateral).  B)  Densitometric analysis of proMMP-9 expression.  Both LPS and 
PBS induce proMMP-9 expression 12 hours post-surgery; however, proMMP-9 remains 
elevated through at least the 24 hour time point only in the LPS group.  Unlike MMP-2 
and MMP-3, no active MMP-9 was detected at any time point.  Data presented as mean ± 
standard error of the mean.  Asterisks indicate significance compared to PBS group. 
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 The response of proMMP-9 to LPS differed from those described for MMP-2 and 
MMP-3 in two ways.  First, proMMP-9 expression was consistently elevated at the same 
magnitude 12 and 24 hours post-surgery.  This suggests that proMMP-9 expression peaks 
before proMMP-2 or proMMP-3.  Events resulting in increased MMP-9 must be in full 
swing by the 12 hour time point.  Second, no MMP-9 activation was detected in any 
samples from the LPS group.  The lack of active MMP-9 was surprising given the well 
described ability of MMP-3 to remove the MMP-9 prodomain (161).  The lack of active 
MMP-9 may indicate that the expression of these two MMPs differs spatially.  The high 
variability in the 48 hour LPS group could be caused by the nature of the temporal 
proMMP-9 expression pattern.  In some animals upregulation may last slightly longer 
than 48 hours, while in others it may end just prior to this time point.  In future 
experiments, this time point should not be used to assay proMMP-9 expression in 
response to LPS. 
 Two-way analysis of proMMP-13 densitometry data revealed that there was no 
overall experimental effect (F=2.02, p=0.124), meaning that LPS had no effect on MMP-
13 expression.  In addition to this lack of an effect, there were some peculiarities with the 
MMP-13 western blots that were not observed in the 6-OHDA studies (Figure 4.8).  
Upon examination of the western blots, there was a clear decrease in proMMP-13 in each 
24 hour LPS sample.  In addition to this apparent MMP-13 effect, there was an obvious 
LPS-induced decrease in detection of the loading control, which was also particularly 
evident in the 24 hour samples (Figure 4.8A).  This was the case for both β-actin and 
cyclophilin-A (data not shown).  The effect of LPS on loading control was not noticeable 
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FIGURE 4.8: Effect of LPS on Nigral MMP-13 Expression 
MMP-13 measurements after intranigral LPS (n=4) or PBS (n=4) injection.  Cyclophilin-
A expression was measured to ensure equal protein loading.  A) Representative MMP-13 
western blot (I=Ipsilateral, C=contralateral).  B) Densitometric analysis of proMMP-13 
expression.  No experimental effect on proMMP-13 was detected.  Data presented as 
mean ± standard error of the mean. 
ProMMP-13
LPS           PBS          LPS          PBS             LPS     PBS
12 hours                      24 hours                  48 hours
C       I       C       I       C       I       C       I    C       I       C      I  
β-Actin
A.
B.
0
20
40
60
80
100
120
140
12 hr 24 hr 48 hr
Time Point
P
e
rc
e
n
t 
C
o
n
tr
a
la
te
ra
l 
P
ro
M
M
P
-
1
3
 E
x
p
re
s
s
io
n
LPS
PBS
   
114 
in experiments examining MMP-2, MMP-3, or MMP-9.  The only methodological 
difference between these western blots was that samples for MMP-13 were assayed under 
non-reducing conditions, due to antibody detection requirements.  This suggests that 
something present in non-reduced samples from the 24 hour LPS group interfered with 
protein detection.  In the future, other MMP-13 detection methods should be considered.  
Preliminary attempts were made with two additional MMP-13 antibodies, but proMMP-
13 detection was unsuccessful (data not shown).    
 Detection of the activated form of MMP-2 and MMP-3 does not necessarily mean 
that these proteases are active in vivo.  For instance, TIMPs inhibit activated MMPs.  
Upon sample reduction with dithiothreitol coupled with heat denaturation, TIMP-MMP 
interactions should be broken, resulting in the detection of the activated form of MMP at 
its proper molecular weight.  In an attempt to address this, non-denatured samples from 
LPS and PBS injected rats collected 24 hours post-surgery were incubated with a FRET 
peptide substrate that is reportedly preferentially recognized by MMP-3.  When this was 
done, substrate degradation was detected in equally high amounts in both LPS and PBS 
samples, regardless if they were from the ipsilateral or contralateral SNc (Figure 4.9).  
Since western blots only show active MMP-3 in ipsilateral samples from the LPS group 
at this time point, equal detection of substrate degradation in all nigral samples indicates 
that additional proteases recognize the substrate.  The appropriate controls were done to 
eliminate the presence of degraded substrate in the substrate preparation and the presence 
of proteases in the assay buffer.  Purified APMA-activated recombinant MMP-3 was 
capable of cleaving the FRET substrate. 
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FIGURE 4.9: MMP-3 Fluorogenic Substrate Assay 
Recombinant human MMP-3 activated with APMA treatment displayed a steady increase 
in fluorescent activity over the course of the experiment (n=1).  This increase was not 
present in untreated MMP-3 samples and EDTA was capable of blocking the APMA 
effect.  These observations confirm the ability of the assay to detect active MMP-3.  
Fluorescence in tissue samples was much greater than the fluorescence detected in the 
recombinant human MMP-3 preparations.  In addition, there was no apparent difference 
between lesioned vs. unlesioned tissue or between LPS vs. PBS.  This does not match the 
western blot data and suggests that other proteins present in the protein samples are 
capable of cleaving the FRET substrate. (Ipsi = ipsilateral, Contra = contralateral) 
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 In an effort to identify potential MMP targets, CTGF/CCN2 protein expression 
was measured.  The hinge region of CTGF/CCN2 that connects the insulin-like growth 
factor binding protein and von Willebrand factor motifs to the thrombospondin-1 and C-
terminal motifs is vulnerable to both MMP-2 and MMP-3-mediated proteolysis (Chapter 
2, Figure 2.3), although MMP-3 is much more efficient than MMP-2 (83).  Furthermore, 
active MMP-3, recently localized to the nucleus, was shown to activate CTGF/CCN2 
gene transcription by directly binding to the CTGF/CCN2 promoter (57).  In the current 
study, CTGF/CCN2 was detected at all time points in both ipsilateral and contralateral 
protein samples collected from each rat (Figure 4.10A).  Mean densitometry values were 
compared using two-way ANOVA (Figure 4.10B).  In ipsilateral samples, there was a 
significant experimental effect on CTGF/CCN2 protein expression (F=3.7, p=0.01).  No 
significant interaction effect between the treatment groups and time points was found 
(F=3.1, p=0.06); however, there was a significant effect due to treatment (F=11.7, 
p=0.002), with the principle difference detected 24 hours post-surgery.  At this time 
point, intranigral injection of LPS induced a 5-fold increase in CTGF/CCN2 expression 
compared to PBS (p=0.008).  In contrast, no contralateral treatment effect was observed 
(F=0.5, p=0.47).  In addition to increased CTGF/CCN2 protein expression, preliminary 
data shows that a limited amount of CTGF/CCN2 proteolysis may occur at the 24 hour 
time point (Figure 4.10A).  Upon longer film exposure, a faint band at ~20kDa, the 
predicted molecular weight for MMP-cleaved CTGF/CCN2, was detectable only in the 
LPS group at the 24 hour time point.  Additional studies are required to further 
characterize the identity of this low molecular weigh immunoreactivity, but the  
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FIGURE 4.10: Effect of LPS on Nigral CTGF/CCN2 Expression 
CTGF/CCN2 measurements after intranigral LPS (n=6) or PBS (n=6) injection.  
Cyclophilin-A expression was measured to ensure equal protein loading.  A) 
Representative western blot demonstrating temporal changes in CTGF/CCN2 expression 
(I=ipsilateral, C=contralateral).  Densitometric analysis of CTGF/CCN2 expression in 
nigral tissue samples.  At 24 hours, LPS induced a 5-fold increase in CTGF/CCN2 
expression compared to PBS in ipsilateral tissue samples.  In addition, a faint band at 
20kDa was associated with the LPS group at 24 hours, which could represent MMP-
cleaved CTGF/CCN2 (circle).  Data presented as mean ± standard error of the mean.  
Asterisks indicate significance compared to PBS group. 
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correlation of its appearance with the presence of both active MMP-2 and MMP-3 is 
intriguing.  
  
4.4 Discussion 
 Neuroinflammation in PD contributes to progressive, chronic loss of DA neurons 
(14, 16, 232).  Intranigral injection of LPS causes selective degeneration of nigrostriatal 
DA neurons purely through neuroinflammation, making it an ideal model to study the 
neuroinflammatory mechanisms involved in neurodegeneration (32, 84).  Changes in the 
extracellular environment invariably accompany neuroinflammatory reactions, including 
increased proteolytic activity.  The results from the above studies indicate that the 
response to LPS includes dramatic alterations in the expression and activation of several 
MMPs; changes which occur at time points that are consistent with the neurodegenerative 
phase of the model used.  In addition, this is the first study to report an increase in 
CTGF/CCN2 expression in association with DA neurodegeneration.  CTGF/CCN2 is 
potentially involved in neurodegenerative diseases and has been identified as a target for 
MMP-3-mediated proteolysis and transcriptional control (57, 83, 212, 225).   
 Direct injection of LPS into the SNc triggers a localized neuroinflammatory 
response that results in massive anterograde DA neurodegeneration (32, 84).  Due to the 
anterograde nature of this lesion, cell body degeneration is obvious days before striatal 
depletion of DA axon terminals.  Within 48 hours of LPS exposure, 70-80% of TH+ 
nigral neurons are lost (94, 96).  Importantly, by the 30th day, no further degeneration 
can be detected, indicating that neurodegeneration is permanent and complete at the level 
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of the SNc 48 hours after LPS infusion (95, 96).  In contrast to the SNc, striatal TH 
expression remains at control levels 48 hours post-surgery (96).  Significant striatal TH 
depletion has been reported as early as 9 days post-surgery, progressing to completion by 
the 15th day (5, 84).  These observations were confirmed qualitatively with the LPS 
injection protocol used in the current studies.  Immense loss of TH+ DA neurons was 
revealed by immunohistochemistry performed on midbrain sections collected 48 hours 
post-surgery.  In addition, marginal loss of TH in the striatum was evident 7 days post-
surgery and had reached 60% by day 30.  Based on these results and previous reports, it 
would appear that most striatal TH depletion takes place 7-9 days following intranigral 
administration of LPS (5). 
 There were several reasons for the selection of the intranigral mode of LPS 
administration.  First, the time course for neurodegeneration is well established compared 
to the other LPS models available.  This was an important characteristic, since the 
principal goal of these studies was to measure MMP and CTGF/CCN2 expression at time 
points relevant to neurodegeneration.  Second, intranigral injection of LPS produces a 
lesion that is comparable to the extent of neurodegeneration present in human PD.  
Intrastriatal LPS injection has been attempted, though injection of comparable quantities 
needed to produce neurodegeneration when delivered directly to the SNc results in injury 
that is largely confined to the striatum, while the cell bodies in the SNc are spared (84).  
An alternative intrastriatal LPS injection model has been developed; however, generation 
of this model requires at least 60µg of LPS injected in 8 different locations spread over 
the entire striatum (91).  Third, the short neurodegenerative time course associated with 
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intranigral LPS injection allowed for easy selection of a small number of time points in 
which to quickly determine if MMPs and CTGF/CCN2 were potentially involved in DA 
death.  Unfortunately, the acute time course is also the model’s biggest fault, since 
neurodegeneration associated with PD is thought of as a chronic process.  Chronic DA 
neurodegenerative models have been developed in which LPS is delivered systemically 
or directly to the SNc via osmotic mini-pumps.  Osmotic mini-pumps release tiny 
amounts of LPS over a long period of time resulting in slower, delayed 
neurodegeneration that begins after 2 weeks (68).  The start of neurodegeneration in this 
model corresponds to the initiation of microglial activation.  Systemic LPS administration 
results in nigral degeneration that progresses from 23% at 7 months to 47% at 10 months 
post-treatment, suggesting that the model more closely resembles PD (173).  Altered 
MMP and CTGF/CCN2 expression detected in the current study provide a rational basis 
to explore these proteins further in these chronic neurodegenerative LPS models. 
 Detection of increased MMP-2 and MMP-3 expression and activation indicate 
that MMP regulation in response to intranigral LPS injection is a complex process.  
Multiple mechanisms must be involved that lead to both upregulation of the proform and 
removal of the prodomain.  The large increase in proMMP-2 and proMMP-3 observed 
following LPS injection hints at upregulation of proMMP at the transcriptional level; 
still, post-transcriptional or post-translational mechanisms cannot be ruled out as the 
cause for increased proMMP protein expression.  Several components of the microglial 
response to LPS are strong candidates for regulation of proMMP expression, including 
TNF-α, IL-1β, ROS, and nitric oxide.  Transcriptional upregulation of MMP-3 often 
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requires the binding of phosphorylated c-Jun to the AP-1 DNA binding site located in the 
MMP-3 gene promoter (51, 239).  Phosphorylation of c-Jun is controlled by activation of 
the c-Jun N-terminal kinase pathway, which can be activated by TNF-α, IL-1β, ROS, and 
nitric oxide (82, 139, 203).  In addition, both IL-1β and ROS have been shown to 
increase MMP-2 transcription and protein expression (207, 229).   
 The activation of MMP-2 and MMP-3 detected by western blot following LPS 
injection indicates that mechanisms that control the cysteine switch are involved in the 
response generated by LPS exposure.  MMP-2 activation requires the binding of its 
hemopexin-like domain by TIMP-2, which then forms a complex with MT-MMP.  The 
MT-MMP cleaves the MMP-2 prodomain, resulting in MMP-2 activation and TIMP-2 
dissociation (150).  MT1-MMP and MT5-MMP are expressed constitutively within the 
brain and represent strong candidates that activate MMP-2 in response to LPS (27, 200).   
Constitutive MT1-MMP and MT5-MMP in the brain suggests that the activation of 
MMP-2 seen after intranigral LPS injection may depend on regulation of MT-MMP 
activation.  In addition, microglia-derived neuroinflammatory constituents, including 
TNF-α, appear to regulate proMMP-2 activation through regulation of MT1-MMP 
expression (199).  Activation of proMMP-3 requires proteolytic removal of the 
prodomain, an action carried out by serine proteases or other activated MMPs (150).  The 
serine protease plasmin is an efficient activator of proMMP-3 (151); however, its 
distribution in the SNc has not been explored.  In addition, the inactive zymogen form of 
plasmin, plasminogen, requires the action of urokinase or tissue plasminogen activator 
for activation (29), neither of which have been explored in models of PD.   
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 An attempt was made to measure MMP-3 activity in protein samples collected 24 
hours post-surgery using a FRET-based substrate assay; however, the results suggested 
that the substrate used could be detected by additional proteins present in both LPS-
treated and control samples.  It is suspected that this may be a common problem 
associated with these substrate assays; therefore, their use may be more appropriate for 
more isolated systems, such as cell culture or in vitro enzyme kinetic assays.  In the 
future, alternative methods to measure MMP activity should be employed.  These include 
gelatin and casein zymography for the detection of activated MMP-2 and MMP-3, 
respectively.  The FRET-based assay was chosen based on its lower activity detection 
threshold compared to zymographic methods.  The lack of sensitivity inherent with a gel-
based assay could be overcome by immunoprecipitation to pull down all of the MMP-2 
or MMP-3 present in a sample prior to running the zymogram assay. 
 Increased MMP-2 and MMP-3 activity could contribute to DA neurodegeneration 
in a variety of ways.  First, increased MMP-2 and MMP-3 activity mediates BBB 
disruption in stroke and other models of neuroinflammation (26, 27, 79, 240).  Although 
BBB disruption has not been conclusively demonstrated in PD patients, BBB leakage 
occurs in response to 6-OHDA and MPTP, and emerging evidence points to the 
peripheral immune system as an important component in PD (31, 146, 248).  Second, 
MMP-3 is required for maximal microglial activation by LPS and can induce certain 
aspects of an activated microglial response by itself (106, 108).  This suggests that MMP-
3 could contribute to neurodegeneration by supporting microglia-mediated DA 
neurotoxicity.  Third, MMP-3 could act intracellularly to promote DA neurodegeneration, 
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as was recently shown to occur in BH4-treated DA cells (37).  Fourth, α-synuclein is a 
target for MMP-2 and MMP-3 proteolysis (217).  In particular, the α-synuclein fragments 
generated by MMP-3-mediated proteolysis promote α-synuclein fibril formation and 
consequent aggregation, which increases its toxicity towards DA neurons (121, 217).  
Furthermore, aggregated α-synuclein directly activates resting microglia (246), although 
it is not clear if aggregates formed following degradation by MMP-3 duplicate this effect.  
Whether CTGF/CCN2 is involved in any of these processes remains to be seen, but the 
increased CTGF/CCN2 expression at the same time points as increased MMP-2 and 
MMP-3 expression and activation indicates that CTGF/CCN2 could mediate some of 
these effects. 
 Upon discovery that active MMP-3 was induced by intranigral LPS injection, it 
was expected that MMP-9, if present, would also be activated.  Activated MMP-3 is 
capable of activating MMP-9 in a process that involves two MMP-3-dependent 
proteolytic events within the MMP-9 prodomain (161, 201).  Despite the ability of MMP-
3 to activate MMP-9, only the 92kDa band corresponding to proMMP-9 was detected by 
western blot following intranigral LPS injection.  The following scenario may explain the 
lack of active MMP-9.  TIMP-1 regulates proMMP-9 activation by binding to its C-
terminal hemopexin-like domain (150).  Even when bound to MMP-9, TIMP-1 retains its 
ability to inhibit active MMPs, including MMP-3; however, interaction with an active 
MMP results in dissociation of the proMMP-9:TIMP-1 complex, freeing proMMP-9 for 
activation by TIMP-free active MMP-3 (150).  Therefore, the total amount of active 
MMP must exceed the amount of TIMP-1 present in the tissue to permit MMP-3-
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mediated activation of proMMP-9.  The presence of TIMP-1 in the ventral midbrain may 
explain the lack of proMMP-9 activation.  TIMP-1 has been detected in the human SNc 
(127); therefore, it would not be surprising if the rat SNc also expressed TIMP-1.  
Another possible explanation involves the spatial distribution pattern of MMP-3 and 
MMP-9.  They could be expressed in different locations within the SNc in such as way 
that they are unable to interact.  Immunohistochemical experiments are needed to address 
potential differences in spatial distribution and to identify the cell types associated with 
MMP upregulation.  Also, it cannot be ruled out that the antibody used was not 
sufficiently sensitive to detect low levels of active MMP-9.  Gelatin zymography could 
be done in order to completely rule out the presence of active 84kDa MMP-9. 
 Unlike MMP-2, -3, and -9, proMMP-13 expression did not change in response to 
LPS, despite the fact that transcriptional regulation of MMP-13 is very similar to that 
described above for MMP-3 and MMP-9.  In fact, the promoters for MMP-3, MMP-9, 
and MMP-13 each contain AP-1 and Ets-1 recognition sites just upstream from the 
TATA box that are involved in TNF-α and IL-1β-mediated regulation of these genes (51, 
122, 239).  These results suggest that MMP-13 is not involved in LPS-mediated 
neuroinflammation.  The function of MMP-13 in the brain is poorly understood; 
however, recent data from cerebral ischemia models support the idea that MMP-13 is not 
involved in neuroinflammation.  Cerebral ischemia causes a prolonged increase in MMP-
13 expression within and surrounding cortical neurons beginning 3 days after reperfusion.  
Expression remains elevated during the injury recovery phase, implicating MMP-13 in 
post-injury neuronal remodeling (154).  In addition, MMP-13 is expressed in normal 
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brain, suggesting that it serves an important physiological role and that its expression is 
regulated by mechanisms different from those involved in upregulation of the other 
MMPs in response to neuroinflammation.  In the current study, proMMP-13 was 
expressed in contralateral and ipsilateral nigral tissue in all animals.  Similar results were 
reported in the previous chapter which also examined striatal tissue samples from the 
intrastriatal 6-OHDA model.  Others have also detected proMMP-13 expression within 
neurons of non-injured cortex (154).   
 The increase in CTGF/CCN2 expression in response to neuroinflammation-
induced nigrostriatal damage is a novel finding.  MMP-3 is capable of regulating 
CTGF/CCN2 function through proteolytic cleavage of CTGF/CCN2 protein and by 
directly binding to the CTGF/CCN2 promoter to trigger transcription (57, 83).  Full 
length CTGF/CCN2 expression increased 5-fold following intranigral LPS injection and 
preliminary data hints that a limited amount of CTGF/CCN2 degradation occurs in 
correlation with increased MMP-2 and MMP-3 activation.  This suggests that if MMPs 
are involved in the regulation of CTGF/CCN2 function, it could occur though 
transcriptional and/or post-translational regulation. 
 Increased MMP-2 and MMP-3 protein expression and activity is associated with 
neuroinflammation-induced DA neurodegeneration.  In addition, this is the first report to 
demonstrate that CTGF/CCN2 could be involved in PD pathology.  Furthermore, the 
results further extend support for a significant role for MMP-3 in DA neurodegeneration.  
Studies that interrupt MMP and/or CTGF/CCN2 function are needed to further 
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characterize the role of these proteins in neurodegeneration and to assess their potential 
as a target for the development of novel neuroprotective therapies for PD.    
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CHAPTER 5  
Matrix Metalloproteinase and Connective Tissue Growth Factor 
Expression in Lipopolysaccharide-treated BV-2 Microglia 
 
5.1 Introduction 
 In the preceding chapter, nigral MMP and CTGF/CCN2 protein expression was 
measured following intranigral LPS injection.  Increased expression and activation of 
MMP-2 and MMP-3 was temporally associated with neuroinflammation-induced DA 
neurodegeneration.  ProMMP-9 protein expression also increased in response to LPS, but 
it was not activated, while proMMP-13 was unaffected.  In association with activated 
MMP-2 and MMP-3, there was a significant increase in CTGF/CCN2 protein expression 
along with potentially low levels of MMP-cleaved CTGF/CCN2.  The strong temporal 
relationship between MMP-2 and MMP-3 activation, CTGF/CCN2 upregulation, and 
LPS-induced DA injury suggests that these proteins may participate in events leading to 
microglial activation or DA cell death.   
 Identification of the cell types responsible for altered MMP and CTGF/CCN2 
expression will provide valuable information regarding the potential role of these proteins 
in DA neurodegeneration.  Microglia are likely candidates for MMP-3 and MMP-9.  In 
primary rat microglia cultures, LPS treatment induces MMP-3 and MMP-9 expression in 
a dose-dependent fashion (237).  In addition, MMP-3 upregulation in microglia occurs
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during reperfusion injury following ischemic stroke (79, 187, 208).  Expression of MMP-
2 in microglia has not been described; however, astrocytes express MMP-2, which is kept 
localized to the plasma membrane of astrocytic end feet, placing MMP-2 in prime 
position to regulate the opening of the BBB during neuroinflammation (27).  
Characterization of CTGF/CCN2 expression in the brain is limited.  It has been detected 
in specific populations of pyramidal neurons in normal brain and in reactive astrocytes 
following brain injury or in response to neurodegeneration (87, 111, 197, 198, 212), but 
expression in microglia has not been described. 
 In response to LPS, microglia transform from a resting state to an activated state 
which is characterized by enhanced proliferation, morphological transformation, 
proinflammatory cytokine production, nitric oxide release, and ROS generation (14, 16).  
This dramatic response occurs through receptor-mediated mechanisms, many of which 
involve the binding of LPS to TLR4, which requires the presence of LPS binding protein 
and CD14 (56).  Since microgliosis is a prominent consequence of nigral LPS exposure 
and microglial-derived proinflammatory factors promote DA neurodegeneration, it was 
hypothesized that changes in MMP and CTGF/CCN2 expression directly involved 
microglia.   
 The following chapter describes a preliminary attempt to address this hypothesis 
in vitro using BV-2 cells, an immortalized murine microglial cell line commonly used to 
study the microglial response to LPS (13, 18).  The goal of this study was to measure 
MMP-2, -3, -9, and CTGF/CCN2 protein expression in response to LPS in order to 
determine the suitability of this model for further study of MMP-CTGF/CCN2 
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interactions.  In addition, this data would provide a first look at microglia as the potential 
source for alterations in MMP and CTGF/CCN2 protein expression in LPS-induced DA 
neurodegeneration. 
 
5.2 Materials and Methods 
 Materials.  DMEM, L-glutamine, penicillin/streptomycin, PBS, 4-12% 
polyacrylamide 10-well bis-tris gels, 0.25% trypsin-EDTA, 0.45µm nitrocellulose 
membranes, sample reducing agent, LDS sample buffer, MES running buffer, antioxidant 
solution, western blot transfer buffer, and MMP-3 ELISA kit were acquired from 
Invitrogen Corp. (Carlsbad, CA).  Amicon Ultra-15 centrifugal filter devices with a 3kDa 
molecular weight cutoff were procured from Millipore (Billerica, MA).  Culture flasks 
and plates, SDS, CaCl2·2H2O, NaCl, sodium deoxycholate, tris-HCl, Tween-20 and 
bovine serum albumin (fraction V) were purchased from Fisher Scientific (Pittsburgh, 
PA).  NP-40, NaOH, APMA, and Triton X-100 were obtained from Sigma-Aldrich (St. 
Louis, MO).  FBS was secured from Gemini Bio-products (West Sacramento, CA).  
Protease inhibitor cocktail was purchased from Calbiochem (San Diego, CA).  Full length 
recombinant human MMP-3 was procured from Abcam, Inc. (Cambridge, MA).  Goat 
anti-human CTGF/CCN2 (Cat# sc-14939) and bovine anti-goat IgG-HRP (Cat# sc-2350) 
were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).  SuperSignal 
West Dura extended duration HRP substrate solution was obtained from Pierce 
(Rockford, IL).  Goat anti-mouse MMP-2 (Cat# AF1488), goat anti-mouse MMP-3 
(Cat#AF548), and goat anti-mouse MMP-9 (Cat# AF909) were obtained from R&D 
   
130 
Systems, Inc. (Minneapolis, MN).  Non-fat dry milk was bought from The Kroger Co. 
(Cincinnati, OH).  Methanol was purchased from Colonial Scientific, Inc. (Richmond, 
VA). 
 BV-2 Cell Culture.  Passage 3 murine BV-2 microglial cells were kindly 
provided by Dr. Michele Block.  Cells were maintained in DMEM supplemented with 
10% FBS, 2mM L-glutamine, 100U/mL penicillin, and 100µg/mL streptomycin.  Cells 
were passed regularly as needed and culture media was replaced every 3rd day.  For 
experiments, cells were plated in 6-well plates or T25 flasks at a density of 3x104 to 
4x104 cells/cm2 in 2% FBS media.  For ELISA and nitrite assays, cells were treated with 
0, 10, or 100ng/mL LPS in media containing 2% FBS.  For western blot experiments, 
cells were activated with 100ng/mL LPS in media containing 2% FBS for 16 hours.  
Then cells were placed in serum-free, LPS-free media and conditioned media was 
collected 24 hours later for MMP and CTGF/CCN2 protein detection.   
 Protein Extraction.  Media was saved and cells were rinsed three times with 
2mL PBS.  Saved media was kept on ice and concentrated as described below.  PBS 
washes were saved and centrifuged at 1000rpm for 6 minutes to collect cells that had 
detached.  The supernatant was discarded and the cell pellet was homogenized in 50µl 
ice-cold protein extraction buffer (50mM Tris-HCl pH 7.2, 150mM NaCl, 1% sodium 
deoxycholate, 1% NP-40, 0.5% SDS) containing a protease inhibitor cocktail.  Cells 
remaining in T25 flasks or 6-well plates were homogenized in 250µl or 150 µL ice-cold 
extraction buffer, respectively.  Homogenates were collected into 1.5mL microcentrifuge 
tubes, repeatedly passed through a 26-guage needle connected to a 1mL syringe, and 
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centrifuged at 14,000 x g for 30 minutes at 4°C.   Supernatants were saved and stored at     
-80°C until use.  Protein concentration was determined with the DC protein assay (Bio-
Rad Laboratories, Hercules, CA) using bovine serum albumin solutions prepared in 
protein extraction buffer to construct the standard curve. 
 Concentration of Conditioned Media.  Conditioned media (10mL) was 
centrifuged for 6 minutes at 1000rpm at 4°C to remove cellular debris.  Supernatants 
were transferred to sample reservoirs of Amicon Ultra 15mL filter units with a 3kDa 
molecular weight cut-off.  Filter units were centrifuged at 2500rpm in a refrigerated 
centrifuge set at 4°C.  Centrifugation was continued until media volume had been 
reduced to approximately 250µl (20:1).  Concentrated conditioned media was transferred 
from sample reservoir to a 1.5mL microcentrifuge tube, and protease inhibitor cocktail 
was added to each media sample (5µl per sample).  Concentrated conditioned media was 
stored at -80°C until use.  Protein concentration was determined with the DC protein 
assay (Bio-Rad Laboratories, Hercules, CA) using bovine serum albumin solutions 
prepared in DMEM to construct the standard curve.  Filtered media collected from 
centrifugation was used to measure nitrite as described below.  Nitric oxide is small 
enough to pass through the filter membrane. 
 Griess Assay.  The Griess assay (Promega, Madison, WI) was employed to 
measure nitrite in cell culture conditioned media to provide an indirect measure of nitric 
oxide production by BV-2 microglia.  The nitrite standard curve was prepared by diluting 
1µL 100mM nitrite in 999µL DMEM containing 2% FBS.  Serial dilutions were 
performed in 96-well plates to generate 100, 50, 25, 12.5, 6.25, 3.13, and 1.56µM nitrite.  
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Sulfanilamide solution was added to each standard and sample.  Plate was incubated at 
room temperature for 10 minutes, protected from light.  Then, N-1-
napthylethylenediamine dihydrochloride solution was added to each standard and sample, 
and then the plate was incubated at room temperature for an additional 10 minutes, 
protected from light.  Absorbance was measured at 450nm using a Fluostar Optima plate 
reader (BMG Labtech, Durham, NC). 
 TNF-α ELISA.  TNF-α was quantified in conditioned media (not concentrated) 
collected 24 hours after LPS treatment following the manufacturer’s instructions 
(eBioscience, San Diego, CA).  Briefly, wells were incubated with capture antibody 
overnight at 4°C.  After 5 washes, wells were blocked for 1 hour at room temperature, 
washed, and then incubated with 50µL of conditioned media overnight at 4°C.  Wells 
were washed, incubated in detection antibody for 1 hour, washed again, incubated in 
avidin-HRP for 30 minutes, washed, and incubated in substrate solution for 15 minutes. 
Stop solution was added to each well prior to measuring A450nm.  Sample TNF-α 
concentration was calculated from a TNF-α standard curve.  TNF-α ELISA was 
performed by Steve Bakos in Dr. Richard Costanzo’s lab. 
 MMP-3 ELISA.  Protein lysates and conditioned media (not concentrated) 
samples were collected 24 hours after treatment with 100ng/mL LPS in 2% FBS media.  
MMP-3 ELISA was performed following manufacturer’s instructions.  Briefly, 50µl of 
each sample or MMP-3 standard was combined with 50µl incubation buffer in 8-well 
strips precoated with MMP-3 capture antibody.  Biotinylated anti-MMP-3 was added to 
each well and the plate was incubated for 2 hours at room temperature.  After 4 washes, 
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wells were incubated in streptavidin-HRP solution for 30 minutes at room temperature.  
Wells were washed 4 times and then were incubated in 100µL chromogen solution for 35 
minutes.  An equal volume of stop solution was added to each well and then A450 was 
measured using a Fluostar Optima plate reader.  Sample MMP-3 content was calculated 
from a standard curve constructed from human recombinant MMP-3 formulated at the 
following concentrations in ng/mL: 0, 0.625, 1.25, 2.5, 5, and 10. 
 Western Blot.  LDS Sample buffer and sample reducing agent were added to 
concentrated conditioned media (20µg) and protein lysates (30µg).  Samples were heated 
to 70°C for 10 minutes, loaded on 4-12% polyacrylamide bis-bris gels, separated by 
SDS-PAGE (50 minutes at 200V), and transferred to nitrocellulose membranes (2 hours 
at 30V).  Membranes were blocked for 1 hour in 5% non-fat dry milk prepared in TBST.  
Membranes were incubated in MMP-2, MMP-3, MMP-9, or CTGF/CCN2 primary 
antibody overnight at 4°C.  Membranes were washed 4 x 5 minutes in TBST and were 
incubated in peroxidase conjugated bovine anti-goat IgG or goat anti-rabbit IgG 
secondary antibodies for 90 minutes at room temperature.  Membranes were washed 6 x 
5 minutes in TBST.  Immunoreactivity was visualized with SuperSignal West Dura 
substrate followed by exposure to film.    
 Activation of Human Recombinant MMP-3.  APMA stock solution (10mM) 
was prepared in 50mM NaOH.  1mL APMA stock solution was diluted to 2mM APMA 
with 4mL assay buffer (50mM Tris-HCl pH 7.5, 5mM CaCl2·2H20, 0.05% Triton X-100).  
Recombinant human MMP-3 stock solution was diluted to 5ng/µl with assay buffer.  
Equal volumes (25µl) of 5ng/µl MMP-3 and 2mM APMA were combined in 0.6mL 
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microcentrifuge tubes and were incubated for 4 hours at 37°C.  Reaction mixtures were 
immediately combined with concentrated conditioned media samples used to determine 
the ability of activated MMP-3 to degrade 52kDa CTGF/CCN2 immunoreactivity. 
 Statistical Analysis.  Statistical tests were performed using JMP software 
(version 7.0).  MMP-3 ELISA and Griess Assay nitrite data were compared with one-way 
ANOVA (α=0.05) followed by the post-hoc Tukey-Kramer test to determine where 
significant differences resided.  Quantitative data is presented as mean ± standard 
deviation. 
 
5.3 Results 
 Since LPS directly activates microglia through receptor mediated mechanisms, it 
was hypothesized that changes in MMP and CTGF/CCN2 expression detected following 
intranigral LPS injection occurred in microglia.  Initial experiments aimed at addressing 
this hypothesis studied the effect of LPS on MMP and CTGF/CCN2 expression in the 
immortalized murine BV-2 microglia cell line.  To demonstrate LPS activation of this 
cell line, BV-2 cells were treated with 0, 10, or 100 ng/mL LPS in 2% FBS media for 24 
hours.  TNF-α protein and nitrite were measured in the collected conditioned media by 
ELISA and Griess assay, respectively.  TNF-α production increased in response to LPS 
treatment (Figure 5.1A).  The magnitude of this increase was similar for both the 10 and 
100ng/mL treated cells.  Similar to TNF-α, LPS treatment induced a significant increase 
in nitric oxide production (Figure 5.1B, p=0.002).  Nitric oxide and TNF-α were barely 
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FIGURE 5.1: Activation of BV-2 Microglial Cells with LPS 
BV-2 microglia were treated with LPS (0-100 ng/mL) for 24 hours.  Conditioned media 
was collected for TNF-α and nitrite measurements.  A)  TNF-α ELISA (n=1).  LPS 
treatment increased TNF-α secretion by BV-2 microglia.  Little TNF-α was present in 
conditioned media harvested from untreated control cells.  B)  Griess Assay (n=2).  LPS 
treatment caused a concentration dependent increase in nitric oxide production.  
Untreated cells generated very low levels of nitric oxide.  Data presented as mean ± 
standard deviation.  Asterisks denote significance compared to untreated controls.
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detectable in untreated control cultures.  These results demonstrate that LPS induces 
activation of BV-2 microglia, consistent with the literature on this cell line (108). 
 Next, the effect of LPS on MMP-3 expression was measured by ELISA.  BV-2 
microglia were cultured and treated with LPS for 24 hours as described.  At the end of 
treatment, conditioned media and protein lysates were collected and ELISA was 
performed (Figure 5.2).  MMP-3 was detected in BV-2 lysates, but LPS had no 
measurable effect on its expression (p=0.08).  MMP-3 was not detected in conditioned 
media samples, indicating that the MMP-3 concentration was below the detection limit of 
the ELISA.  As an alternative method for MMP-3 detection, western blot was performed 
on concentrated conditioned media samples.  
  Conditioned media must be collected under serum free conditions for 
measurement of secreted MMPs by western blot.  This requirement presented a challenge 
since full activation of microglia is TRL4 receptor dependent.  The binding of LPS to this 
receptor requires LPS-binding protein, which is only present in serum (56); therefore, 
serum is essential for LPS to maximally activate microglia.  It was decided to compare 
nitric oxide production by microglia during LPS treatment in 2% FBS media to nitric 
oxide production after LPS and serum are removed.  Conditioned media samples were 
collected after cells were treated with 100ng/mL LPS for 16 hours in 2% FBS media.  
After media collection, cells were cultured in serum free media.  After 24 hours, serum-
free conditioned media was collected and concentrated.  As before, 100ng/mL LPS 
treatment induced a significant increase in nitric oxide production compared to untreated 
controls (Figure 5.3).  Importantly, BV-2 microglia sustained this nitric oxide production 
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FIGURE 5.2: Effect of LPS on MMP-3 Expression in BV-2 Microglia 
BV-2 microglial cells were treated with 0-100ng/mL LPS for 24 hours.  Conditioned 
media and protein lysates were collected and MMP-3 was measured by ELISA.  
Treatment with LPS had no effect on MMP-3 present in protein lysates (p=0.08).  MMP-
3 in conditioned media was below the detection limit of the assay.  Data presented as 
mean ± standard deviation (n=2).  
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FIGURE 5.3: Effect of Serum Withdrawal on LPS-induced Nitric Oxide Production 
in BV-2 Microglia.  BV-2 microglia were treated with 100 ng/mL LPS for 16 hours in 
the presence of 2% FBS.  After 16 hours, serum was removed and activated cells were 
incubated in serum free media for 24 hours.  Conditioned media was collected and nitric 
oxide production was compared in samples collected just before serum was removed 
(during) to samples collected 24 hours after serum removal (after).  LPS induced nitric 
oxide production in BV-2 microglia (p<0.001).  Nitric oxide production was sustained 
after removal of LPS and serum from the culture (p<0.001), indicating that BV-2 
microglia remained in an activated state.  Data presented as mean ± standard deviation 
(n=3).  Asterisks denote significance compared to vehicle-treated controls. 
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once the cells were switched to serum free media, indicating that the activated state was 
maintained.  Once this was established, MMP expression was measured in concentrated 
conditioned media and BV-2 protein lysates (Figure 5.4).  ProMMP-3 was detected in 
cell lysates, while mainly the active form of MMP-3 was detected in concentrated 
conditioned media; however, 100ng/mL LPS treatment had no apparent effect on MMP-3 
expression or activation compared to controls.   
 The effect of LPS on gelatinase expression was also examined by western blot.  
Pro and active MMP-2 was detected in BV-2 lysates, while little was present in 
conditioned media.  Similar to the results for MMP-3, LPS had no effect on MMP-2 
expression or activation.  In contrast, proMMP-9 was detected at low levels in 
conditioned media collected from untreated control cells.  Treatment with LPS 
dramatically increased proMMP-9 expression, but no active MMP-9 was detected.  
MMP-9 was not present in protein lysates. 
 The presence of CTGF/CCN2 in concentrated conditioned media and cell lysates 
was also measured by western blot using samples treated with or without 100ng/mL LPS.  
CTGF/CCN2, a 38kDa protein, was not detected in any samples at this molecular weight.  
Instead, immunoreactivity in concentrated conditioned media samples was focused at 
~52kDa (Figure 5.4).  This band was barely detectable in cell lysates and 100ng/mL LPS 
treatment did not alter its expression in media samples.  CTGF/CCN2 is capable of 
binding to many proteins through its four structural motifs, including TGF-β which binds 
to the von Willebrand type C motif, IGF-1 which binds to the IGF binding protein motif, 
and VEGF which binds to both the cysteine knot and thrombospondin-1 motifs (49).  
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FIGURE 5.4: Effect of LPS on MMP-2, MMP-3, MMP-9, and CTGF/CCN2 Protein 
Expression in BV-2 Microglia.  BV-2 microglia were treated with 100ng/mL LPS for 16 
hours in the presence of 2% FBS.  Serum and LPS were removed and cultures were 
incubated in serum free media for 24 hours.  Conditioned media and protein lysates were 
collected and protein expression was measured by western blot.  LPS had no effect on 
MMP-2, MMP-3, or CTGF/CCN2 protein expression.  Immunoreactivity for 
CTGF/CCN2 was concentrated at 52kDa.  No 38kDa CTGF/CCN2 was detected.  LPS 
treatment strongly induced proMMP-9 expression, which was found only in conditioned 
media.  No active MMP-9 was detected. 
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This ability of CTGF/CCN2 to interact with many other proteins brought up the 
possibility that the 52kDa immunoreactive CTGF/CCN2 band consisted of CTGF/CCN2 
and a tightly bound binding partner.  It was hypothesized that if this was CTGF/CCN2 
bound to another protein, then the addition of activated MMP-3 to concentrated 
conditioned media samples would result in digestion of this band.  It was predicted that 
the 52kDa band would be reduced to ~20kDa, similar to what has been reported for 
MMP-3-mediated cleavage of CTGF/CCN2 (83).  To test this, recombinant human 
MMP-3 was incubated in APMA for 4 hours at 37°C to activate MMP-3 (57).  Activated 
MMP-3 was then incubated for 12 hours at 37°C in concentrated conditioned media from 
cells that had been treated with 100ng/mL LPS.  At the conclusion of the incubation, 
EDTA (20mM) was added to terminate MMP-3-mediated proteolysis.  Samples were 
then analyzed by western blot.  APMA treatment resulted in significant activation of 
MMP-3; however, activated MMP-3 had no effect on the 52kDa immunoreactive band 
(Figure 5.5).  The data suggests that this band is not a MMP-3 target; however, it does not 
rule out the possibility that this band contains CTGF/CCN2 protein.  It is possible that the 
interaction between CTGF/CCN2 and the interacting protein block access to the 
CTGF/CCN2 hinge region, which could prevent MMP-mediated proteolysis.  However, 
it is clear that LPS has no effect on the 52kDa band intensity, which does not match the 
in vivo effect observed for CTGF/CCN2.  Based on this, combined with the lack of 
microglial CTGF/CCN2 expression described in other central nervous system injury 
models, it seems possible that the 52kDa band is not CTGF/CCN2; however, further 
studies are needed to confirm this. 
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FIGURE 5.5: Effect of Activated MMP-3 on 52kDa CTGF/CCN2 
Immunoreactivity.  CTGF/CCN2 can be degraded by MMP-3 into two 20kDa bioactive 
fragments.  Recombinant proMMP-3 was activated with APMA treatment (4hrs).  
Activated MMP-3 was incubated with conditioned media samples obtained from LPS-
stimulated BV-2 microglia for 16 hours at 37°C.  A) CTGF/CCN2 western blot.  
Incubation of conditioned media samples with activated MMP-3 did not result in 
degradation of the 52kDa immunoreactive band.  B) MMP-3 western blot confirming that 
APMA treatment caused MMP-3 activation. 
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5.4 Discussion 
 When injected into the SNc, LPS triggers MMP-3 and MMP-9 expression and 
upregulates basal expression of CTGF/CCN2 and MMP-2 at time points that match the  
neurodegenerative response, suggesting that these proteins may be involved in 
neuroinflammation-induced DA neurodegeneration.  Lesion formation in response to LPS 
is driven by neurotoxic factors derived from activated microglia.  BV-2 microglia are 
commonly used to study the characteristics of microglial activation in response to LPS 
and were used in the above experiments to examine the effect of LPS on MMP and 
CTGF/CCN2 protein expression.  LPS treatment resulted in robust activation of BV-2 
microglia that was characterized by significant upregulation of TNF-α and increased 
release of nitric oxide.  In addition, proMMP-9 expression was induced by LPS 
treatment; however, MMP-2 and MMP-3 expression and activation did not change in 
response to LPS, while 38kDa CTGF/CCN2 was not detected.  These experiments 
identify microglia as the potential source for MMP-9 expression observed in the in vivo 
response to intranigral LPS. 
 MMP-9 expression was induced by LPS treatment, a response that could be 
detected with as little as 1ng/mL LPS (data not shown).  This strong response may have 
important implications regarding the temporal expression pattern of MMP-9 described in 
the in vivo LPS model of PD.  In vivo, proMMP-9 expression peaked prior to the 12 hour 
time point, well before maximum MMP-2 and MMP-3 expression were detected.  Since 
microglia activate within hours of LPS exposure, the early peak of proMMP-9 may be 
due to increased expression in microglia.  It is difficult to predict the functional 
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significance of the increase in proMMP-9 expression exhibited by microglia, since no 
active MMP-9 was present in either the BV-2 or rat model, suggesting a lack of MMP-9-
mediated proteolysis.  It is interesting to note that the C-terminal hemopexin-like domain 
of MMP-9 can be bound by TIMP-1 when in its proform (150).  If an excess of proMMP-
9 were present, MMP-9 could potentially act as a TIMP-1 sink.  By binding to TIMP-1, 
proMMP-9 may make it more likely that other MMPs present could become and remain 
proteolytically active.  Such a role for MMP-9 has never been described and several 
studies have shown that the TIMP-1 bound to proMMP-9 is still capable of binding to 
and inhibiting active MMPs, including MMP-3 (150).  The ability of TIMP-1 to continue 
to bind other MMPs even when bound to proMMP-9 indicates that proMMP-9 cannot 
sequester TIMP-1 away from other MMPs. 
 The lack of an MMP-3 response to LPS in BV-2 microglia was not completely 
unexpected, even though microglia have been identified as a source for MMP-3 in 
various models of neuroinflammation and neurological diseases (26, 79, 208).  In 
cultured cells, expression of MMP-3 mRNA was shown to not be affected by LPS 
treatment in BV-2 microglia; however, a strong induction of MMP-3 was noted in LPS-
treated primary rat microglia (237).  MMP-3 expression has also been described in 
neurons and astrocytes.  Stressed DA neurons express MMP-3 following treatment with 
MPTP or BH4, and primary astrocyte cultures express MMP-3 following LPS treatment 
(37, 102, 106).  In addition, MMP-3 has been localized to reactive astrocytes in models of 
traumatic brain injury (63, 101).   
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 MMP-2 was expressed by BV-2 microglia, but LPS had no effect on this 
expression or on MMP-2 activation.  MMP-2 expression has never been co-localized 
with microglia in vivo; however, in agreement with the studies described in this chapter, 
primary microglia cultures constitutively express MMP-2 (45, 124, 125).  Several studies 
have demonstrated that LPS has no effect on constitutive MMP-2 expression in primary 
microglia, but LPS does cause a significant increase in MMP-2 expression in astrocytes 
(124-126).  In addition, data from cerebral ischemia/reperfusion models suggest that 
astrocytes are likely sources of MMP-2 in vivo.  In these models, MMP-2 expression is 
localized to astrocytic end feet processes surrounding capillary epithelial cells (27, 47). 
 Little is known about CTGF/CCN2 function in the central nervous system and its 
expression has never been described in microglia.  In the uninjured brain, CTGF/CCN2 is 
expressed by subpopulations of pyramidal neurons and neurons present in the olfactory 
bulb (87, 111).  In response to injury and neurodegeneration, CTGF/CCN2 expression 
has been described in reactive astrocytes (86, 197, 198, 212, 225).  In BV-2 microglia, a 
52kDa band of immunoreactivity was detected by the CTGF/CCN2 antibody, which is 
12-14kDa larger than the molecular weight of full length CTGF/CCN2.  Given the ability 
of CTGF/CCN2 to bind to growth factors, cytokines, and other proteins within the ECM, 
it was possible that this high molecular weight CTGF/CCN2 immunoreactivity 
represented CTGF/CCN2 bound to a binding partner.  Since CTGF/CCN2 is susceptible 
to MMP-3-mediated cleavage, it was reasoned that treatment of concentrated conditioned 
media with APMA-activated MMP-3 would result in degradation of the 52kDa band and 
the appearance of the 20kDa CTGF/CCN2 fragments characteristic of MMP-mediated 
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CTGF/CCN2 cleavage  (83).  Degradation did not occur when concentrated conditioned 
media was incubated with activated MMP-3 for 16 hours, suggesting that the 52kDa band 
recognized by the CTGF/CCN2 antibody cannot be degraded by MMP-3.  Interference 
with MMP-3 access to the CTGF/CCN2 cleavage site located between the von 
Willebrand factor and thrombospondin-1 motifs caused by the presence of a 
CTGF/CCN2 binding partner cannot be ruled out.  In addition, MMP-3 western blot of 
activated MMP-3 revealed that most of the activated MMP-3 present in reaction mixtures 
lacked the C-terminal hemopexin-like domain.  It may be possible that MMP-3-mediated 
cleavage of CTGF/CCN2 requires recognition of the cleavage site by the hemopexin-like 
domain.  The presence of TIMPs in concentrated conditioned media could have also 
interfered with MMP-3 proteolytic activity, preventing it from degrading the 52kDa 
band.  An alternative explanation is that the 52kDa band does not represent CTGF/CCN2 
immunoreactivity.   
 These experiments indicate that BV-2 microglia are not the ideal model to study 
interactions between MMPs and CTGF/CCN2.  Strong induction of proMMP-9 was 
observed following LPS treatment; however, MMP-2, MMP-3, and CTGF/CCN2 
expression was unaltered.  The lack of an effect on these three proteins also supports the 
idea that the MMP response to LPS-mediated neurodegeneration is complex, likely 
involving microglia and other cell types, such as astrocytes and neurons.  Mixed 
mesencephalic cultures established from embryonic mice or rats represents an alternative 
model to study these proteins in vitro.  In addition, immunohistochemical studies are 
needed to determine which cell types participate in the dramatic changes in MMP and 
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CTGF/CCN2 expression that accompany neuroinflammation-mediated DA 
neurodegeneration.  Spatial characterization of these proteins will greatly assist in 
determining the functional consequences of their overexpression in PD models.   
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CHAPTER 6  
General Discussion 
 
6.1 Summary of Important Findings  
 This project has successfully measured the temporal expression pattern of four 
MMPs in three different models of PD: 1) 6-OHDA treated DA SH-SY5Y neuroblastoma 
cells, 2) unilateral intrastriatal 6-OHDA injection in rats, and 3) unilateral intranigral LPS 
injection in rats.  In SH-SY5Y cells, 6-OHDA treatment caused a time-dependent 
increase in MMP-13 mRNA expression, but did not alter constitutive MMP-2 expression 
nor did it induce MMP-3 or MMP-9.  MMP-13 upregulation coincided with the start of 
cell viability decline, suggesting that MMP-13 could be involved in the neurotoxic 
response to 6-OHDA.  To confirm the temporal relationship between MMPs and 6-
OHDA-mediated neurotoxicity, DA neurodegeneration and MMP expression was 
measured in the unilateral 6-OHDA PD rat model.  In contrast to the SH-SY5Y model, 
MMP-13 expression did not change at the time points examined, which corresponded to 
the known time course of striatal and nigral DA neurodegeneration.  In addition, 6-
OHDA caused an overall increase in nigral proMMP-2 expression, but did not induce 
activation.  In the striatum, a delayed increase in proMMP-2 expression was observed in 
both 6-OHDA and ascorbic acid injected rats, suggesting that this was due to mechanical 
injury.  Similar to the SH-SY5Y model, 6-OHDA did not induce MMP-3 or MMP-9
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expression.  Given the role of MMPs in neuroinflammation and their presence in other 
models of neurodegeneration, I was surprised to find that 6-OHDA was not associated 
with significant changes in MMP activation in vivo.  At this point, it was decided to 
characterize the MMP response in neuroinflammation-induced DA neurodegeneration to 
provide a detailed comparison of temporal MMP expression in an inflammatory and 
neurotoxin model.  LPS was used to lesion the nigrostriatal system through 
neuroinflammatory mechanisms.  In this model, MMP-2, MMP-3, and MMP-9 
expression increased at time points associated with nigral DA neurodegeneration.  In 
addition, increased MMP-2 and MMP-3 expression was accompanied by activation of 
these two MMPs.  No change in proMMP-13 expression was detected in response to 
LPS.  
  In the LPS study, measurement of CTGF/CCN2 was included.  CTGF/CCN2 is a 
target of MMP-2 and MMP-3 proteolytic activity, and MMP-3 was recently shown to 
directly regulate trans-activation of the CTGF/CCN2 gene in a novel transcription factor 
mechanism (57, 83).  In parallel with increased MMP-3 expression and activation, 
upregulation of CTGF/CCN2 was detected along with degraded products that potentially 
represent cleaved CTGF/CCN2, a result that will require further examination.  This is the 
first study to describe alterations in CTGF/CCN2 expression in PD, and the temporal 
relationship between CTGF/CCN2, MMP-3, and DA neurodegeneration suggests that 
CTGF/CCN2 may serve an important function in neuroinflammation-induced DA 
neurodegeneration.   
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 The subsequent sections below describe the potential significance of the MMP 
and CTGF/CCN2 response as it relates to PD.  Particular emphasis is placed on MMP-2 
and MMP-3, since the active form of these MMPs was prominent in the LPS model.  The 
potential functions of MMP-2, MMP-3, and CTGF/CCN2 in neuroinflammation and DA 
neurodegeneration are discussed in detail.  An effort is made to compare 6-OHDA and 
LPS-mediated neurodegeneration with known PD pathology.  Finally, future experiments 
aimed at further characterization of the functional role of MMP-2, MMP-3, and 
CTGF/CCN2 in models of PD are outlined. 
 
6.2 Comparing 6-OHDA and LPS Animal Models to Human Parkinson’s Disease: Is 
there an Argument for MMP involvement in PD? 
 Factors that drive progressive neurodegeneration in PD remain to be elucidated; 
however, strong evidence supports that chronically activated microglia contribute to 
degeneration of DA neurons (14, 16).  The leading mechanism proposed to explain how 
microglia function in neurodegeneration involves the self-sustaining neurotoxic cycle 
(14, 16).  In this cycle, damaged DA neurons release signaling proteins and other factors 
that initiate an activated microglial response.  In return, microglia-derived 
proinflammatory cytokines, ROS, and nitric oxide exert neurotoxic effects on remaining 
DA neurons.  This cycle is self-sustaining due to microglia-activating factors released by 
DA neurons and to neurotoxic factors elaborated by activated microglia. 
 Initiation of the self-sustaining neurotoxic cycle could potentially be neurotoxin- 
or inflammogen-mediated (14, 16). To address whether MMPs are involved in either 
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case, MMP expression was measured in response to 6-OHDA or LPS.  6-OHDA had no 
effect on MMP activation, while LPS induced MMP-2, MMP-3, and MMP-9 expression 
that was accompanied by activation of MMP-2 and MMP-3.  MMP-13 was not affected 
by either 6-OHDA or LPS in vivo.  One major difference that might explain the 
significantly different MMP responses concerns the microglial reaction and level of 
nigral neuroinflammation associated with each model.      
 Neurotoxicity associated with the LPS model occurs purely through 
neuroinflammation-mediated mechanisms (32, 56, 84).  In contrast, 6-OHDA causes 
significant neuronal death through its direct interaction with the DA neuron; however, a 
microglial reaction does accompany neurodegeneration, which is believed to be involved 
in slow loss of DA neurons at later time points (41, 193, 215).  Studies that examine these 
models refer to the microglial reaction in general terms as an activated microglia 
response; however, there are different stages of the activation response that could have 
potentially significant consequences towards whether or not significant changes in MMPs 
are observed.  A full microglial activation response is characterized by rapid population 
expansion involving both proliferation of resident microglia and migration of microglia 
to the injured site from surrounding regions; release of proinflammatory cytokines, ROS, 
and nitric oxide; and morphological transformation from a highly ramified resting state to 
an amoeboid phagocyte (14, 16, 113).  Importantly, intermediate activation states are 
known to exist.  Microglia can be induced to proliferation and migrate without generating 
a neurotoxic proinflammatory environment or they can trigger neuroinflammation 
without becoming fully activated phagocytes (Nixon 2008; Tambuyzer, 2009).     
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 Microglial markers commonly used to examine microglial reactions are not 
specific for particular activation states or even capable of specifically labeling only an 
activated phenotype (70, 113, 218).  These markers include the peripheral benzodiazepine 
receptor, CD11b, Iba1, MHC Class II, and GSA-lectin.  The only exception appears to be 
CD68 (ED1 in rats), which specifically labels phagocytic cells, including fully activated 
microglia (46, 158).  When examining the ED1 response, a crucial difference between the 
LPS and 6-OHDA models is brought to the surface.  Intrastriatal or intranigral injection 
of 6-OHDA fails to increase the number of ED1+ microglia over that associated with 
needle-stick injury caused by the surgery (50, 93).  This strongly indicates that 
neuroinflammation occurring secondarily to 6-OHDA neurotoxicity does not involve a 
maximal microglia response.  When CD11b is used, a clear microglial reaction is 
detected in both the striatum and SNc after intrastriatal 6-OHDA injection (41).  More 
CD11b+ microglia are present, suggesting that population expansion has occurred. 
Morphologically, they are not as highly ramified as resting microglia, but they have not 
achieved a phagocyte-like appearance, indicating that they are at an intermediate 
activated state (41).   In contrast, intranigral injection of LPS is associated with a 3-fold 
increase in the number of ED1+ microglia compared to control, and they are present 
throughout the damaged nigra (94), supporting that neuroinflammation in the presence of 
LPS involves a fully activated microglial response. 
 In addition to the stark contrast in ED1 staining, other components of 
neuroinflammation are different between these two models (Table 6.1).  For example, in 
mixed mesencephalic cultures, more than 500pg/mL of TNF-α accumulated in  
   
153 
 
 
 
T
a
b
le
 6
.1
 C
o
m
p
a
ri
s
io
n
 o
f 
6
-O
H
D
A
 a
n
d
 L
P
S
 m
o
d
e
ls
 w
it
h
 P
D
C
h
a
ra
c
te
ri
s
ti
c
6
-H
y
d
ro
x
y
d
o
p
a
m
in
e
L
ip
o
p
o
ly
s
a
c
c
h
a
ri
d
e
P
a
rk
in
s
o
n
's
 D
is
e
a
s
e
N
ig
ra
l 
D
A
 D
e
g
e
n
e
ra
ti
o
n
6
0
-7
0
%
 (
K
ir
ik
 e
t 
a
l.
 1
9
9
8
)
8
0
%
 (
Ir
a
va
n
i 
e
t 
a
l,
 2
0
0
5
)
6
0
-8
0
%
 (
K
ir
ik
 e
t 
a
l.
 1
9
9
8
)
M
ic
ro
g
li
a
l 
R
e
a
c
ti
v
it
y
M
H
C
-I
I+
 (
C
a
rv
e
y
 e
t 
a
l.
 2
0
0
5
) 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
C
D
1
1
b
+
 (
C
ic
c
h
e
tt
i 
e
t 
a
l.
 2
0
0
2
) 
  
  
  
  
  
  
  
  
  
  
  
  
  
 
E
D
1
- 
(I
c
z
k
ie
w
ic
z
 e
t 
a
l.
 2
0
0
7
; 
D
e
p
in
o
 e
t 
a
l.
 2
0
0
3
)
M
H
C
-I
I+
 (
A
ri
m
o
to
 e
t 
a
l.
 2
0
0
7
) 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
C
D
1
1
b
+
 (
Ic
z
k
ie
w
ic
z
 e
t 
a
l.
 2
0
0
5
) 
  
  
  
  
  
  
  
  
  
  
E
D
1
+
 (
Ic
z
k
ie
w
ic
z
 e
t 
a
l.
 2
0
0
5
)
M
H
C
-I
I+
 (
M
c
G
e
e
r 
e
t 
a
l.
1
9
8
8
) 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
C
D
1
1
b
 ?
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
**
C
D
6
8
+
 (
C
ro
is
ie
r 
e
t 
a
l.
2
0
0
5
)
P
ro
in
fl
a
m
m
a
to
ry
 C
y
to
k
in
e
s
*T
N
F
-α
: 
1
.5
 f
o
ld
  
 (
M
la
d
e
n
o
vi
c
 e
t 
a
l.
 2
0
0
4
) 
  
  
  
  
  
  
  
  
  
  
  
IL
-1
β
: 
n
o
n
e
 (
D
e
p
in
o
 e
t 
a
l.
 2
0
0
3
)
*T
N
F
-α
: 
3
-f
o
ld
  
 (
K
im
 e
t 
a
l.
 2
0
0
9
) 
  
  
  
  
  
  
  
  
  
  
  
  
  
 
IL
-1
β
: 
2
-f
o
ld
  
 (
D
e
p
in
o
 e
t 
a
l.
 2
0
0
3
)
T
N
F
-α
: 
3
.7
-f
o
ld
  
 (
M
o
g
i 
e
t 
a
l.
 1
9
9
4
a
) 
  
  
  
  
  
  
  
  
  
  
IL
-1
β
: 
3
.5
-f
o
ld
  
 (
M
o
g
i 
e
t 
a
l.
 1
9
9
4
b
)
α
-S
y
n
u
c
le
in
N
o
 L
e
w
y
 B
o
d
ie
s
; 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
S
y
n
-/
- 
m
ic
e
 a
re
 n
o
t 
re
s
is
ta
n
t 
to
 6
-O
H
D
A
 (
A
lv
a
re
z
-
F
is
c
h
e
r 
e
t 
a
l.
 2
0
0
8
)
N
o
 L
e
w
y
 B
o
d
ie
s
; 
s
y
n
-/
- 
m
ic
e
 a
re
 r
e
s
is
ta
n
t 
to
 L
P
S
 
(G
a
o
 e
t 
a
l.
 2
0
0
8
);
  
α
-s
y
n
 p
h
o
s
p
h
o
ry
la
ti
o
n
, 
n
it
ra
ti
o
n
, 
a
n
d
 a
g
g
re
g
a
ti
o
n
 (
C
h
o
i 
e
t 
a
l.
 2
0
0
8
)
α
-s
y
n
+
 L
e
w
y
 B
o
d
ie
s
; 
  
α
-s
y
n
 d
e
g
ra
d
a
ti
o
n
, 
p
h
o
s
p
h
o
ry
la
ti
o
n
, 
n
it
ra
ti
o
n
, 
a
n
d
 a
g
g
re
g
a
ti
o
n
  
  
  
  
  
  
  
  
 
(S
a
vi
tt
 e
t 
a
l.
 2
0
0
6
)
B
B
B
 I
n
v
o
lv
e
m
e
n
t
F
o
c
a
l 
D
is
ru
p
ti
o
n
 (
C
a
rv
e
y
 e
t 
a
l.
 2
0
0
5
)
D
is
ru
p
te
d
 (
J
i 
e
t 
a
l.
 2
0
0
8
; 
T
o
m
a
s
-C
a
m
a
rd
ie
l 
e
t 
a
l.
 
2
0
0
4
)
N
o
t 
y
e
t 
s
h
o
w
n
 d
ir
e
c
tl
y
 (
M
o
n
a
h
a
n
 e
t 
a
l.
 2
0
0
8
)
M
M
P
 R
e
s
p
o
n
s
e
N
o
 c
h
a
n
g
e
 i
n
 M
M
P
-3
, 
M
M
P
-9
 o
r 
M
M
P
-1
3
; 
 n
ig
ra
l 
p
ro
M
M
P
-2
 b
u
t 
n
o
t 
a
c
ti
va
ti
o
n
  
 a
c
ti
ve
 M
M
P
-2
 a
n
d
 M
M
P
-3
; 
 p
ro
M
M
P
-9
 
e
x
p
re
s
s
io
n
, 
n
o
 c
h
a
n
g
e
 i
n
 p
ro
M
M
P
-1
3
  
M
M
P
-1
 a
n
d
 M
M
P
-9
 i
n
 s
u
b
s
e
t 
o
f 
p
a
ti
e
n
ts
 (
L
o
re
n
z
l 
e
t 
a
l.
 2
0
0
2
)
*m
R
N
A
 l
e
ve
ls
**
C
D
6
8
 i
s
 t
h
e
 h
u
m
a
n
 o
rt
h
o
lo
g
u
e
 t
o
 r
a
t 
E
D
1
   
154 
conditioned media 6 hours after LPS treatment, while only 45pg/mL accumulated 24 
hours after an equally neurotoxic application of 6-OHDA (137).  In vivo, intranigral LPS 
injection resulted in a 3-fold increase in TNF-α mRNA expression (105), compared to a 
~1.5-fold increase following intrastriatal 6-OHDA injection (143).  In another example, 
no change in IL-1β protein expression was detected following intrastriatal 6-OHDA 
injection, while a 200% increase was observed after intranigral LPS injection (50).   
 These results support that the neuroinflammation resulting from 6-OHDA is not 
as severe as neuroinflammation associated with LPS.  This could explain why dramatic 
changes in MMP expression and activation accompany DA neurodegeneration in the LPS 
model and not in the 6-OHDA model.  TNF-α and IL-1β are classic inducers of MMP-3 
and MMP-9 expression (51, 177, 207).  The modest increase in these cytokines that 
accompany neuroinflammation in the 6-OHDA model may not be sufficient to induce 
MMP expression.  In contrast, the sizeable upregulation of TNF-α and IL-1β following 
LPS injection could provide a strong enough signal to induce MMP expression. 
 Major differences exist between the microglial reactions associated 6-OHDA and 
LPS.  The changes in MMP expression and activation associated with the LPS model 
suggest that MMPs participate in neuroinflammatory reactions characterized by the 
presence of fully activated microglia.  Given these clear differences between the models 
in regards to neuroinflammation and MMP expression, an important question is which 
model more closely matches the ongoing microglial response in human PD?  The initial 
study that examined microglial activation in PD patients demonstrated that there were 
numerous activated microglia present in the SNc, with many closely associated with 
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remaining TH+ DA neurons (138).  The authors suggested that the activated microglia 
were in the process of phagocytizing damaged DA neurons; however, they labeled 
microglia with MHC class II, which is upregulated in microglia from multiple activation 
states.  A more recent study measured activated microglia in postmortem nigral tissue 
samples using CD68, which specifically labels maximally activated phagocytic 
microglia.  Samples from PD patients displayed numerous CD68+ microglia, which had 
macrophage-like morphology and cytoplasm that contained neuromelanin granules, 
indicating that they were active phagocytes (46).  Examination of TNF-α and IL-1β levels 
in human striatal tissue samples revealed that these proinflammatory cytokines are 
elevated 366% and 350%, respectively, in PD patients compared to neurologically 
normal controls (144, 145).  These studies, which directly examine human PD tissue, 
strongly suggest that the chronic neuroinflammatory reaction ongoing in PD more closely 
resembles neuroinflammation associated with LPS (Table 6.1).  Further experiments are 
required, but this supports the idea that changes in MMP expression detected in the LPS 
model may also be a part of the ongoing neuroinflammatory reaction present in PD 
patients.   
 Clearly, the neurotoxic response to neuroinflammation is greater in the LPS 
model than is present in PD, since DA degeneration was completed 48 hours post-LPS 
administration, whereas loss of DA neurons in PD is a slow, chronic process that occurs 
over years.  Recently, a chronic LPS model has been developed in which LPS is 
delivered in a single intraperitoneal bolus.  This model results in gradual DA 
neurodegeneration that occurs over a 10 month period.  It would be interesting to 
   
156 
determine the role of MMPs in a chronic LPS model, which more closely models the 
progressive nature of PD.   
 
6.3 Dual-role for Matrix Metalloproteinases in Inflammation-induced Dopaminergic 
Neurodegeneration  
 Recent studies employing MPTP and BH4 suggest that activation of MMP-3 is 
detrimental to DA neurons by contributing to microglia activation and promoting 
neurotoxicity through some unknown intracellular mechanism (37, 106).  In the current 
project, neuroinflammation-mediated degeneration was associated with increased MMP-2 
and MMP-3 expression and activation.  Although evidence implicates MMP-2 and MMP-
3 as important components of neurodegeneration, additional experimental work is 
required to elucidate the precise mechanisms by which they contribute.  In the following 
section, two distinct mechanisms are proposed that address potential functional 
consequences of increased nigral MMP activity in PD: BBB dysfunction and promotion 
of microglial activation.   
 Contribution to BBB Dysfunction.  MMPs play a major role in BBB breakdown 
associated with ischemia/reperfusion injury and models of neuroinflammation.  MMPs 
target the basal lamina surrounding capillaries, which is rich in laminin, fibronectin, and 
type IV collagen.  In addition, strong evidence indicates that MMPs can degrade occludin 
and claudin which are major structural components of tight junctions that tightly adjoin 
adjacent capillary endothelial cells (188, 240).  The mechanism by which MMPs interfere 
with BBB function has been studied extensively in stroke models.  In these models, 
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MMPs mediate the breakdown of the BBB in two phases.  First, within hours of 
ischemia, a transient increase in MMP-2 activity derived from astrocytic end feet causes 
mild BBB disruption, which does not contribute directly to neuronal injury caused by 
reperfusion (26).  Second, a prolonged increase in MMP-3 and MMP-9 activity mediates 
longer-lasting, more severe disruption that directly contributes to reperfusion-induced 
neuronal injury (26).  Importantly, pericyte-derived MMP-3 activity may be required for 
activation of proMMP-9 (187).  
 In the PD models used in the current project, MMP-2 and MMP-3 activity 
increased following intranigral injection of LPS, but not intrastriatal injection of 6-
OHDA.  In both models, others have demonstrated that BBB disruption occurs at time 
points consistent with active neurodegeneration.  In the LPS model, entry of IgG into the 
brain parenchyma, an index of BBB function, begins 6 hours post-surgery, peaks at 24 
hours, and lasts at least through 6 days, although, BBB restoration is complete by day 14 
(222, 223).  In another study, Evan’s Blue dye extravasation was significantly more 
pronounced when LPS was delivered to the SNc compared to the cortex (100).  With the 
temporal expression profile of MMPs described in this project, it is reasonable to predict 
that MMPs are involved in BBB breakdown in the LPS model by a mechanism that is 
similar to stroke models; however, MMP-9 activity is crucial in BBB pathology in stroke 
models, which was determined to be absent by western blot in nigral tissue samples.  
Perhaps the antibody used in the current project was not sufficiently sensitive to detect 
low levels of active MMP-9, if present.  Further investigation into MMP-9 is warranted.  
Other MMP-9 antibodies could be employed or gelatin zymography could be attempted 
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to detect active MMP-9 in nigral tissue samples.  In addition, double-labeled 
immunohistochemistry experiments could provide support for BBB involvement if 
MMPs are localized around blood vessels.   
 Similar to the LPS model, medial forebrain bundle and intrastriatal 6-OHDA 
models exhibited significant albumin leakage into both the SNc and striatum 10 days 
post-surgery (31).  Leakage was closely associated with areas of DA loss in the SNc.  
Given that MMP-2, MMP-3, and MMP-9 are critical for BBB disruption in stroke 
models, it is interesting that leakage occurs in 6-OHDA models, which lack a measurable 
MMP response.  Other mechanisms must be responsible for BBB damage following 
administration of 6-OHDA.  In the intrastriatal 6-OHDA model, increased expression of 
β3 integrin, a marker for proliferating capillary endothelial cells, was noted around focal 
areas of BBB leakage, suggesting that angiogenesis occurs in response to 6-OHDA, a 
process that has been associated with leakage in other experimental models (31, 146).  
Additional studies are needed to determine the mechanism of BBB disruption in 6-
OHDA and other neurotoxin-specific models. 
 Direct disruption of the BBB has never been demonstrated in PD patients.  They 
lack noticeable brain edema, suggesting that widespread BBB disruption is not associated 
with the disease (146).  Despite this, there is evidence that the BBB is compromised to 
some extent in PD.  For example, there is a significant increase in endothelial cell number 
in PD patients, suggestive of enhanced angiogenesis, which has been associated with 
BBB leakage (64, 146).  In addition, there are increased numbers of cytotoxic and 
memory T cells within the SNc, indicating that they have attained greater access to the 
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brain parenchyma (146).  Although, widespread BBB disruption is not present in PD 
patients, localized disruption of BBB function could still play a significant role in disease 
progression (146).   
 Supporting Microglial Activation.  Recent work has demonstrated that MMP-3 
is required for microglial activation in a mixed mesencephalic culture model following 
MPTP treatment (106); however, the specific mechanisms by which MMP-3 triggers 
microglial activation remain to be elucidated.  Similar to this in vitro model, intranigral 
injection of LPS caused a significant time-dependent increase in MMP-3 expression and 
activation (chapter 4), raising the possibility that MMP-3 may contribute to the robust 
microglial reaction induced by LPS.  In support of this, MMP-3 inhibition with NNGH (a 
hydroxamate-based MMP inhibitor with reported preference towards MMP-3) treatment 
partially attenuates nitric oxide, ROS, and TNF-α production by LPS-treated microglia 
(237).  These experiments not only identify microglia as cells that potentially express 
MMP-3, they also suggest that MMP-3 mediates maximum activation of LPS-exposed 
microglia.   
 There are several potential mechanisms by which MMP-3 could contribute to 
microglial activation (Figure 6.1).  Of particular interest to PD, is the apparent interaction 
of MMP-3 with α-synuclein.  In addition to activated microglia and loss of pigmented 
nigral DA neurons, accumulation of α-synuclein within intracellular Lewy Bodies 
represents one of the major pathological characteristic of PD (99, 120); however, recent 
evidence points towards secreted α-synuclein as playing an important role in DA 
neurodegeneration associated with neuroinflammation.  α-Synuclein is found in CSF 
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FIGURE 6.1: Proposed Roles for MMP-2, MMP-3, and CTGF/CCN2 in the Support 
of Microglial Activation.  MMP inhibition prevents maximum microglial activation by 
LPS, indicating that MMPs perform critical functions that promote microglial activation.  
In PD, this could be accomplished in three ways: 1) stressed DA neurons release α-
synuclein and activated MMP-3.  MMP-3 generates α-synuclein fragments, which shifts 
α-synuclein conformation equilibrium towards oligomerization and aggregation.  
Aggregated α-synuclein directly interacts with microglia to cause activation.  2)  MMP-3 
and astrocyte-derived MMP-2 target laminin, resulting in reorganization of extracellular 
laminin that promotes its interaction with the 67kDa non-integrin laminin receptor 
expressed by microglia.  Binding of laminin to this receptor contributes to activation.  3) 
Intracellular MMP-3 can contribute to increased CTGF/CCN2 expression by reactive 
astrocytes through its transcription factor-like activity.  CTGF/CCN2 can promote 
microglial activation by stimulating microglial migration towards sites of 
neurodegeneration and by serving as a microglial proliferation signal to increase the 
overall microglial population.  The effects of CTGF/CCN2 on microglia could be 
mediated by interaction of CTGF/CCN2 with integrin receptors. 
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from both PD patients and age matched controls, and cell culture experiments have 
demonstrated that DA cells are capable of constitutively secreting this protein (20, 59, 60, 
119, 216).  Although α-synuclein CSF concentrations do not differ between those with PD 
and age-matched controls, the conformational state of α-synuclein is predominantly in the 
oligomer/aggregated state in PD patients, while monomeric α-synuclein is the major form 
present in controls (20, 60).   
 Consistent with the theory that aggregated α-synuclein is toxic towards DA 
neurons, addition of aggregated α-synuclein to mixed mesencephalic cultures specifically 
induces DA neurodegeneration (246).  The degenerative response was not observed in 
neuronal enriched cultures or microglia-depleted cultures; however, introduction of 
microglia to neuronal enriched cultures recapitulated the neurodegenerative response 
observed in mixed mesencephalic cultures, demonstrating the importance of microglia in 
α-synuclein-mediated DA neurodegeneration (246).  In addition, two transgenic mouse 
models that specifically overexpress α-synuclein in nigral DA neurons have an associated 
neuroinflammatory response, supporting that α-synuclein can activate microglia in vivo 
(216, 220).  Similar to MMP-3, direct application of α-synuclein to primary microglia 
cultures triggers activation characterized by increased ROS, but, unlike MMP-3, TNF-α or 
nitric oxide release was not induced (106, 108, 246).  Activation of microglia by MMP-3 
in mixed mesencephalic cultures may involve its ability to cleave α-synuclein.  Two 
independent studies have confirmed that MMP-3 can cleave α-synuclein and that α-
synuclein partially digested by MMP-3 readily aggregates (121, 217).   
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 Modification and aggregation of α-synuclein may play an important role in 
neuroinflammation-induced DA neurodegeneration mediated by LPS.  Mice genetically 
deficient in α-synuclein exhibit remarkable resistance to DA neurodegeneration when LPS 
is injected into the SNc, despite a seemingly unaltered neuroinflammatory response (69).  
When human α-synuclein is overexpressed in these genetically deficient mice, LPS 
triggers α-synuclein nitration, phosphorylation, and aggregate formation, indicating that 
intranigral LPS can alter the conformational state of α-synuclein (69).  Other studies 
provide support for modification of α-synuclein in LPS PD models.  For example, 
intrapalladial injection of LPS in Fisher 344 rats induced α-synuclein nitration and 
oligomerization (38).  Given the ability of MMP-3 to cleave and promote α-synuclein 
aggregation (121, 217), coupled with the observation that MMP-3 expression and 
activation peak at time points consistent with DA neurodegeneration, the reported 
alteration in α-synuclein aggregation in various LPS models could vary well depend on 
MMP-3.  Additional experiments should be done to address this possible scenario.   In 
contrast to the LPS models, α-synuclein does not appear to play a major role in 6-OHDA-
induced neurotoxicity.  Injection of 6-OHDA into the medial forebrain bundle does not 
alter α-synuclein expression (231).  In addition, the extent of striatal dopamine depletion 
induced by 6-OHDA was identical in wild-type and α-synuclein-/- mice, indicating that α-
synuclein is not a major component of 6-OHDA neurotoxicity (2). 
 In addition to promoting α-synuclein aggregation, MMP-2 and MMP-3 activity 
could promote microglial activation through modification of the local ECM present in the 
SNc.  The brain ECM differs substantially from the ECM present elsewhere in that it lacks 
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fibrous collagen and only low amounts of laminin, fibronectin, vitronectin, and perlecan 
are present (191).  Instead, brain ECM is rich in tenascins and chondroitin sulfate 
proteoglycans, including aggrecan, neurocan, brevican, and versican (238).  Of these ECM 
molecules, MMP-2 and MMP-3 have been shown to degrade aggrecan (238).  Little is 
known regarding the organization of the nigral ECM.  DA neurons lack chondroitin sulfate 
proteoglycan-rich perineuronal nets characteristic of many other brain regions (25, 88); 
however, the DA cell bodies are in close proximity to aggrecan-rich axonal coats and are 
said to be “embedded in a matrix-associated fiber plexus (25).”  In addition to aggrecan, 
the SNc expresses testican mRNA and laminin (134, 202).  MMP-mediated ECM 
reorganization could potentially promote damaging microgliosis in PD.  In support of this, 
activation of the 67kDa non-integrin laminin receptor occurs in response to MPTP in 
primary mesencephalic cultures (230).  Blockade of the receptor with laminin receptor 
antibodies attenuated MPTP-induced neurodegeneration and microglial superoxide 
production.  Furthermore, exogenous addition of laminin to these cultures was sufficient to 
induce DA neurodegeneration (230).  Additional studies are needed, but re-organization of 
laminin mediated by MMP-2 or MMP-3 proteolytic activity such that it promotes 
interaction between laminin and the 67kDa non-integrin receptor could represent a 
potential mechanism through which MMPs promote microglial activation.   
 
6.4 Potential Role for Connective Tissue Growth Factor in Parkinson’s Disease  
 The increase in CTGF/CCN2 expression in response to neuroinflammation-induced 
nigrostriatal damage is a novel finding.  The role of CTGF/CCN2 in the central nervous 
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system is poorly understood; however, it is upregulated in numerous fibrotic diseases, as 
well as peripheral inflammatory diseases including atherosclerosis and rheumatoid arthritis 
(42, 181).  In fact, increased CTGF/CCN2 expression in these two diseases occurs in the 
same locations that overexpress MMPs (132).  In normal brain, CTGF/CCN2 expression is 
found in the olfactory bulb and subsets of pyramidal neurons, suggesting that CTGF/CCN2 
serves important physiological functions for these neuronal populations (87, 111).  In 
neurodegenerative diseases, CTGF/CCN2 expression is increased in amyloid-β plaques 
associated with Alzheimer’s disease and spinal cord lesions associated with amyotrophic 
lateral sclerosis (212, 225).  In these cases, CTGF/CCN2 expression is mainly confined to 
reactive astrocytes.   
 The function of CTGF/CCN2 in neurodegeneration is not known; however, 
CTGF/CCN2 can induce proliferation and migration in a wide variety of cell types through 
interaction with integrin receptors (35).  In PD and other neurodegenerative diseases, the 
activated microglial response is characterized by microglial population expansion, 
production of proinflammatory cytokines, and release of reactive oxygen and nitrogen 
species (14, 113).  Intense focus has been placed on the role of microglial-derived 
cytokines and radicals, but the mechanisms that regulate the number of microglia present 
during neuroinflammation are poorly understood.  Microglial population expansion can be 
caused by multiple factors, including proliferation of resident microglial cells and 
migration of microglia from neighboring brain regions (113).  Regulation of microglial 
migration and proliferation appears to be at least partly mediated by β1 and β2-containing 
   
165 
integrins (142, 155), both of which are capable of interacting with CTGF/CCN2 (35).  
CTGF/CCN2 could potentially act on microglia through interaction with these integrins.   
 The functional consequences of increased CTGF/CCN2 expression warrant further 
scrutiny.  The temporal relationship between increased CTGF/CCN2 expression, the 
appearance of fragments that could represent cleaved CTGF/CCN2, and the increase in 
MMP-3 expression and activity raises the intriguing possibility that CTGF/CCN2 may be 
involved in MMP-3-mediated functions, including support of microglial activation.  This 
project only provides correlative evidence that these two proteins are involved in PD and 
future experiments must directly address whether there is a functional connection between 
MMP-3 and CTGF/CCN2 and determine the significance of this for PD. 
 
6.5 Future Directions 
 Unanswered questions abound with this project and several paths could be taken to 
further elucidate the role of MMPs and CTGF/CCN2 in neuroinflammation-mediated DA 
neurodegeneration.  As mentioned previously, the studies presented in the preceding 
chapters provide only correlative data in support of the involvement of MMPs, specifically 
MMP-2 and MMP-3, in nigral degeneration in response to LPS.  Likewise, western blot 
data showing that CTGF/CCN2 protein expression increases in parallel with the MMPs is 
correlative.  Data demonstrating direct involvement of MMP-2, MMP-3, or CTGF/CCN2 
in DA neurodegeneration is lacking.  In addition, identification of the cell types 
responsible for the observed changes in MMP expression would provide valuable 
information regarding their potential role in the nigral neuroinflammatory response. This 
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information could be used to design future functional studies aimed at elucidated the 
precise mechanisms by which MMPs and CTGF/CCN2 contribute to PD.  It is also 
important to determine if MMP-2, MMP-3, and CTGF/CCN2 expression changes in 
human PD. 
 Neuroprotection Studies.  The next experiments must address the neuroprotective 
potential of perturbing the MMP or CTGF/CCN2 response in the LPS model.  If 
experiments were to be continued using the rat, a pharmacological approach could be taken 
to inhibit MMP activity, although this approach has significant limitations.  First, the 
currently available MMP inhibitors are broad spectrum in nature.  For example, GM6001, 
a MMP inhibitor commonly used in vivo, potently blocks the activity of MMP-1, MMP-2, 
MMP-3, MMP-8, and MMP-9 with Ki values in the low nanomolar range (67).  Several 
inhibitors have been reported to exhibit strong inhibition towards one or two MMP 
members; however, these inhibitors have not been tested on other MMPs.  For instance, 
NNGH is marketed by several suppliers as a specific MMP-3 inhibitor, but if one examines 
the literature, MMP-3 is the only MMP that has been tested with this inhibitor (129).  If 
tested, it is probable that NNGH would be found to inhibit other MMPs.  A second 
limitation is that MMP inhibitors cannot cross an intact BBB (71).  The BBB could be 
bypassed through direct infusion of the inhibitor to the SNc.  Alternatively, infusion into 
the lateral ventricle could minimize tissue damage to the SNc and would allow for the drug 
to be delivered multiple times if a cannula was pre-implanted allowing easy access.  
Alternatively, breakdown of the BBB following intranigral administration of LPS could 
allow passage of inhibitor injected systemically.  Given the challenges and limitations 
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involved with pharmacological inhibition of MMP-2 and MMP-3, a better strategy might 
be to employ genetic knockout mice.  MMP-2 and MMP-3 knockout mice have been 
developed (61, 106).  Intranigral injection of LPS in wild type, MMP-2-/-, and MMP-3-/- 
mice would be a simple way to determine whether either MMP contributes significantly to 
neuroinflammation-induced DA neurodegeneration.  In addition, this approach would 
allow for the development of MMP-2/3 double knock out mice.  If MMP-2 or MMP-3 is 
important in neuroinflammation-induced DA neurodegeneration, then genetic knockout of 
either or both should result in significant neuroprotection against LPS-mediated injury. 
 Disrupting the function of CTGF/CCN2 may prove more problematic due to the 
current lack of pharmacological inhibitors and knockout models.  CTGF/CCN2-/- mice die 
immediately after birth due to respiratory failure caused by catastrophic skeletal 
developmental defects (97), making it difficult to examine the effect of genetic ablation of 
CTGF/CCN2 on LPS-induced neurodegeneration.  Although CTGF/CCN2-/- mice do not 
survive past birth, there may be methods to circumvent this limitation.  For example, 
mixed mesencephalic cultures used in various PD studies must be established from E14 
mice; therefore, it should still be possible to measure DA neurodegeneration following 
LPS exposure in cultures established from E14 CTGF/CCN2-/- mice.  Alternatively, siRNA 
techniques could be used to knockdown CTGF/CCN2 expression in cell culture and animal 
models.  
 Stereological assessment of the number of DA neurons remaining in the SNc has 
traditionally been the method used to assay neuroprotection in most in vivo PD models; 
however, several end points could be used to determine how ablation of MMP-2 and/or 
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MMP-3 protects DA neurons from LPS.  First, the microglial reaction induced by LPS 
could be studied to determine if loss of MMP-2 or MMP-3 ameliorates neuroinflammation.  
Microglia immunohistochemistry could be done to assess the proliferative and 
morphological effect of loss of MMP-2 or MMP-3 in response to LPS.  In addition, 
production of neuroinflammatory cytokines, expression of iNOS, and ROS generation 
could be measured to determine specific aspects of the microglial response that are 
affected by ablation of MMP-2 or MMP-3.  Second, BBB integrity could be measured in 
wild type and knock out mice to assess the role of MMPs in LPS-induced BBB 
dysfunction.  These experiments could involve measurement of dye extravasation and 
examination of MMP-mediated tight junction protein degradation.  Third, the effect on α-
synuclein physiology and neurotoxicity after LPS injection could be examined.  
Aggregation of α-synuclein in the SNc has been demonstrated in the rat following 
intrapalladial LPS injection and the mouse following intranigral LPS injection (38, 69).  It 
would be interesting to determine if loss of MMP-2 or MMP-3 prevents the aggregation of 
α-synuclein in the LPS model. 
 Confocal Microscopy Experiments.  The second important set of experiments 
requires the identification of cell types that express MMPs and CTGF/CCN2 in response to 
LPS-induced DA neurodegeneration.  This could most easily be addressed with double-
labeling immunofluorescence experiments which may be done in primary mesencephalic 
cultures or on midbrain tissue sections following LPS treatment in mice or rats.  Glial 
fibrillary acidic protein, TH, and CD11b or ED1 can be used to specifically label 
astrocytes, DA neurons, and activated microglia, respectively.  Detection of each of these 
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cell types could be combined with simultaneous detection of MMP-2, MMP-3, or 
CTGF/CCN2 to determine which cells express which proteins.  These experiments should 
assist in elucidating the function of these proteins in vivo.  For instance, concentration of 
MMP or CTGF/CCN2 immunoreactivity in astrocytes and microglia associated with the 
vasculature would suggest important involvement in BBB disruption, while expression in 
cells in areas of active neurodegeneration would indicate a direct role in 
neuroinflammation-induced DA injury. 
 
6.6 Concluding Remarks 
 Currently approved therapies for PD provide symptomatic relief in the early years 
following diagnosis; however, these treatments fail to arrest the underlying cause of 
chronic neurodegeneration and eventually loss their therapeutic benefit.  These 
shortcomings underscore the importance for developing novel neuroprotective therapies, 
which requires a more complete understanding of the causes of PD and the mechanisms 
that drive neurodegeneration.  Only 5-10% of PD cases can be attributed directly to 
functional mutations in a select number of proteins (221).  The cause for remaining PD 
cases is unknown, but likely results from a combination of genetic and environmental 
factors.  Among environmental factors, exposure to both neurotoxins (6-OHDA, MPTP, 
rotenone, paraquat, maneb) and inflammogens (diesel exhaust particles, LPS) are 
hypothesized to contribute to increased PD risk, although, direct evidence in humans is 
lacking (34, 141).  In this dissertation, the 6-OHDA and LPS models of PD were examined 
and it was found that these two models involve completely different MMP responses, 
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suggesting that MMPs may be involved in PD predominantly triggered by certain 
environmental factors, but not others.  If this is the case, then changes in MMP expression 
would be expected to be observed in only a subset of PD patients.  In support of this, a 
small histopathology study has reported drastically increased MMP-1 in 2 out 5 patients 
examined and elevated MMP-9 expression in 1 patient (127).     
 Accumulating evidence points towards important processes ongoing outside of the 
DA neuron that contribute significantly to disease pathology, including chronic 
neuroinflammation and alterations in extracellular proteins (14).  Along these lines, 
induction of active MMP-2 and MMP-3 along with increased CTGF/CCN2 protein 
expression was correlated with LPS-induced neurodegeneration.  Additional experiments 
are needed aimed at identifying the cell types associated with these changes and at testing 
the neuroprotective potential of blocking MMP or CTGF/CCN2 function in inflammation-
induced degeneration.  Depending on the results of these crucial studies, methods that 
interfere with MMP or CTGF/CCN2 function could represent novel neuroprotective 
therapeutic strategies for PD. 
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APPENDIX I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE A1-1: SH-SY5Y Differentiation 
SH-SY5Y cells exhibit a neuroblast-like appearance, lacking important morphological 
features characteristic of mature neurons.  Therefore, SH-SY5Y differentiation prior to 6-
OHDA treatment was considered.  To induce differentiation (Encinas et al. 2000), SH-
SY5Y cells were cultured in DMEM/F-12 containing 10% FBS, 1% Pen/Strep, and 
10µM retinoic acid (RA) for 5 days (media was changed on day 3).  This was followed 
by a 5 day treatment with serum-free DMEM/F-12 supplemented with 50ng/mL brain-
derived neurotrophic factor (BDNF, media was changed on the third day).  A) Untreated 
SH-SY5Y cells.  B)  SH-SY5Y cells treated 5 days with DMSO and 5 days with PBS, the 
vehicles for retinoic acid and BDNF, respectively, show no morphological change 
compared to untreated cells. Cells not found in clusters had a characteristic unipolar 
appearance with a short neurite (*).  C)  RA + BDNF differentiation resulted in extensive 
neurite growth.  D)  Low density area of differentiated cells showing that cell clusters 
extend multiple long neurites that make contact with several neighboring clusters.  Some 
neurites branch to contact more than one neighboring cell or neurite (arrow heads).  Panel 
C scale bar=50µm and is applicable to the other three panels. 
A.
C. D.
B.
Undifferentiated SH-SY5Y Cells Vehicle-treated SH-SY5Y Cells
Differentiated SH-SY5Y Cells (high density) Differentiated SH-SY5Y Cells (low density)
*
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FIGURE A1-2: Neuronal Marker Expression in Undifferentiated and Differentiated 
SH-SY5Y Cells.  Western blots comparing neuronal marker expression in 
undifferentiated and differentiated SH-SY5Y cells (n=1).  Differentiation of SH-SY5Y 
cells with retinoic acid and BDNF had no effect on β-tubulin III or TH protein 
expression, suggesting that differentiation does not result in loss of DA characteristics.  
Differentiation resulted in a slight increase in MAP2 protein expression and low levels of 
neurofilament-L (NF-L) expression was detected only in differentiated cells.  hNT cell 
lysates were included as a positive control for NF-L and MAP2 expression. 
 
Undif Dif
TH, 60kDa
Cyclophilin A,18 kDa
β-tubulin III, 50kDa
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MAP2
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FIGURE A1-3: Dose-dependent 6-OHDA Toxicity in Undifferentiated and 
Differentiated SH-SY5Y Cells.  Vulnerability to 6-OHDA-mediated neurotoxicity was 
compared between undifferentiated and differentiated SH-SY5Y cells.  Cells were treated 
with 6-OHDA concentrations ranging from 0-90µM for 24 hours.  Cell viability was 
measured using the trypan blue exclusion method (results for undifferentiated SH-SY5Y 
cells appear alone in figure 3.3).  Statistical comparisons were made with two-way 
ANOVA.  Overall there was a significant model effect (p<0.001); however, there was no 
interaction between culture conditions (undifferentiated vs. differentiation) and 6-OHDA 
concentration (p=0.09).  When considering culture conditions independently from 6-
OHDA concentration, differentiated SH-SY5Y cell viability was significantly greater 
compared to undifferentiated cells (p<0.001).  When considering 6-OHDA concentration 
independently from culture conditions, 6-OHDA induced a significant dose-dependent 
decline in cell viability (p<0.001).  The lack of an interaction effect is likely due to low 
sample size, particularly in the differentiated group.  The data hints that differentiated 
SH-SY5Y cells are less vulnerable to 6-OHDA-mediated neurotoxicity than their 
undifferentiated counterparts.  In support of this, the LD50 for undifferentiated cells was 
37.6 ± 6.82µM, while the LD50 for differentiated cells was right-shifted to 55.3 ± 
10.7µM.  Data presented as mean ± standard deviation. 
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FIGURE A1-4: Time-dependent 6-OHDA-mediated Neurotoxicity in 
Undifferentiated and Differentiated SH-SY5Y Cells.  The difference in the 6-OHDA 
dose-dependent relationship between undifferentiated and differentiated SH-SY5Y cells 
could have resulted from differences in the time-dependent 6-OHDA effect.  In this 
experiment (n=1), undifferentiated and differentiated SH-SY5Y cells were treated with 
45µM 6-OHDA for 0-96 hours.  Cell viability was measured at each time point using the 
trypan blue exclusion method.  In undifferentiated SH-SY5Y cells, the decrease in cell 
viability occurred some time after 6 hours and was complete by 24 hours.  In contrast, the 
start of cell viability decline in differentiated SH-SY5Y cells was evident 6 hours after 
treatment and was complete by 24 hours.  In agreement with the dose-dependent 
relationship, maximum cell viability loss was greater in undifferentiated cells at the 24 
hour time point, remaining this way through the 96 hours.  Data in figures A3 and A4 
suggested that differentiation results in a decrease in vulnerability to 6-OHDA-mediated 
neurotoxicity.  For this reason, differentiation was discontinued and MMP mRNA 
measurements were made in undifferentiated SH-SY5Y cells. 
 
Time-dependent 6-OHDA Effect 
0
20
40
60
80
100
120
0 20 40 60 80 100 120
Treatment Duration (Hours)
P
e
rc
e
n
t 
C
o
n
tr
o
l 
V
ia
b
le
 C
e
ll
 C
o
u
n
t
Undifferentiated
Differentiated
   
211 
 
 
 
Appendix II 
 
 
 
 
FIGURE A2-1: Temporal CTGF/CCN2 Expression following Intrastriatal 6-OHDA 
Injection.  CTGF/CCN2 expression increased significantly 24 hours after intranigral LPS 
injection and fragments were detected that could represent cleaved CTGF/CCN2 (Figure 
4.10).  CTGF/CCN2 expression was measured in the 6-OHDA rat model to provide a 
comparison between neurotoxin and inflammation-induced DA neurodegeneration. 
CTGF/CCN2 expression was measured in striatal and nigral protein samples collected 1, 
5, and 10 days post-6-OHDA injection.  Measurements were made in 2 rats per group.  
A) Ipsilateral nigral CTGF/CCN2 expression did not change compared to contralateral 
expression in the vehicle or 6-OHDA groups.  This was to be expected if MMP-3 
regulates CTGF/CCN2 expression in PD models, since no nigral proMMP-3 or active 
MMP-3 was detected in 6-OHDA injected rats (Figure 3.11).  B)  Striatal CTGF/CCN2 
expression was more variable with no discernable expression pattern emerging within 
these sample sets.
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Appendix III 
 
 
 
 
FIGURE A3-1: Amphetamine Challenge in LPS-lesioned Rat 
Several methods have been developed to measure functional deficits in unilateral rodent 
models of PD.  When amphetamine is injected i.p., it triggers massive dopamine release 
from nigral DA neurons.  If one side of the nigrostriatal tract is significantly damaged, then 
dopamine release is asymmetric, causing the rat to rotate in the direction ipsilateral to the 
nigrostriatal tract lesion.  This test was performed on one intranigral LPS-injected rat to 
determine if nigrostriatal damage associated with this model is sufficient to induce 
ipsilateral rotational behavior.  Amphetamine sulfate was injected i.p. and rat was placed in 
a circular enclosure.  Ipsilateral and contralateral full body rotations were counted 
manually for 90 minutes.  A) Net ipsilateral rotations were condensed into 5-minute time 
intervals.  The maximum rotational rate over a 5-minute interval reached 1.6 rpm 80-85 
minutes after injection; however, a rotation rate of ~1 rpm was maintained over most of the 
test.  B) Total ipsilateral and contralateral rotations were compared.  There was a clear 
tendency for the rat to rotate in the ipsilateral direction (75 ipsilateral rotations vs. 4 
contralateral rotations).  Recent reports with the LPS model suggest that amphetamine 
should induce rotational rates near 6 rpm (96).  The reason for the discrepancy is unknown.   
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